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Surprisingly, similar to various cancer cells, Müller glial cells and light-sensing photoreceptors of the 
mammalian retina display the Warburg effect (aerobic glycolysis), an unusual metabolism whereby 
the cells tend to convert glucose into lactate via glycolysis regardless of oxygen availability. In cancer, 
the glycolytic enzyme pyruvate kinase M2 (PKM2) promotes lactate production and acts as a 
coactivator for the transcription factor hypoxia-inducible factor-1 (HIF-1), stimulating glycolysis; thus, 
PKM2 is implicated in driving the Warburg effect. PKM2 has also been shown to be expressed in the 
retina and cultured Müller cells (MCs). 
 
This thesis elucidates MC glucose metabolism and tests the hypothesis that PKM2 drives the 
Warburg effect in cultured MCs. 
 
Primary rat MCs, the SV40-immortalised rMC-1 MC line and a novel spontaneously immortalised rat 
SIRMu-1 MC line were used as experimental models. The SIRMu-1 is a novel spontaneously 
immortalised cell line that was derived from primary MCs during the course of this thesis. It retains 
similar cellular morphology to cultured primary rat MCs. Immunofluorescence, western blotting and 
RNA sequencing show that the SIRMu-1 cells closely resemble primary MCs in regard to overall 
transcriptome and expression of the MC markers cellular retinaldehyde-binding protein, glutamine 
synthetase, S100, vimentin and glial fibrillary acidic protein at both the mRNA and the protein levels. 
SIRMu-1 cells, however, proliferate rapidly, do not senesce and have a high transfection efficiency. 
RNA sequencing also shows that the SIRMu-1 cells were derived from a male rat. The cell line is a 
valuable experimental tool to study MCs. 
 
Glucose metabolism of primary MCs, rMC-1 and SIRMu-1 cells was investigated using lactate 
assays and a Seahorse XFe96 Analyser system. Primary MCs and rMC-1 cells display the Warburg 
effect, while SIRMu-1 cells depend predominantly on oxidative phosphorylation. This shows that the 




As the rMC-1 cells retain the Warburg effect observed in primary MCs, they were used to investigate 
the role of PKM2. Short hairpin RNA-mediated PKM2 knockdown and CRISPR/Cas9-mediated 
PKM2 knockout did not significantly alter the high glycolytic activity of rMC-1 cells, indicating that 
PKM2 is not a main driver of the Warburg effect in cultured MCs. This demonstrates that the role of 
PKM2 in the Warburg effect is cell type-dependent. This project improves our understanding of MC 
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CHAPTER 1:  Introduction 
1.1 Overview 
The retina serves as the primary organ for the generation of vision. This ocular tissue contains 
photoreceptor cells that convert light to electrical signals which are processed by specialised neurons 
and transmitted via retinal ganglion cells along the optic nerve to the brain for higher processing. 
One of the major cell types of the retina is the Müller cell (MC), a type of resident glial cell that 
provides structural and functional support to retinal neurons. (Barrett et al., 2012; Bringmann et al., 
2006; Mescher, 2010; Vecino et al., 2016). Interestingly, unlike most other physiological cells in the 
body, and in particular the brain, the mammalian retina displays an unusual glucose metabolism, 
termed the Warburg effect, also known as aerobic glycolysis (reviewed in Paper 1 (Ng et al., 2015)) 
(Cohen and Noell, 1960; Poitry-Yamate et al., 1995; Tornquist and Alm, 1979; Warburg, 1925; 
Warburg et al., 1924; Warburg et al., 1930; Winkler, 1981, 1995; Winkler et al., 2000; Winkler et al., 
2003). This describes the phenomenon where cells preferentially convert glucose into lactate via 
glycolysis, despite the presence of abundant oxygen, which should theoretically drive mitochondrial 
oxidative phosphorylation (OXPHOS) (Koppenol et al., 2011; Warburg et al., 1927). The Warburg 
effect is a common feature of most cancer cells (Koppenol et al., 2011; Vander Heiden et al., 2009) 
and is also displayed in other highly proliferative cells, such as stimulated lymphocytes (Abdel-
Haleem et al., 2017). Although Warburg’s team noted the presence of aerobic metabolism in the 
retina in the 1920s (Warburg, 1925; Warburg et al., 1924; Warburg et al., 1930), this phenomenon 
received relatively little attention until recently. Given the large energy requirements of the retina and 
the potentially important role that impaired energy metabolism plays in a number of common blinding 
conditions (Bringmann et al., 2006; Hartong et al., 2008), it is clearly pertinent to investigate the 
mechanisms and control of aerobic glycolysis in this tissue. The work presented in this thesis, 
therefore, aimed to elucidate the existence of the Warburg effect in the retina and more specifically 
in MCs which provide support to most of the cells in this tissue. Furthermore, this thesis sought to 
investigate whether the glycolytic enzyme pyruvate kinase M2 (PKM2), which has been shown to 
drive the Warburg effect in various cancer cells (Christofk et al., 2008a; Clower et al., 2010; Goldberg 




1.2 Glucose metabolism: glycolysis and oxidative phosphorylation   
Energy is essential to cellular survival and function. Cells use adenosine triphosphate (ATP) to 
transfer energy. In order to produce ATP, most quiescent, differentiated cells utilise cytoplasmic 
glycolysis and mitochondrial OXPHOS (Fig. 1.1 and 1.2). In the glycolytic pathway (Fig. 1.1), which 
comprises a series of sequential cytoplasmic enzymatic reactions, a single glucose molecule is 
converted via several intermediates to two molecules of pyruvate, producing two ATP molecules. In 
the last step of glycolysis, pyruvate is generated from phosphoenolpyruvate (PEP), a reaction 
catalysed by pyruvate kinase (PK) (Fig. 1.1).  
 
When levels of oxygen are sufficient, pyruvate is predominantly converted into acetyl Coenzyme A 
(acetyl CoA) by the pyruvate dehydrogenase complex consisting of three enzymes, including 
pyruvate dehydrogenase (PDH) (Fig. 1.1 and 1.2A). Acetyl CoA then enters the tricarboxylic acid 
(TCA) cycle in the mitochondrion, ultimately resulting in the production of ATP by OXPHOS. More 
specifically, the TCA cycle generates NADH (reduced nicotinamide adenine dinucleotide (NAD)) and 
FADH2 (reduced flavin adenine dinucleotide) which are energy-rich molecules that act as electron 
donors in the subsequent electron transport chain (ETC) (Fig. 1.1). The ETC consists of four protein 
complexes (complexes I, II, III and IV) that transfer electrons from a series of electron donors to 
electron acceptors via redox reactions, with oxygen as the final electron acceptor (Fig. 1.1). The 
transfer of electrons releases energy which pumps protons (hydrogen ions, H+) from the 
mitochondrial matrix across the inner membrane to the intermembrane space (Fig. 1.1). This creates 
a proton gradient causing H+ to re-enter the matrix, a process which powers the generation of ATP 
by ATP synthase (also referred to as complex V) (Fig. 1.1). This process of electron transfer from 
NADH and FADH2 to oxygen to produce ATP is OXPHOS, and the oxidation of glucose by oxygen 
ultimately produces water (H2O) and carbon dioxide (CO2). Overall, under aerobic conditions ~30-33 
ATP molecules are produced by the complete oxidation of one glucose molecule (Brand, 2005; 
Mookerjee et al., 2017; Mookerjee et al., 2015).  
 
Under hypoxic conditions, the majority of pyruvate is converted to lactate by lactate dehydrogenase 
A (LDHA) via anaerobic glycolysis (Fig. 1.2B), which yields only two ATP molecules per one glucose 
molecule (Vander Heiden et al., 2009). Lactate is then exported out of the cells. The conversion of 
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pyruvate to lactate by LDHA regenerates NAD+ (an oxidised form of NAD) to continuously feed the 
glycolytic pathway (Goda and Kanai, 2012).  
 
Under aerobic or anaerobic conditions, metabolic intermediates from the glycolytic pathway can be 
directed to biosynthesis, including lipid, nucleic acid and amino acid production (Fig. 1.1). These 
products are subsequently used as substrates for the production of biomass needed for cellular 
proliferation (Mucaj et al., 2012; Vander Heiden et al., 2009). Anabolic synthesis of amino acids and 
lipids are also carried out by mitochondria (Ahn and Metallo, 2015). Furthermore, the pentose 
phosphate pathway (PPP), which runs parallel to glycolysis and is also fed by metabolites of glucose, 
plays a significant role in cellular protection against oxidative stress (Stincone et al., 2015). Thus, 
whether aerobic or anaerobic pathways are used, glucose metabolism is central to cellular energy 
production, and essential for survival, normal function and proliferation.  
 
1.3 The Warburg effect/aerobic glycolysis 
Proliferating cells, including cancer cells, commonly metabolise glucose by a different process from 
that of quiescent cells described above; they tend to convert glucose to lactate via glycolysis even in 
the presence of abundant levels of oxygen (Fig. 1.2C); this is a much less efficient way to produce 
ATP (Hsu and Sabatini, 2008; Koppenol et al., 2011; Vander Heiden et al., 2009; Warburg, 1956; 
Warburg et al., 1927). The upregulated conversion of glucose into lactate results in higher glucose 
consumption and lactate production (Hsu and Sabatini, 2008; Koppenol et al., 2011; Vander Heiden 
et al., 2009; Warburg, 1956; Warburg et al., 1927). This process is known as aerobic glycolysis and 
eponymously as the Warburg effect, after Otto Warburg who first described the phenomenon in 
cancer cells in the 1920s. Warburg and colleagues found that under aerobic conditions cancer cells 
produced a larger amount of lactate compared to normal tissues and converted the majority of 
glucose into lactate, rather than use it for respiration (Warburg, 1956; Warburg et al., 1924; Warburg 
et al., 1927; Warburg et al., 1930). In addition to cancer cells, several non-cancerous highly 
proliferative cells have been shown to display the Warburg effect, including activated macrophages 
and T-lymphocytes of the immune system, endothelial cells and pluripotent embryonic stem cells 






Figure 1.1. Cellular glucose metabolism. To produce energy, cells metabolise glucose to pyruvate via the 
glycolytic pathway which is a series of multiple enzymatic reactions. Pyruvate can either be converted into acetyl 
CoA or lactate. In the former case, acetyl CoA enters the tricarboxylic acid (TCA) cycle which ultimately produces 
NADH (reduced nicotinamide adenine dinucleotide) and FADH2 (reduced flavin adenine dinucleotide), high 
energy molecules that act as electron donors in the electron transport chain (ETC). The ETC is composed of 
four protein complexes (complexes I, II, III and IV). The transfer of electrons through these protein complexes 
to oxygen, the final electron acceptor, creates a proton gradient by pumping protons (hydrogen ions, H+) from 
the mitochondrial matrix across the inner membrane to the intermembrane space. The proton gradient causes 
H+ to re-enter the matrix, powering the generation of ATP by ATP synthase (complex V). These processes make 
up oxidative phosphorylation (OXPHOS). Glycolytic intermediates can also be shunted to biosynthetic pathways 
(indicated in red). Two-way arrows indicate reversible reactions and one-way arrows irreversible reactions. 
Enzymes that catalyse each step are shown in blue boxes. GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; HK, hexokinase; LDH, lactate dehydrogenase; PPP, pentose phosphate pathway; PFK1, 
phosphofructokinase 1; PGI, phosphoglucose isomerase; PGK, phosphoglycerate kinase; PGM, 





Figure 1.2. Glucose metabolism in quiescent cells and in cancer and other proliferating cells under 
aerobic and anaerobic conditions. Cells convert glucose into pyruvate via the glycolytic pathway. (A) In 
quiescent/differentiated cells, when there is abundant oxygen most pyruvate is converted into acetyl CoA, 
leading to oxidative phosphorylation (OXPHOS), a process which requires oxygen. (B) In hypoxia, 
quiescent/differentiated cells turn most pyruvate into lactate and this is anaerobic glycolysis. (C) Cancer and 
other proliferating cells tend to preferentially convert pyruvate into lactate regardless of oxygen availability, a 




Originally, Warburg postulated that aerobic glycolysis was involved in carcinogenesis and occurred 
as a result of defective mitochondria (Warburg, 1956). However, more recent studies have indicated 
that mitochondria are functional in most cancer cells, suggesting that limited oxidative capacity is not 
the reason behind the Warburg effect in cancer (reviewed in (Moreno-Sanchez et al., 2007; Vander 
Heiden et al., 2009)). A number of explanations for the existence of the Warburg effect in proliferating 
cells have been proposed. One widely purported explanation is that the Warburg effect fulfils 
metabolic requirements of proliferating cells because it leads to a greater amount of glycolytic 
intermediates and thereby provides a mechanism to divert such intermediates to biosynthesis 
required for cell growth and proliferation (Vander Heiden et al., 2009). However, the stoichiometry of 
this explanation is arguably flawed because if the vast majority of carbon atoms from glucose are 
converted to lactate despite the presence of oxygen (by definition, the Warburg effect), then there 
are inadequate carbon atoms for biosynthesis (Liberti and Locasale, 2016; Mookerjee et al., 2017). 
Furthermore, there is evidence that only a small proportion of carbon atoms from glucose in highly 
glycolytic cancer cells, such as non-small cell lung cancer cell lines H1299 and A549, is converted 
to biosynthetic precursors such as amino acids or nucleotides (Hosios et al., 2016). Hence, there are 
theoretical and empirical reasons to doubt this “biosynthesis hypothesis”. An arguably more likely 
explanation for the presence of the Warburg effect is that cells with high energy demands metabolise 
glucose to lactate via glycolysis for much more immediate ATP production and regeneration of 
NAD+. This process is therefore self-reinforcing, continuously supplying the correct cellular 
environment for maintenance of the glycolytic pathway (Liberti and Locasale, 2016; Mookerjee et al., 
2017). Although the conversion of glucose to lactate via glycolysis is considered a less efficient way 
to produce ATP per glucose molecule than OXPHOS, glycolysis can occur more rapidly leading to 
rapid ATP synthesis with higher glucose consumption (Liberti and Locasale, 2016). Among other 
explanations is that cells use glycolysis rather than OXPHOS for energy generation to free up 
mitochondria for other processes such as biosynthesis of amino acids and lipids (Liberti and 
Locasale, 2016). 
 
Although reasons behind the existence of the Warburg effect and how it benefits cancer cells remain 
largely uncertain and require further investigations, several mechanisms and agents implicated in 
driving the Warburg effect have been characterised. Key drivers of the Warburg effect in cancer 
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include the phosphoinositide 3-kinase (PI3K) pathway (Ward and Thompson, 2012), the transcription 
factor and proto-oncogene Myc (Dejure and Eilers, 2017), the transcription factor hypoxia-inducible 
factor-1 (HIF-1) (Semenza, 2012) and the glycolytic enzyme PKM2 (Chaneton and Gottlieb, 2012; 
Dayton et al., 2016b), the latter of which forms the focus of this thesis. Among other effects, these 
factors upregulate glucose uptake, increase glycolytic flux and/or inhibit OXPHOS through various 
downstream signalling pathways and hence, drive the Warburg effect.   
 
1.4 PKM2 and its roles in the Warburg effect in proliferative cells 
1.4.1 PKM2: an isoform of pyruvate kinase 
PKM2 has been shown to promote the Warburg effect in cancer and proliferating cells (Christofk et 
al., 2008a; Clower et al., 2010; Goldberg and Sharp, 2012; Palsson-McDermott et al., 2015). It is one 
of four currently known isoforms of PK, a cytoplasmic enzyme that catalyses the final step of 
glycolysis: the conversion of PEP into pyruvate. The other three isoforms are pyruvate kinase M1 
(PKM1), L (PKL) and R (PKR). The PKLR gene encodes PKL and PKR under the control of different 
promoters (Noguchi et al., 1987). PKL is expressed in liver and kidney and PKR in erythrocytes 
(Imamura and Tanaka, 1972; Imamura et al., 1973). PKM1 is a closely-related alternatively-spliced 
isoform of PKM2; both are encoded by the PKM gene (Noguchi et al., 1986). PKM1 is primarily 
expressed in muscle tissue, brain, fibroblasts and bladder, while PKM2 is expressed in most cells 
with the exception of muscle cells (Bluemlein et al., 2011; Imamura and Tanaka, 1972; Tsutsumi et 
al., 1988) (reviewed in (Luo and Semenza, 2012)). 
 
The PKM gene contains 12 exons, with PKM1 mRNA and PKM2 mRNA each having 10 common 
exons (exons 1-8, 11 and 12) and a single mutually-exclusive exon due to alternative splicing: exon 
9 for PKM1 and exon 10 for PKM2 (Fig. 1.3) (Chaneton and Gottlieb, 2012; Noguchi et al., 1986). 
Both PKM1 and PKM2 proteins are comprised of 531 amino acids. The mutually-exclusive exons 9 
and 10 each encodes 56 amino acids (residues 381-436) with only 22 being variant between the 
human PKM1 (NCBI Reference Sequence: NP_872270.1) and PKM2 (NCBI Reference Sequence: 
NP_002645.3) (Noguchi et al., 1986); this results in very similar predicted molecular weights between 
PKM1 (58.06 kDa) and PKM2 (57.94 kDa) (molecular weights calculated based on reference 
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sequences using an online tool, https://web.expasy.org/protparam/; (Gasteiger et al., 2005)). 
Similarly, the mouse PKM1 (NCBI Reference Sequence: NP_001240812.1) and PKM2 (NCBI 
Reference Sequence: NP_035229.2) differ by only 22 amino acids with predicted molecular weights 
of 57.99 kDa and 57.84 kDa, respectively, and the rat PKM1 (GenBank: AAB93666.1) and PKM2 
(GenBank: AAB93667.1) differ by just 21 amino acids with predicted molecular weights of 57.82 kDa 
and 57.78 kDa, respectively (Gasteiger et al., 2005).  
 
A number of factors have been found to influence the alternative splicing of the PKM gene primary 
RNA transcript. At high concentrations, three heterogeneous nuclear ribonucleoproteins (hnRNPs), 
hnRNPI, hnRNPA1 and hnRNPA2, commonly upregulated in cancer cells, promote the excision of 
exon 9 and processing to PKM2 mRNA (Chen et al., 2012; Clower et al., 2010). At low 
concentrations, however, these factors inhibit exon 10 inclusion, thereby promoting processing to 
PKM1 mRNA (Chen et al., 2012; Clower et al., 2010).  
 
A common perception in the published literature is that in cancer there is a specific switch from PKM1 
to PKM2 expression, leaving PKM2 as the predominant PKM isoform which can thus drive the 
metabolic changes in cancer cells (Chaneton and Gottlieb, 2012). However, this perception is based 
on studies using antibodies; one such study, for example, used western blotting and showed that 
several cancer cell lines exclusively expressed PKM2 (Christofk et al., 2008a). However, it should 
be noted that the antibodies used in these studies have not been well validated for specificity, calling 
into question some of these findings (reviewed in (Chaneton and Gottlieb, 2012)). Nevertheless, a 
proteomic study has recently reported that PKM2 predominates over PKM1 in both cancers and 
normal tissue-matched controls and that, in fact, expression of both PKM1 and PKM2 are increased 






Figure 1.3. Alternative splicing of the PKM gene. Pyruvate kinase M1 (PKM1) and pyruvate kinase M2 
(PKM2) are both encoded by the PKM gene. PKM1 mRNA and PKM2 mRNA have 10 common exons and a 
mutually-exclusive exon due to alternative splicing: exon 9 for PKM1 and exon 10 for PKM2. E, exon. Based on 




1.4.2 PKM2 and the Warburg effect 
A variety of studies support a specific role for PKM2 in the Warburg effect. Firstly, PKM2-specific 
knockdown (KD) by small interfering RNA (siRNA) decreased lactate production by approximately 
two-fold in the human colorectal carcinoma cell line HCT116, indicating that a decrease in PKM2 
protein levels results in a decrease in the Warburg effect (Goldberg and Sharp, 2012). Secondly, 
shRNA-mediated PKM2 KD in human lung carcinoma H1299 cells led to a decrease in glucose 
consumption and lactate production (Siddiqui et al., 2018). Thirdly, in two human lung carcinoma 
lines, H1299 and A549, and a human renal cell carcinoma line, SN12C, PKM2 deficient cells rescued 
with mouse PKM2 exhibited a lower oxygen consumption and a higher lactate production (hence an 
increase in the Warburg effect) compared with cells rescued with mouse PKM1 (Christofk et al., 
2008a). This adds support to the idea that PKM2, but not PKM1, is involved in the regulation of the 
Warburg effect. Fourthly, in the glioblastoma cell line A-172 KD of hnRNPI, or the combined KD of 
hnRNPA1 and hnRNPA2, which promote the alternative splicing to PKM1 mRNA thereby decreasing 
PKM2 protein levels, also decreased lactate production (Clower et al., 2010). Finally, PKM2 isoform-
specific deletion reduced aerobic glycolysis in macrophages activated by lipopolysaccharide (LPS) 
(Palsson-McDermott et al., 2015), demonstrating a specific role of PKM2 in the Warburg effect in a 
non-cancerous context. 
 
PKM2 expression in cancer has also been implicated in cellular proliferation and tumourigenesis. 
However there are conflicting data; some studies have reported that PKM2 is important for cancer 
cell proliferation and viability (Christofk et al., 2008a; Goldberg and Sharp, 2012; Siddiqui et al., 
2018), while others have shown that it is not essential (Dayton et al., 2016a; Israelsen et al., 2013). 
Nevertheless, unlike these conflicting roles of PKM2 in cellular proliferation, most data support the 
involvement of PKM2 in promoting the Warburg effect. 
 
1.4.3 Allosteric regulation of PKM2 and glucose metabolism 
Unlike PKM1, which only exists as a constitutively high-activity tetramer, PKM2 has been reported 
to exist as both a high-activity tetramer and a low-activity monomer or dimer (Fig. 1.4) (Ashizawa et 





Figure 1.4. Role of PKM2 in the Warburg effect in cancer cells. PKM2 exists in two forms: an enzymatically 
active tetramer and a less active dimer. The upstream glycolytic intermediate fructose 1,6-bisphosphate (FBP), 
serine and succinylaminoimidazolecarboxamide ribose-5′-phosphate (SAICAR) promote formation of the active 
tetramer PKM2, whereas tyrosine-phosphorylated polypeptides and post-translational modifications of PKM2 
(oxidation, phosphorylation and acetylation) favour the formation of the less active dimer. The dimeric form of 
PKM2 can act as a coactivator of the transcription factor hypoxia-inducible factor-1 (HIF-1) in the nucleus, 
leading to an increased expression of HIF-1 target genes, many of which are involved in promoting glycolytic 
metabolism including SLC2A1 (the gene encoding glucose transporter 1, GLUT1), LDHA (lactate 
dehydrogenase A) and PDK-1 (pyruvate dehydrogenase kinase-1). PKM, which encodes PKM2, is also a target 




The tetrameric form is more enzymatically active as it has a higher affinity for its substrate, PEP. 
Thus, the tetrameric form favours the conversion of PEP into pyruvate. The monomeric or dimeric 
form has a lower affinity for PEP and is less active, leading to the accumulation of upstream glycolytic 
intermediates. Hence the low-activity form of PKM2 has been proposed to promote diversion of such 
intermediates to biosynthetic pathways, leading to the production of biomolecules for cellular 
proliferation (Chaneton and Gottlieb, 2012; Dayton et al., 2016b; Luo and Semenza, 2012). Thus it 
has been hypothesised that, being able to alternate between the high-activity tetrameric and the low-
activity monomeric/dimeric forms, PKM2 regulates whether the cells convert glucose into pyruvate 
for energy production or use glucose for biosynthesis (Mazurek, 2011).  
 
The switch between the active tetrameric and the less active monomeric or dimeric forms of PKM2 
is controlled by several factors. The upstream glycolytic intermediate fructose 1,6-bisphosphate 
(FBP) (Fig. 1.4) can bind to PKM2 and this promotes tetramer formation, thereby increasing PKM2 
enzymatic activity (Bailey et al., 1968). This event is unique to PKM2 and not PKM1, as the 22 amino 
acid residues in PKM2 that are different from PKM1 form a binding pocket for FBP (Dombrauckas et 
al., 2005; Noguchi et al., 1986), enabling PKM2 allosteric regulation. Serine and succinyl-
aminoimidazolecarboxamide ribose-5′-phosphate (SAICAR), an intermediate of the de novo purine 
nucleotide synthetic pathway, also increase PKM2 enzymatic activity (Fig. 1.4) (Chaneton et al., 
2012; Keller et al., 2012; Morgan et al., 2013). On the other hand, a number of mechanisms have 
been shown to decrease PKM2 activity. Tyrosine-phosphorylated polypeptides associated with 
receptor tyrosine kinase signalling, when bound to PKM2 release FBP, promote dimeric formation 
and inhibit PKM2 enzymatic activity (Fig. 1.4) (Christofk et al., 2008b). In addition, PKM2 activity is 
controlled by post-translational modifications; phosphorylation of tyrosine residue 105 of PKM2 by 
fibroblast growth factor receptor type 1 (FGFR1), oxidation of cysteine residue 358 induced by 
intracellular reactive oxygen species (ROS), and acetylation of lysine residue 305 under high glucose 
concentration reduce PKM2 enzymatic activity (Fig. 1.4) (Anastasiou et al., 2011; Hitosugi et al., 
2009; Lv et al., 2011). These mechanisms implicate PKM2 in regulating cellular metabolic responses 
to growth factor signalling, oxidative stress and nutrient conditions. The ability of PKM2 to be 
differentially regulated to switch between quaternary structures, with different enzymatic activities, 
and thereby influence the fate of glucose within cells implicates it in control of cellular metabolism. 
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However, it is not clear how the enzymatic function of PKM2 can favour the conversion of pyruvate 
to lactate and promote the Warburg effect.  
 
1.4.4 Non-enzymatic functions of PKM2  
In addition to its enzymatic role in the glycolytic pathway in the cytosol, the dimeric form of PKM2 
has been found in the nucleus where it has been shown to have additional functions (Gao et al., 
2012). PKM2 can act as a protein kinase leading to histone and other protein modifications, events 
which can also influence cancer proliferation (Yang et al., 2012). More importantly in terms of 
metabolic regulation, dimeric PKM2 can also enhance activities of transcription factors including β-
catenin (Yang et al., 2011) and HIF-1 (Fig. 1.4) (Luo et al., 2011).  
 
HIF-1 is a heterodimeric transcription factor that is vital for regulating various cellular responses to 
hypoxia; it consists of an oxygen-regulated HIF-1α subunit and a constitutive HIF-1β subunit, also 
known as ARNT (Semenza and Wang, 1992; Wang et al., 1995). Under conditions of physiological 
oxygen levels (normoxia), HIF-1α is efficiently hydroxylated by prolyl hydroxylases (PHDs), which 
have three isoforms (PHD 1-3), and also by an asparaginyl hydroxylase known as factor inhibiting 
HIF or FIH, leading to inactivation of HIF-1 (Epstein et al., 2001; Lando et al., 2002a; Lando et al., 
2002b). This occurs because when hydroxylated by PHDs, HIF-1α is targeted for ubiquitination by 
the von Hippel-Lindau protein (pVHL) and subsequently for rapid proteosomal degradation. 
Furthermore, hydroxylation of HIF-1α by FIH prevents the interaction of the HIF-1α C-terminal 
transactivation domain with the coactivators CBP and p300 and therefore inhibits its transcriptional 
activity. When oxygen is below physiological levels (hypoxia), the activities of the PHDs and FIH are 
reduced as they are oxygen-dependent; thus HIF-1α avoids hydroxylation and becomes stabilised 
and active. It translocates to the nucleus and dimerises with HIF-1β, forming the HIF-1 complex 
which can bind to hypoxia response elements (HREs) in the regulatory regions of target genes to 
induce gene expression (Chilov et al., 1999).  
 
HIF-1 has also been implicated in driving the Warburg effect in cancer (Semenza, 2012). Among the 
large set of HIF-1 target genes (approximately 200), many are involved in energy metabolism, 
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including the genes encoding glucose transporter 1 (GLUT1), LDHA and pyruvate dehydrogenase 
kinase-1 (PDK-1), as well as key enzymes in the glycolytic pathway (Goda and Kanai, 2012; Hu et 
al., 2003). The upregulation of GLUT1, LDHA and PDK-1 by HIF-1 results in the increased cellular 
uptake of glucose, the increased production of lactate and the inactivation of PDH leading to a 
decrease in acetyl CoA formation, respectively. Ultimately, the induction of these and other HIF-1 
target genes promotes the upregulation of glycolysis and the inhibition of OXPHOS. This, and the 
observation that HIF-1α is active in many cancer cells, due to hypoxic conditions in tumours or 
genetic abnormalities independent of oxygen availability (Ke and Costa, 2006; Zhong et al., 1999), 
implicates HIF-1 activity in cancer metabolism and, importantly, the Warburg effect. 
 
There are a number of functional connections between PKM2 and HIF-1, with important implications 
for regulating the Warburg effect. Firstly, studies have shown that the PKM gene, which encodes 
PKM1 and PKM2, is a direct target gene of HIF-1 (Fig. 1.4) (Luo et al., 2011; Semenza et al., 1994). 
More relevantly, it has been shown that PKM2 can act as a coactivator of HIF-1α to increase target 
gene induction in the HeLa cervical cancer cell line and the Hep3B hepatoblastoma cell line. 
Specifically, PKM2 enhances HIF-1 binding and p300 recruitment to HREs of HIF-1 target genes, 
resulting in increased transactivation of target genes, including those that upregulate glycolysis (Fig. 
1.4) (Luo et al., 2011). In HeLa cells, PKM2 KD mediated by short hairpin RNA (shRNA) reduced 
expression of the HIF-1 target genes SLC2A1 (the gene encoding GLUT1), LDHA and PDK1 (Luo 
et al., 2011). This regulation is specific for PKM2, as the PKM1 isoform cannot regulate HIF-1 activity 
(Luo et al., 2011).  
 
In addition, PKM2 can interact directly with PHD3, one of the HIF prolyl hydroxylases. The interaction 
between PKM2 and PHD3 results in both increased PKM2 binding to HIF-1α and PKM2 coactivator 
activity (Luo et al., 2011). In RCC4 cells, a VHL-deficient renal cell carcinoma line in which HIF-1 is 
constitutively expressed and active (Maxwell et al., 1999), PHD3 KD decreased glucose uptake, 
glycolytic flux and lactate production whilst increasing oxygen consumption in normoxia (Luo et al., 
2011), which further supports a stabilisation-independent role for PHD3 in regulating HIF-1, mediated 
by PKM2. The interaction of HIF-1 and PKM2 has also been reported in macrophages activated by 
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LPS, and cells with PKM2 deletion exhibited a decreased expression of HIF-1α target genes 
(Palsson-McDermott et al., 2015).  
 
Hence the interaction of PKM2 with HIF-1 may explain a putative mechanism by which PKM2 can 
drive the Warburg effect in cancer, where PKM2 not only controls the production of pyruvate by its 
enzymatic function, but also the fate of pyruvate through regulation of lactate production and 
OXPHOS mediated by HIF-1 (Fig. 1.4). 
 
1.5 Retina 
Although it is not a proliferating tissue, the mammalian retina also displays the Warburg effect 
(reviewed in Paper 1 (Ng et al., 2015) (Appendix 7.1)) (Lindsay et al., 2014; Tornquist and Alm, 1979; 
Winkler, 1995; Winkler et al., 2000).  
 
The eye is generally considered to be comprised of three distinct layers: the outer protective layer 
consisting of sclera and cornea, the middle vascular layer containing choroid, ciliary body and iris, 
and the innermost layer, the retina (Barrett et al., 2012; Kolb, 1995b; Mescher, 2010) (Fig. 1.5A). 
The retina is a complex tissue containing a number of prominent cell types: retinal neurons, including 
the light-sensing photoreceptors, bipolar cells, ganglion cells, amacrine cells and horizontal cells, 
and glial cells such as MCs (Barrett et al., 2012) (Fig. 1.5B). There are two types of photoreceptors, 
rods and cones (Fig.1.5B and C). Rod cells, being highly sensitive, are used for vision under low light 
conditions, while cones are responsible for colour perception (Kolb, 1995a). A photoreceptor consists 
of the synaptic terminal zone, the cell body containing the nucleus, the inner segment containing 
mitochondria, and the constantly-renewed outer segment which contains visual pigments and is 
connected to the inner segment by the cilium (Barrett et al., 2012; Bibliowicz et al., 2011) (Fig. 1.5C). 
Photoreceptors, bipolar cells, ganglion cells, amacrine cells and horizontal cells form distinct and 
specialised classes of retinal neurons. MCs comprise the major type of glial cell in the retina and are 
generally thought to provide functional and structural support for all retinal neurons (reviewed in 




The retinal cells are organised into three distinct cellular layers, the outer nuclear layer (ONL), the 
inner nuclear layer (INL) and the ganglion cell layer (GCL), which are separated by two layers of 
synapses, the outer plexiform layer (OPL) and the inner plexiform layer (IPL) (Kolb, 1995b) (Fig. 
1.5B). Among the three cellular layers, the ONL is the nearest to the choroid (the farthest from the 
vitreous cavity) and the GCL is the closest to the vitreous humour (Fig. 1.5B). The ONL contains rod 
and cone photoreceptor cell bodies, the INL contains perikarya of bipolar cells, horizontal cells, 
amacrine cells and MCs, and the GCL contains ganglion cells and some displaced amacrine cells 
(Barrett et al., 2012; Kolb, 1995b) (Fig. 1.5B). Separating these cellular layers are the two layers of 
synapses, the OPL and the IPL (Barrett et al., 2012). In the OPL, the layer of synapses between the 
ONL and the INL, horizontal cells form lateral connections among photoreceptors (Barrett et al., 
2012) (Fig. 1.5B). In the INL, the layer of synapses between the INL and the GCL, amacrine cells 
make connections among ganglion cells and bipolar cells (Barrett et al., 2012) (Fig. 1.5B). Of note, 
while MC bodies are in the INL, their processes span the entire retina (Fig. 1.5B), providing the retinal 
neurons with a supporting framework (Mescher, 2010). Moreover, the end feet of MCs form the inner 
limiting membrane, the boundary between the retina and the vitreous (Fig. 1.5B) (Barrett et al., 2012). 
The outer limiting membrane separates the inner segment of photoreceptors from their cell bodies, 
and the retinal pigment epithelium (RPE), the layer adjacent to the choroid, comprises cells which 
surround and support the outer segments of retinal photoreceptors (Fig. 1.5B). 
 
Rod and cone photoreceptors detect light and convert it into electrical signals, via an elaborate 
intracellular signalling cascade (Kolb, 1995a). These electrical signals are sent via bipolar cells to 
ganglion cells, whose axons form the nerve fibre layer and the optic nerve, transporting the signals 








Figure 1.5. The eye and the retina. (A) A diagram of the mammalian eye. Modified (This is a part of the original 
figure; the original also contains a schematic enlargement of the retina, which is omitted here.) from (Kolb, 
1995b) (http://webvision.med.utah.edu/) for academic purposes under an Attribution, Noncommercial 4.0 
International (CC BY-NC) Creative Commons license (https://creativecommons.org/licenses/by-
nc/4.0/legalcode). (B) The organisation of the retina. Note that light enters through the inner limiting membrane. 
Reproduced with permission from Wilkinson-Berka, J.L (2004), Diabetes and retinal vascular disorders: role of 
the renin-angiotensin system, Expert reviews in molecular medicine, Volume 6, Issue 15, Pages 1-18. 
(Wilkinson-Berka, 2004). (C) Rod and cone photoreceptor structure, with light entering basally. Reprinted from 
Progress in Molecular Biology and Translational Science, Volume 100, Bibliowicz, J., Tittle, R.K., and Gross, 
J.M., Toward a better understanding of human eye disease insights from the zebrafish, Danio rerio, Pages No. 




1.6 Retinal metabolism 
Unlike most other tissues, which primarily rely on OXPHOS to meet their energy demands, the non-
proliferative mammalian retina, specifically the photoreceptors and MCs, display the Warburg effect 
(reviewed in Paper 1 (Ng et al., 2015)) (Cohen and Noell, 1960; Poitry-Yamate et al., 1995; Tornquist 
and Alm, 1979; Warburg, 1925; Warburg et al., 1924; Warburg et al., 1930; Winkler, 1981, 1995; 
Winkler et al., 2000; Winkler et al., 2003). This distinct metabolism of the retina is surprisingly similar 
to cancer and other proliferating cells, and renders the retina one of the very few non-proliferative 
cells and tissues that exhibit the Warburg effect, others of which include Sertoli cells in the testis 
(Oliveira et al., 2015).  
 
It is not certain why the Warburg effect exists in the retina (Paper 1 (Ng et al., 2015) (Appendix 7.1)). 
It has been postulated that retinal tissue, specifically the photoreceptors, has similar metabolic 
requirements to those of proliferating cells (Casson et al., 2012) possibly because of a high turnover 
rate of photoreceptor outer segments (Young, 1967). However, this “biosynthesis hypothesis” suffers 
the same stoichiometric flaw as it does in cancer. Alternatively, photoreceptors are highly energy 
demanding (Okawa et al., 2008) and may rely on the Warburg effect for rapid ATP production. 
Regarding MCs, it has been postulated that they may rely on aerobic glycolysis to produce lactate 
to supply to neurons (Bringmann et al., 2006; Poitry-Yamate et al., 1995). On the other hand, Winkler 
and colleagues reported that retinal neurons mainly utilise glucose and not lactate (Winkler et al., 
2004), and Lindsay et al. proposed that MCs use photoreceptor-derived lactate as a substrate to 
produce energy (Lindsay et al., 2014). With these conflicting data, this matter requires further 
investigation. 
 
Furthermore, and importantly, in contrast to cancer and other proliferating cells, little was known 
about the molecular drivers of the Warburg effect in the retina, which led to the work presented in 




1.7 Background summary and project rationale 
In summary, cancer cells (Hsu and Sabatini, 2008; Koppenol et al., 2011; Vander Heiden et al., 2009; 
Warburg, 1956; Warburg et al., 1927) and the mammalian retina (reviewed in Paper 1 (Ng et al., 
2015)) (Cohen and Noell, 1960; Poitry-Yamate et al., 1995; Tornquist and Alm, 1979; Warburg, 1925; 
Winkler, 1981, 1995; Winkler et al., 2000; Winkler et al., 2003) both display the Warburg effect. The 
reason for this unusual type of metabolism in the retina is unclear but may emulate the same 
teleology as cancer. (Casson et al., 2012; Ng et al., 2015). Various factors driving the Warburg effect 
in cancer cells have been characterised but not much is known about such factors in the retina. 
 
We hypothesised that the mechanisms that drive the Warburg effect in the retina and proliferating 
cells such as cancer cells are conserved. More specifically, a number of studies support PKM2 as a 
driver of the Warburg effect in cancer cells (Christofk et al., 2008a; Clower et al., 2010; Goldberg and 
Sharp, 2012; Siddiqui et al., 2018), and PKM2 is known to be expressed in the mammalian retina 
(Morohoshi et al., 2012). The findings led to the central hypothesis of this thesis, that PKM2 drives 
the Warburg effect in MCs. The studies herein were undertaken to investigate whether PKM2 played 
a role in establishing and maintaining the Warburg effect in the mammalian retina in a similar manner 
to cancer cells. 
 
The retina is critical for vision, and retinal diseases commonly cause blindness. In addition, the retina 
has large energy requirements, and impaired energy metabolism plays a potential pathogenic role 
in a number of diseases (Bringmann et al., 2006; Hartong et al., 2008). It is, therefore, crucial to 
characterise the molecular factors and mechanisms by which retinal energy metabolism, specifically 
the Warburg effect, is driven. Understanding this phenomenon could potentially lead to new 
therapeutic strategies for retinal diseases. Furthermore, if the mechanisms driving the Warburg effect 
in cancer cells and the retina are conserved, novel drugs that target regulators of the Warburg effect 
in cancer (Tennant et al., 2010; Vander Heiden et al., 2010a; Yu et al., 2016) could adversely affect 




It has been well established that cultured MCs from mammalian retinas display a strong Warburg 
effect as shown in freshly-isolated guinea pig MCs (Poitry-Yamate et al., 1995), primary human MCs 
(Winkler et al., 2000) and the immortalised rMC-1 rat MC line (Winkler et al., 2003). Moreover, MCs 
can be easily cultured and used to determine aspects of retinal function and metabolism (Limb et al., 
2002; Sarthy, 1985; Sarthy et al., 1998; Savage et al., 1988). In practical terms, the laboratory of the 
candidate’s co-supervisor, Robert Casson (Department of Ophthalmology and Visual Sciences, 
Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia), routinely utilise rat retinas 
for the generation and maintenance of primary retinal cultures, containing both neurons and glial 
cells (Wood et al., 2005; Wood et al., 2003). In contrast to photoreceptor cells, cultured primary rat 
MCs can easily be generated from these primary retinal cultures (Sarthy, 1985; Wood et al., 2005), 
which we have also demonstrated and utilised previously (Honours thesis (Kittipassorn, 2013)). 
Furthermore, cultured primary rat MCs were shown to express PKM2, by using a well-characterised 
antibody (Paper 2 (Casson et al., 2016) in Appendix 7.2), in the candidate’s Honours thesis 
(Kittipassorn, 2013). Thus, cultured primary rat MCs were chosen as a model to study the Warburg 
effect in the mammalian retina in this PhD project.  
 
A well-established SV40-transformed rat MC line rMC-1 (Sarthy et al., 1998) and a novel 
spontaneously immortalised rat MC line SIRMu-1 (Paper 4 (Kittipassorn et al., 2019a) in Chapter 3), 
which was generated during the course of this thesis, were also used to complement the experiments 
on primary MCs.  
 
1.8 Hypotheses and aims 
Hypotheses 
1. The SIRMu-1 cell line originated from primary MCs  
2. Cultured rat MCs display the Warburg effect  





1. To establish and characterise a novel spontaneously immortalised rat MC line SIRMu-1 
(Chapter 3) 
2. To determine whether cultured rat MCs display the Warburg effect (Chapter 4) 
2.1. To develop and optimise techniques for metabolic analysis 
2.2. To characterise metabolism of glucose in cultured primary rat MCs  
2.3. To characterise metabolism of glucose in the SV40-transformed rat MC line 
rMC-1 and the spontaneously immortalised rat MC line SIRMu-1 compared to 
primary MCs 
3. To investigate whether PKM2 drives the Warburg effect in MCs (Chapter 5) 
3.1. To study the effect of PKM2 KD on the metabolism of glucose in MCs 
3.2. To study the effect of PKM2 KO on the metabolism of glucose in MCs 
 
1.9 Experimental approach 
Experiments were performed on cultured rat primary MCs, the SV40-immortalised rat MC line rMC-
1 (Sarthy et al., 1998) and a novel spontaneously immortalised rat MC line SIRMu-1, derived by the 
candidate (Paper 4 (Kittipassorn et al., 2019a)). 
 
Aim 1: To establish and characterise a novel spontaneously immortalised rat MC line 
SIRMu-1 
During the course of studying retinal metabolism using primary MCs, a population of immortalised 
rat MCs spontaneously arose. A monoclonal line of these novel cells was isolated by single cell 
isolation by serial dilution and named SIRMu-1 (spontaneously immortalized rat Muller cell line). To 
determine if the SIRMu-1 cells retained the properties of primary MCs, expression of MC marker 
proteins was characterised by immunofluorescence and western blotting, and expression of MC 
marker mRNA by RNA sequencing (RNA-seq). RNA-seq data were also used to study the overall 
transcriptome of SIRMu-1 cells. In addition, transfection efficiency was determined by transfecting 
the cells with a fluorescence protein-encoding plasmid using various commercially-available 
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transfection reagents. All experiments were also performed on primary MCs and/or the rMC-1 cell 
line for comparisons. 
 
Aim 2: To characterise MC glucose metabolism 
 Aim 2.1. To develop and optimise metabolic analysis techniques 
Experimental techniques to investigate cellular metabolism had never been performed in the 
candidate’s laboratories before. Therefore, assays performed using a Seahorse extracellular flux 
analyser (Agilent Technologies) were developed and optimised in order to measure cellular oxygen 
consumption and extracellular acidification, which are a common indicator of OXPHOS and 
glycolysis, respectively.  
 
 Aim 2.2. To characterise metabolism of glucose in cultured primary rat MCs  
Primary rat MCs grown in culture medium with glucose as a sole substrate for energy production 
were subjected to metabolic analysis by lactate assays and a Seahorse extracellular flux analyser. 
These analyses were carried out to characterise glucose metabolism of these cells and to determine 
whether they displayed the Warburg effect. Lactate assays measured the levels of lactate released 
in culture medium, and the Seahorse analyser measured oxygen consumption (representing 
OXPHOS) and extracellular acidification (commonly representing glycolysis); this allowed us to 
determine whether the cells investigated were primarily oxidative or glycolytic, the latter of which 
would be cells that were exhibiting the Warburg effect. 
 
 Aim 2.3. To characterise metabolism of glucose in the SV40-transformed rat MC line rMC-1 
and the spontaneously immortalised rat MC line SIRMu-1 compared to primary MCs  
rMC-1 and SIRMu-1 cells were subjected to the same metabolic analysis as primary MCs described 





Aim 3: To investigate whether PKM2 drives the Warburg effect in MCs 
In order to study the role of PKM2 in MC metabolism, these cells were modified to have a partial or 
a complete loss of PKM2 protein before cellular glucose metabolism was analysed. If PKM2 served 
as an important driver of the Warburg effect in MCs, a decreased PKM2 level and/or the absence of 
PKM2 should result in a significantly reduced glycolytic activity of the cells, indicative of a decrease 
in the Warburg effect.  
 
 Aim 3.1. To study the effect of PKM2 knockdown on the metabolism of glucose in MCs 
PKM2 was knocked down in MCs using shRNAs that specifically targeted this protein and not the 
closely-related isoform PKM1. The shRNAs were introduced into the cells by a lentiviral-based 
system. KD was verified by determining the changes in PKM2 protein level. MCs in which PKM2 had 
been knocked down were then subjected to metabolic analyses in the presence of glucose.  
 
 Aim 3.2. To study the effect of PKM2 knockout on the metabolism of glucose in MCs 
MCs with a complete loss of PKM2 were generated by using clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) genome editing technology to 
remove exon 10 from the PKM gene, thereby knocking out PKM2 without knocking out PKM1. The 
KO cells were verified by PCR, DNA sequencing and western blotting. MCs where PKM2 had been 
knocked out were then subjected to metabolic analyses in the presence of glucose in a similar 












CHAPTER 2:  Materials and methods 
This chapter covers materials and methods for Aim 2 (to determine whether cultured rat MCs display 
the Warburg effect; Chapter 4) and Aim 3 (to investigate whether PKM2 drives the Warburg effect in 
MCs; Chapter 5) of the thesis. Materials and methods for Aim 1 (to establish and characterise a novel 
spontaneously immortalised rat MC line SIRMu-1) are described in Paper 4 (Kittipassorn et al., 
2019a) and Paper 5 (Kittipassorn et al., 2019b) in Chapter 3. 
 
2.1 Mammalian cell cultures and techniques  
2.1.1 Primary cultures and cell lines  
Cells used in this thesis and their sources are described in table 2.1 
 
Table 2.1. Primary cultures and immortalised cell lines used in this thesis 
Primary (1o) culture/cell line Source 
1o rat mixed retinal cultures Gifts from Dr John Wood and Teresa Mammone, 
Laboratory of Professor Robert Casson* 
1o rat Müller cell (MC) cultures Derived from 1o rat mixed retinal culture by the candidate 
rMC-1 rat MC line  A gift of Dr Vijay Sarthy#, obtained from Dr Binoy 
Appukuttan† 
SIRMu-1 rat MC line Generated during the course of this thesis 
1o mouse embryonic fibroblasts 
(MEFs) 
A gift from Alexis Gerassimou, Laboratory of Professor 
Murray Whitelaw* 
HeLa human cervical cancer cell line  
 
A gift from Dr Jane Sibbons, Laboratory of Dr Kirk Jensen* 
Originally obtained from ATCC (CCL-2) 
HEK 293FT human embryonic 
kidney cell line 
A gift from Laboratory of Associate Professor Michael 
Beard*. Originally obtained from ThermoFisher Scientific 
(#R70007).  
 
* University of Adelaide, Adelaide, SA, Australia;  
# Northwestern University, Chicago, IL, USA 
† Flinders University, Adelaide, SA, Australia 
ATCC, American Type Culture Collection  
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As an immortalised human cell line used in metabolic experiments in this thesis, HeLa cells were 
submitted to CellBank Australia (Westmead, NSW, Australia) for human cell line authentication 
testing. The results were consistent with the cells having correct identity with 96% of alleles identical 
to HeLa cells from the American Type Culture Collection (ATCC) catalogue (CCL-2) (Appendix 7.4). 
Primary MCs, rMC-1 cells and SIRMu-1 cells were characterised and authenticated in Paper 4 
(Kittipassorn et al., 2019a) in Chapter 3. Primary MEFs and rat mixed retinal cultures were generated 
directly from animals in the laboratories of the candidate’s co-supervisors, Professor Murray 
Whitelaw and Professor Robert Casson, respectively (University of Adelaide, Adelaide, SA, 
Australia). HEK 293FT cells were used for lentiviral production. 
 
2.1.2 Generation of primary cultures 
Sprague-Dawley rats were used for the generation of primary mixed retinal and MC cultures. Animal 
handling complied with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes 2004, and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 
Primary mixed retinal cultures were generated by Dr John Wood and Teresa Mammone (Laboratory 
of Professor Robert Casson) as described previously (Wood et al., 2005; Wood et al., 2003) and in 
Paper 4 (Kittipassorn et al., 2019a) in Chapter 3. Primary MC cultures were derived from primary 
mixed retinal cultured by the candidate as described previously (Osborne, 1990; Wood et al., 2005) 
and in Paper 4 (Kittipassorn et al., 2019a) in Chapter 3. 
 
Primary mouse embryonic fibroblasts (MEFs) were isolated from C57BL/6J mice by Alexis 
Gerassimou (Laboratory of Professor Murray Whitelaw). Embryos were first dissected out from a 
pregnant mouse at embryonic day 11.5, head and internal organs removed, washed with 1x 
phosphate-buffered saline (PBS) and incubated in 1 mL of 0.05% trypsin/EDTA/PBS at 37oC for 5 
minutes. Next, 3 mL of Dulbecco's Modified Eagle Medium (DMEM, +HEPES, #12430062, Life 
Technologies Australia, Scoresby, VIC, Australia) containing 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin and 2 mM L-glutamine was added, and the embryos in trypsin/medium were 
centrifuged at 500 rpm for a minute. Trypsin/medium was then removed, and the embryos 
resuspended in 4 mL fresh medium and dissociated with pipetting. Cells were counted and plated at 
2 x 106 cells per a 15-cm dish in 25 mL fresh medium. 
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2.1.3 Culture maintenance 
All cells were maintained in growth medium described in table 2.2 (unless otherwise stated) at 37oC 
and 5% CO2. Primary mixed retinal cultures were used to generate primary MC cultures as described 
above and were not passaged. All other cell types were passaged when they reached 80-90% 
confluency, using trypsinisation with passage ratios and frequencies as described in table 2.2. Firstly, 
spent medium was aspirated from a culture vessel and cells were washed with 1x PBS and incubated 
in 0.05% trypsin/EDTA/PBS at 37oC for two to ten minutes before fresh growth medium was added. 
Cells were then resuspended in trypsin/medium and a proportion of cells according to the passage 
ratio transferred to a new culture vessel containing appropriate amount of fresh growth medium. Note 
that DMEM was used in the isolation of MEF as per the protocol described in section 2.1.2, but MEM 
was used in the maintenance of MEF for metabolic experiments so that it was consistent with primary 
MCs. 
 
2.1.4 Cryopreservation of cells 
Culture medium was aspirated and cells were washed with 1x PBS and incubated in 0.05% 
trypsin/EDTA/PBS at 37oC for two to ten minutes before fresh growth medium was added. Cells were 
then resuspended in trypsin/medium and centrifuged at 1400 rpm for 3 minutes before 
trypsin/medium was aspirated and the cell pellet resuspended in 10% dimethyl sulfoxide (DMSO) in 
FBS. Next, cell suspension was aliquoted into cryogenic vials. The vials were placed in an 
isopropanol freezing container which was then placed in a -80oC freezer. The isopropanol freezing 
container was used to enable a gradual decrease in temperature (approximately -1oC per minute), 
which is important for cell preservation. Once frozen, the vials were moved to liquid nitrogen storage 
for long term preservation. 
 
2.1.5 Thawing of cryopreserved cells 
A frozen cell vial from a -80oC freezer or liquid nitrogen storage was placed in a 37oC water bath. As 
soon as the vial was just thawed, cell suspension was transferred to a tube already containing fresh 
medium which was then centrifuged at 1400 rpm for three minutes. Next, the supernatant was 
aspirated and the cell pellet resuspended in fresh medium and transferred to a culture vessel. 
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Table 2.2. Growth medium and passage ratio and frequency 
1o culture/cell 
line 
Growth medium Passage ratio and 
frequency 
1o mixed retinal  
cultures 
MEM, 10-20% FBS, 87 mg/L gentamicin sulfate, 
2.2 mg/L amphotericin B, 25 mM glucose,  
2 mM L-glutamine 
-  
1o MCs MEM, 10-20% FBS, 87 mg/L gentamicin sulfate, 
2.2 mg/L amphotericin B, 25 mM glucose,  
2 mM L-glutamine 
1:2 every 7 days 
rMC-1  MEM, 10% FBS, 25 mM glucose,  
2 mM L-glutamine 
1:10 every 2-3 days 
SIRMu-1  MEM, 10-20% FBS, 25 mM glucose,  
2 mM L-glutamine 
1:3 to 1:5 every 2-4 
days 
1o MEFs MEM, 10-20% FBS, 25 mM glucose,  
2 mM L-glutamine 
 
1:2 to 1:3 every 7-10 
days 
HeLa  MEM, 10% FBS, 25 mM glucose,  
2 mM L-glutamine 
 
1:10 every 2-3 days 
HEK 293FT  DMEM, 25 mM glucose, 10% FBS 1:10 every 2-3 days 
 
1o MEFs, primary mouse embryonic fibroblasts; 1o mixed retinal cultures, primary rat mixed retinal cultures; 1o 
MCs, primary rat Müller cells; HEK 293FT, human embryonic kidney cell line; HeLa, human cervical cancer cell 
line; rMC-1, SV40-transformed rat Müller cell line; SIRMu-1, spontaneously immortalised rat Müller cell line; 
DMEM, Dulbecco's Modified Eagle Medium (DMEM, #12430062, Life Technologies Australia); FBS, fetal bovine 
serum (heat inactivated); MEM, minimal essential medium, +Earle's Salts, -L-glutamine, #11090, Life 
Technologies)  
 
2.2 Lactate assay 
L-lactate concentration in culture medium was determined using a Lactate Colorimetric Assay Kit II 
(#K627-100, BioVision, Milpitas, CA, USA) according to the manufacturer’s instructions. Media from 
wells without cells collected at the same time were used as blank controls. Samples for lactate 
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assays were collected from cell culture plates during the preparation process for Seahorse assays 
(see section 2.3.1). 
 
2.3 Seahorse extracellular flux assay  
2.3.1 Seahorse XF Cell Mito Stress Test protocol 
Seahorse XF Cell Mito Stress Tests (#103015-100, Agilent Technologies, Santa Clara, CA, USA) 
were employed to analyse cellular metabolism. In these tests, oxygen consumption rates (OCRs) 
and extracellular acidification rates (ECARs) of cells were measured at a basal state and in response 
to three compounds that were serially injected into wells at specific time points by a Seahorse XFe96 
extracellular flux analyser (Agilent Technologies), under the control of the Wave software. The three 
compounds, in the order of injection, were oligomycin, carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP) and a mix of rotenone and antimycin A (Rot/AA). Assays were performed 
as per the manufacturer’s instructions with modifications described below.  
 
At least 24 hours before cell seeding for Seahorse assays, culture media for all cell types were 
changed from the usual growth media (Table 2.2) to MEM containing 10% FBS, 5.5 mM glucose and 
2 mM L-glutamine. The day before the assay (approximately 16-20 hours before the assay), unless 
otherwise stated, primary MC (15,000 cells/well), rMC-1 (15,000 cells/well), SIRMu-1 (10,000 
cells/well), primary MEF (15,000 cells/well), or HeLa (10,000 cells/well) cells were seeded in MEM 
containing 10% FBS, 5.5 mM glucose and 2 mM L-glutamine (80 µL per well) in a Seahorse 96-well 
cell culture plate (pre-coated with 0.2% gelatin in PBS). Wells A1, A12, H1 and H12 were left without 
cells as blank controls in the Seahorse assay. The cell plate was allowed to rest at room temperature 
for 45-60 minutes to promote even cell distribution (Lundholt et al., 2003) before it was kept in a 
humidified, 37oC incubator with 5% CO2. Sensor probes of a sensor cartridge (#102601-100, Agilent 
Technologies) were hydrated by submerging and incubating in XF calibrant solution (#100840-000, 
Agilent Technologies) in a utility plate (200 µL per well) overnight in a humidified, 37oC incubator 




On the assay day, unless otherwise specified, assay medium was made up from XF base medium 
(#102353-100, Agilent Technologies) and glucose (final concentration 10 mM), warmed to 37oC, pH 
adjusted to 7.35 ± 0.05 with NaOH and sterile filtered. Next, cells were checked under a light 
microscope, washed one time with assay medium, and incubated in fresh assay medium (100 µL 
per well) for an hour in a humidified, 37oC incubator with 5% CO2. The medium of each well was then 
collected and stored at -80oC for later use in lactate assays (see also section 2.2). Cells were washed 
again and fresh assay medium added (175 µL per well). Cells were immediately inspected under a 
light microscope before incubating for approximately 90 minutes in a humidified, 37oC incubator 
without CO2.  
 
While the cells were incubating, the three Cell Mito Stress Test compounds were added to 
designated drug ports of all wells of the sensor cartridge: ports A, oligomycin; ports B, FCCP; ports 
C, Rot/AA. The final concentrations of each compound, unless otherwise stated, were 2 µM for 
oligomycin, 0.5 µM for FCCP and 0.5 µM each for Rot/AA. Compound preparation and addition are 
described in table 2.3. The sensor cartridge was then placed in the Seahorse XFe96 analyser for 
calibration. Once calibration of the sensors and the required cell incubation had completed, the cell 
plate was placed in the Seahorse analyser for simultaneous measurements of OCRs and ECARs at 
basal state and after the addition of oligomycin, FCCP and Rot/AA. Three measurement cycles of 
mix (three minutes)-wait (none)-measure (three minutes) were carried out during each of the four 
conditions. Oligomycin, FCCP and Rot/AA were injected at 16, 36 and 56 minutes after the start of 
the assay, respectively. After the end of each assay, cells were inspected under a light microscope 
and the number of cells per well determined, using the methods described in section 2.3.2, for 
normalisation of OCR and ECAR data. 
 
In a number of assays, additional wells were set up to determine buffer factors. A buffer factor 
(mM/pH) is the amount of H+ that changes the pH level in the medium by one pH unit as measured 
in a Seahorse analysis system and can be determined by adding known amounts of H+ into a well 
over the course of an assay (instead of the three Cell Mito Stress Test compounds) and measuring 
changes in ECARs. Buffer factors of the assay medium (XF base medium containing 10 mM glucose) 
used with the Seahorse XFe96 system in this thesis were determined according to the 
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manufacturer’s instructions (Agilent Technologies user guide “Agilent Seahorse XF Buffer Factor 
Protocol”, 2017). Three serial injections of 25 µL of 5 mM HCl were injected into wells containing 
assay medium without cells instead of oligomycin, FCCP and Rot/AA at the same time points and 
ECARs measured as above. In the control wells, assay medium was serially injected instead of HCl. 
Buffer factors were used in the calculation of proton efflux rates (PERs) (see section 2.3.3.3). 
 








to add to 
ports 
Total volume (µL) per well 






1st - oligo 16 25 175 200 2 
2nd - FCCP 4.5 25 200 225 0.5 
3rd - Rot/AA 5 25 225 250 0.5 
 
conc., concentration; FCCP, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone; oligo, oligomycin; Rot/AA, 
rotenone and antimycin A.  
 
2.3.2 Cell number determination 
The number of cells per well at the end of each Seahorse assay was determined by one of the 
following three methods. The method used for each assay is specified in figure legends. 
 
Trypsinisation method 
Cells in all wells were trypsinised and counted using a hemocytometer or an automated cell counter 
(TC20™ automated cell counter, Bio-Rad Laboratories, Gladesville, NSW, Australia).  
Fluorescence microscopy method 
Cells in representative wells (three wells per experimental group) were stained with Hoechst 33342 
nuclear stain (NucBlue Live ReadyProbes Reagent, #R37605, Life Technologies Australia) and 
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fluorescence images were taken (one image per well) by a fluorescence microscope (Nikon Eclipse 
Ti microscope, Nikon Australia). Fiji (a distribution of ImageJ) software (Schindelin et al., 2012) was 
used to count the number of cells per image and determine the size of the area covered by each 
image, from which the number of cells per well was derived. Every well was observed under a light 
microscope to ensure that the cell confluency of all wells in a group was similar and that wells used 
for cell counting were representative of that group. The average of the number of cells from the three 




Cells in every well were stained with Hoechst 33342 nuclear stain. Fluorescence images of every 
well (16 images per well, covering the whole well surface area) were taken automatically by an 
ArrayScan XTI Live High Content Platform (ThermoFisher Scientific) and the number of cells per well 
determined using the HCS Studio Cell Analysis software. This enabled the normalisation of OCR 
and ECAR data from each individual well with the actual cell number of that well. Access to the 
ArrayScan was gained in September 2018, after which the number of cells per well in all Seahorse 
assays was determined by this method.  
  
2.3.3 Data analysis 
In the Cell Mito Stress Test, OCRs (pmol O2/min) and ECARs (mpH/min), in the basal state, and in 
response to the three compounds, are directly measured by the Seahorse analyser. Typical 
Seahorse Cell Mito Stress Test kinetic profiles for OCAR and ECARs are shown in figure 2.1. The 
three compounds added during the course of the Cell Mito Stress Test affect cellular metabolism, 
and consequently OCRs and ECARs.  
2.3.3.1 Oxygen consumption rates  
OCRs at the first three measurement points before the addition of the compounds are basal OCR 
(OCRbasal). Typically, the injection of the first compound oligomycin, which inhibits ATP synthase 
(complex V), results in a decrease in OCR (Fig. 2.1B). This decrease (the difference between the 
OCRbasal and the oligomycin-induced OCR (OCRoligo)) represents oxygen consumption that is 
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linked to ATP production (Fig. 2.1A, upper panel). The injection of the second compound FCCP, 
which uncouples oxygen consumption from ATP synthesis by transporting H+ across mitochondrial 
inner membrane into the matrix (Fig. 2.1B), results in a maximal increase in OCR which represents 
maximal respiration rate. The difference between the FCCP-induced OCR (OCRFCCP) and the 
OCRbasal is spare or reserve respiratory capacity (Fig. 2.1A, upper panel), and this describes the 
potential for the mitochondria in a particular cell to be brought to a theoretical maximum. Finally, the 
third injection comprising Rot/AA, which completely inhibit OXPHOS by inhibiting complexes I and 
III in the ETC respectively (Fig. 2.1B), leads to a drastic decrease in OCR. Remaining OCR are due 
to non-mitochondrial respiration (OCRnon-mito) (Fig. 2.1A, upper panel). The difference between the 
OCRbasal and the OCRnon-mito indicates basal mitochondrial respiration (OCRmito) (Fig. 2.1A, upper 
panel). The difference between the OCRFCCP and the OCRnon-mito indicates maximal respiration (Fig. 
2.1A, upper panel). Lastly, the difference between the OCRoligo and the OCRnon-mito indicates proton 
leak-linked respiration (Fig. 2.1A, upper panel) which is resulted from ATP synthase-independent 
proton leakage across the inner mitochondrial membrane (Divakaruni et al., 2014).  
 
2.3.3.2 Extracellular acidification rates  
ECARs at the first three measurement points before the addition of the compounds are basal ECARs 
(ECARbasal), representing extracellular acidification in the basal state. Oligomycin, which inhibits ATP 
synthase, leads to an increase in ECAR, indicating increased glycolytic activity to compensate for 
the loss of ATP production from the inhibition of OXPHOS. The difference between the ECARbasal 









Figure 2.1. Seahorse XF Cell Mito Stress Test. (A) A typical kinetic profile of oxygen consumption 
rates (OCRs), extracellular acidification rates (ECARs) and proton efflux rates (PERs) from a Cell 
Mito Stress Test, from which several metabolic parameters can be determined as illustrated. 
Numbers in red indicate measurement points. (B) A schematic diagram of inner mitochondrial 
membrane showing the targets in the electron transport chain (complexes I-V) of three compounds 
(oligomycin, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) and a mixture of 





2.3.3.3 Proton efflux rates  
ECARs (mpH/min) indicate changes in the pH level in the assay medium and can be converted to 
absolute changes in H+, or PERs (pmol H+/min), using the buffer factor (mM/pH) (see section 2.3.1). 
Changes in ECARs after the serial addition of 25 µL of 5 mM HCl or assay medium, performed as 
described above, were used to calculate the buffer factor, using the Seahorse XF Buffer Factor 
Calculator Excel Spreadsheet designed by the manufacturer. The calculated buffer factor was then 
input into the Wave software which automatically calculated and reported PER, based on the 
calculations as described by the manufacturer (Agilent Technologies user guide “Improving 
Quantification of Cellular Glycolytic Rate Using Agilent Seahorse XF Technology”, 2017). An 
example kinetic profile of PERs is shown is figure 2.1. In this thesis, not including optimisation 
experiments, nine independent Seahorse assays were performed: three assays of MC, MEF and 
HeLa cell metabolic characterisation (Chapter 4), three assays on rMC-1 cells with PKM2 knocked 
down (Chapter 5), and three assays on rMC-1 cells with PKM2 knocked out (Chapter 5). Buffer 
factors were determined in the same assay trays as two of the nine Seahorse assays, the rMC-1 
PKM2 KO Seahorse assay number 1 and the rMC-1 PKM2 KO Seahorse assay number 3, resulting 
in a buffer factor of 0.94 mM/pH and 0.84 mM/pH, respectively. Each value was used for data 
analysis of the corresponding Seahorse assays. The average of the two values (0.89) was used for 
data analysis of all other assays.  
 
2.3.3.4 Generation of kinetic graphs and calculation of metabolic parameters 
In Seahorse assays, each experimental group was performed in a number of technical replicate wells 
(numbers of replicate wells in each assay are indicated in figure legends). Due to occasional issues 
with incomplete drug injection by the analyser, loss of cells during washing, or bacterial 
contamination, individual wells that were outliers were excluded from analysis. Outliers were defined 
as individual wells that displayed an atypical profile in a group that displayed a uniform kinetic profile, 
wells that displayed OCRs or ECARs greater than five-fold different than the mean, wells with 
negative OCR or ECAR level at the basal state or after the oligomycin injection or after the FCCP 
injection, wells with obvious bacterial contamination, or wells that had major differences in cell 
confluency compared to the representative wells used for cell number determination (for the assays 
whose cell numbers were determined by the Fluorescence microscopy method).  
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In kinetic graphs of OCRs, ECARs and PERs shown in this thesis, data are presented as mean ± 
SD of each measurement point across replicate wells. Graphs were generated by GraphPad Prism 
Version 8.0.0, using OCR, ECAR and PER data exported from the Wave software result files. 
 
In addition to kinetic graphs, a number of metabolic parameters can be derived from OCR, ECAR 
and PER data in the basal state and/or in response to oligomycin, FCCP, Rot/AA, measured by the 
Seahorse analyser. Calculations of parameters pertinent to this thesis are listed below. These were 
performed based on manufacturer’s instructions for Seahorse Cell Mito Stress Tests as well as the 
work by Mookerjee and colleagues (Mookerjee et al., 2017, 2018). Parameter numbers 1-8 were 
calculated using RStudio and an R script written by Cameron Haydinger (Laboratory of Associate 
Professor Dan Peet, University of Adelaide, Adelaide, SA, Australia). Parameter numbers 9 and 10 
were calculated using Microsoft Excel. 
 
1. Basal OCR (OCRbasal) = the average of OCRs at measurement point 3 across all replicate 
wells 
 
2. Oligomycin-induced OCR (OCRoligo) = the lowest among the following three OCR values: 
• The average of OCRs at measurement point 4 across all replicate wells 
• The average of OCRs at measurement point 5 across all replicate wells 
• The average of OCRs at measurement point 6 across all replicate wells 
 
3. FCCP-induced OCR (OCRFCCP) = the highest among the following three OCR values: 
• The average of OCRs at measurement point 7 across all replicate wells 
• The average of OCRs at measurement point 8 across all replicate wells 
• The average of OCRs at measurement point 9 across all replicate wells 
 
4. Non-mitochondrial respiration (OCRnon-mito) = the lowest among the following three OCR 
values: 
• The average of OCRs at measurement point 10 across all replicate wells 
• The average of OCRs at measurement point 11 across all replicate wells 
• The average of OCRs at measurement point 12 across all replicate wells 
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5. Basal ECAR (ECARbasal) = the average of ECARs of all replicate wells at measurement 
point 3 
 
6. Oligomycin-induced ECAR (ECARoligo) = the highest among the following three ECARs 
values: 
• The average of ECARs at measurement point 4 across all replicate wells 
• The average of ECARs at measurement point 5 across all replicate wells 
• The average of ECARs at measurement point 6 across all replicate wells 
 
7. Glycolytic reserve = ECARoligo – ECARbasal 
 
8. Basal PER (PERbasal) = the average of PERs of all replicate wells at measurement point 3 
 
9. ECAR/OCR ratios = ECARbasal/OCRbasal 
 
10. Mitochondrial respiration (OCRmito) = OCRbasal – OCRnon-mito 
 
11. OCR coupled to ATP production (OCRcoupled)  
= (OCRbasal – OCRoligo)/hyperpolarization correction factor 
= (OCRbasal – OCRoligo)/0.908 
 
Directly calculating OCRcoupled from the difference between OCRbasal and OCRoligo measured 
by the Seahorse analyser results in a slight underestimation of OCRcoupled because the 
oligomycin-dependent hyperpolarization of the mitochondrial inner membrane induces a 
slight increase in OCRoligo (Mookerjee et al., 2017, 2018). This has to be corrected for and 
can be performed as previously described, using the hyperpolarization correction factor of 




2.3.3.5 Contribution of glycolysis and respiration to PER 
PERbasal is not only the result of PER that is due to the conversion of glucose to lactate via glycolysis 
(PERglyco) but also PER that is due to mitochondrial respiration (PERres). This is because CO2 
produced from OXPHOS can partially hydrate in the medium to produce H+ and bicarbonate Ion 
(HCO3-) (Mookerjee et al., 2015). 
 
PERres can be calculated from OCRmito calculated in section 2.3.3.4, using the equation and constant 
values shown below, as described previously (Mookerjee et al., 2015). PERglyco can then be 
calculated by subtracting PERres from PERbasal determined in section 2.3.3.4. All parameters 
described in this section were calculated using Microsoft Excel. 
 
PERres (pmol H+/min) = OCRmito x (Max H+/O2) x (10pH-pK1/(1+(10pH-pK1)) 
 
where max H+/O2  (the maximum amount of H+ released per O2 consumed by respiration) is 1 in the 
case of complete oxidation of glucose, pH of assay medium is presumed to be 7.4, K1 is the combined 
equilibrium constant of CO2 hydration and dissociation to HCO3- and H+, and pK1 at 37oC equals 
6.093 (Garrett and Grisham, 2010; Mookerjee et al., 2015).  
 
PERglyco = PERbasal - PERres 
 
2.3.3.6 Contribution of glycolysis and respiration to ATP production and glucose 
consumption rates 
Total ATP production rate (ATPRtotal) comprises ATPR that is derived from glycolysis (ATPRglyco) and 
from respiration (ATPRres). These parameters can be calculated from the parameters in sections 
2.3.3.4 and 2.3.3.5, as described extensively by Mookerjee and colleagues (Mookerjee et al., 2017, 
2018). The equations and values used for calculation when glucose is the sole substrate (Mookerjee 
et al., 2017), as is the case in this thesis, are briefly explained below. All the parameters described 
in this section were calculated using Microsoft Excel. 
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ATPRglyco (pmol ATP/min)  
=  (ATPR due to glycolysis converting glucose to pyruvate and then to lactate)  
+ (ATPR produced by glycolysis converting glucose to pyruvate that is 
 subsequently converted to HCO3-)      
=  (PERglyco x ATP/lactate) + (OCRmito x 2P/Oglyco)     
=  (PERglyco x 1) + (OCRmito x 2 x 0.167)   
ATP/lactate is the number of ATP molecules produced per one lactate molecule produced. P/Oglyco 
is a P/O ratio (ratio of ATP formed to oxygen atom consumed) caused by glycolysis-produced 
pyruvate that is then fully oxidised and converted to HCO3- (Mookerjee et al., 2017; Mookerjee et al., 
2015). When glucose is the substrate, ATP/lactate equals 1 and P/Oglyco equals 0.167 (Mookerjee et 
al., 2017). P/Oglyco is multiplied by 2 to account for the change from oxygen atom (O) in P/O to oxygen 
molecules (O2) in OCR (Mookerjee et al., 2017, 2018) measured from the Seahorse analyser. 
  
ATPRres (pmol ATP/min) 
=  (ATPR due to OXPHOS) + (ATPR due to substrate-level phosphorylation at 
 succinyl-CoA synthetase in the TCA cycle)   
=  (OCRcoupled x 2P/Ooxphos) + (OCRmito x 2P/OTCA)  
=  (OCRcoupled x 2 x 2.486) + (OCRmito x 2 x 0.121)      
P/Ooxphos and P/OTCA values used above are as previously described (Mookerjee et al., 2017). Both 
P/O ratios are multiplied by 2 to account for the change from O in P/O to O2 in OCR as above.  
   
 
ATPRtotal (pmol ATP/min) = ATPRglyco + ATPRres  
 
ATPRglyc (% of ATPRtotal)  = (ATPRglyc x 100)/ATPRtotal  
    
ATPRres (% of ATPRtotal)  = (ATPRres x 100)/ATPRtotal      
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In a similar fashion to ATPR, total glucose consumption rate (GCRtotal) is made up of GCR that is 
due to glycolysis (GCRglyco) and GCR that is due to respiration (GCRres). The conversion of one 
glucose molecule to two lactate anions indirectly releases 2H+, while the complete oxidation of one 
glucose molecule yields 6H+ (Divakaruni et al., 2014). Therefore, different GCR can be calculated as 
follows. 
      
GCRglyco (pmol/min)  = the amount of glucose converted to lactate 
 = PERglyc/2 
    
GCRres (pmol/min) = the amount of glucose oxidised to HCO3-  
 = PERres/6  
   
GCRtotal (pmol/min)  = GCRglyco + GCRres  
 
GCRglyco (% of GCRtotal)  = (GCRglyco x 100)/GCRtotal 
     
GCRres (% of GCRtotal)  = (GCRres x 100)/GCRtotal  
 
2.4 Protein techniques 
2.4.1 Whole cell extraction 
All cells used in this thesis were adherent cells from which proteins were extracted using the following 
protocol. Spent culture medium was aspirated from the culture vessel and cells washed with ice-cold 
1x PBS. Next, sufficient ice-cold whole cell extract whole cell extract buffer (20 mM HEPES pH 7.8, 
0.42 M NaCl, 0.5% Igepal, 25% glycerol, 0.2 mM EDTA, 1.5 mM MgCl2 with freshly added 1 mM 
DTT, 1 mM PMSF, 2 μg/mL aprotinin, 4 μg/mL bestatin, 5 μg/mL leupeptin, and 1 μg/ml pepstatin) to 
cover the culture vessel surface was added and the cells scraped and transferred into a 1.5 ml tube. 
Cells in whole cell extract buffer were incubated on a rotating shaker at 4oC for 30 minutes and 
centrifuged at 14,000 rpm for 30 minutes, after which the supernatant (protein lysate) was transferred 
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into a new 1.5 mL tube without disturbing the cell pellet. The lysate was then used for a protein 
quantification assay and western blotting or kept at -20oC until use.  
 
2.4.2 Tissue protein extraction 
Mouse liver and muscle tissues were gifts from Dr Daniel Pederick (Laboratory of Professor Paul 
Thomas, University of Adelaide and South Australian Health and Medical Research Institute, 
Adelaide, SA, Australia). Liver, muscle and retinal tissues from adult Sprague-Dawley rats were gifts 
from Teresa Mammone (Laboratory of Professor Robert Casson). Tissues were cut into small pieces 
and each piece weighed and placed in a 6 cm culture dish on ice. Ice-cold whole cell extract buffer 
was then added to the dish (approximately 1 mL of buffer per 100 mg of tissue). The tissue was 
minced with a surgical blade, transferred together with the buffer to a 1.5 mL tube, grinded with a 
tissue grinder, and incubated on a rotating shaker at 4oC for 30 minutes and centrifuged at 14,000 
rpm for 30 minutes, after which the supernatant (protein lysate) was transferred into a new 1.5 mL 
tube without disturbing the tissue pellet. The lysate was then used for a protein quantification assay 
and western blotting or kept at -20oC until use.  
 
2.4.3 Protein quantification 
Protein lysates were quantified by Bio-Rad protein assay (#5000006, Bio-Rad) performed in a clear 
96-well plate according to the manufacturer’s instructions with minor modifications. Protein standards 
of 1, 2, 3, 4 and 5 µg/well were created by adding 2, 4, 6, 8, and 10 µL of 0.5 µg/µL bovine serum 
albumin (BSA) in MQ water into wells, respectively. Next, samples were added to wells in duplicate. 
Volumes of samples added per well varied from 0.5 to 10 µL, depending on protein concentrations. 
200 µL of 1x Dye reagent was added to each well containing standards or samples and thoroughly 
mixed. The same amount was also added to a blank well (0 µg/well control). The plate was then 
incubated at room temperature for at least five minutes and optical densities at 620 nm (OD620) 
assessed. The results were used to plot a standard curve between different protein amounts (0, 1, 
2, 3, 4 and 5 µg/well) and their OD620 values. Protein amount (µg) per well of each sample was 
obtained by applying its OD620 to the standard curve. The protein amount (µg) and the sample 
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volume added (µL) per well were then used to calculate the protein concentration (µg/µL) of each 
sample. 
 
2.4.4 Denaturing SDS-PAGE for protein separation  
For each gel, equivalent amounts (µg protein) of each sample were used. Three parts of protein 
lysates were mixed with one part of 4x SDS loading buffer (0.5 M Tris pH 6.8, β-Mercaptoethanol, 
0.05 M Bromophenol blue, 10% SDS, 10% Glycerol). Lysate/buffer mixtures were incubated at 95oC 
for five minutes and centrifuged at 13,000 rpm at room temperature for five minutes. Sample mixtures 
and protein ladder for size determination (Precision Plus Protein Dual Colour Standards, #161-0374, 
Bio-Rad) were then loaded onto a mini 7.5% or 10% polyacrylamide gel and separated by 
electrophoresis at 120-160 V in 1x glycine/tris/SDS (GTS) buffer.  
 
2.4.5 Western blotting 
2.4.5.1 Protocol 
Proteins were transferred to nitrocellulose membranes either by a wet/tank blotting system (Bio-Rad) 
or a Trans-Blot Turbo Transfer System (Bio-Rad).  
 
The wet/tank transfer was performed in a tank filled with 1x wet transfer buffer at 250 mA for two 
hours at 4oC for one or two mini gels. 1x wet transfer buffer was made by mixing one part of 5x wet 
transfer buffer (58 g TRIS, 290 g glycine, 100 mL 10% SDS, make up to 2 L with MQ water), one 
part of methanol and three parts of RO water.  
 
Trans-Blot Turbo Transfer was performed according to the manufacturer’s instruction, using the 
protocol for 1.5 mm gels (for one mini gel: 1.3 A constant, up to 25 V, ten minutes).  
 
After the transfer, ponceau stain was applied onto the membranes, and the membranes were rinsed 
with RO water to remove excess stain and observe the proteins to determine whether the transfer 
was successful. Western blotting was then continued as described in Paper 4 (Kittipassorn et al., 
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2019a) in Chapter 3. Membranes were blocked with 10% (w/v) skimmed milk in PBS containing 0.1% 
nonionic detergent (TWEEN20, #P1379, Sigma-Aldrich, Castle Hill, NSW, Australia) for one hour on 
a shaker at room temperature and then incubated overnight at 4 °C on a nutator or a rotator with 
primary antibodies (Table 2.4, section 2.4.5.2) diluted in 2% skimmed milk in 0.1% TWEEN20/PBS. 
On the following day, membranes were washed with 0.1% TWEEN20/PBS, incubated in horseradish 
peroxidase-conjugated secondary antibodies for one hour on a shaker at room temperature, washed 
with 0.1% TWEEN20/PBS again, and protein bands visualised using enhanced chemiluminescence 
(ECL) reagents with a ChemiDoc Imaging system (Bio-Rad) and ImageLab software. ECL reagent 
used was either a home-made reagent (per membrane: 100 mM Tris pH 8.5 10 mL, 30% H2O2 3 µl, 
250 mM luminal 50 µl, 90 mM p-coumaric acid 25 µl), Clarity ECL substrate (#170-5060, Bio-Rad) 
or SuperSignal™ West Femto Maximum Sensitivity Substrate (#34095, Life Technologies Australia). 
Band intensity of proteins of interest was quantified using the ImageLab software. 
 
2.4.5.2 Antibodies and dilutions 
Table 2.4. Primary antibodies used in Chapters 4 and 5 of this thesis.  




PKM1 Rabbit CS 7067 1:500 
PKM1 Rabbit PT 15821-1-AP 1:500 
PKM1 Rabbit N NBP2-14833 1:500 
PKM2 Rabbit CS 3198S 1:500-1:1000 
Total PKM Rabbit CS 3190S 1:500-1:1000 
β-Actin Rabbit Abcam ab8227 1:2000 
α-tubulin rat N NB600-506 1:2000 
 
*Source: Abcam (Melbourne, VIC, Australia); CS, Cell Signaling Technology (Danvers, MA, USA); N, Novus 




Secondary antibodies (1:5000 to 1:10,000 dilutions) were horseradish peroxidase conjugated goat 
anti-rabbit IgG (Pierce and Life Technologies Australia) and horseradish peroxidase conjugated goat 
anti-rat IgG (Abcam).  
 
2.5 DNA techniques 
2.5.1 Primers 
All primer sequences are shown from 5’ to 3’. 
 




miR30 isothermal reverse primer for shRNA cloning 
AACAAGATAATTGCTCCTAAAGTAGCCCCTTGAATTCGATTCCGAGGCAGTAGGCA 
 
pENTR1a reverse sequencing primer 
GTGTCTCAAAATCTCTGATGTTAC 
 
gRNA U6 V1 sequencing primer  
GGTTTCGCCACCTCTGACTTG 
 
bgh PA F sequencing primer 
TGCATCGCATTGTCTGAGTAGG 
 









2.5.2.1 Plasmids obtained elsewhere 
pENTR1a-dnucTomato-miR30 
A Gateway Entry vector with the dimeric nuclear Tomato sequence, miR30-based shRNA cassettes 
and the kanamycin resistance gene (Bersten et al., 2015), a gift from Dr David Bersten (Laboratory 
of Professor Murray Whitelaw) 
 
pENTR1a-dnucTomato-miR30-shGL3 1309 
A pENTR1a-dnucTomato-miR30c with shRNA cassettes targeting luciferase (shGL3 1309) (Bersten 
et al., 2015), a gift from Veronica Bhakti (Laboratory of Professor Murray Whitelaw) 
 
pLV410 (empty)  
A lentiviral, mammalian expression, Gateway Destination vector with the ampicillin resistance gene 
(Bersten et al., 2015), a gift from Dr David Bersten (Laboratory of Professor Murray Whitelaw), 




Lentiviral plasmids used in this thesis include pCMV-dR8.2 dvpr (a second-generation lentiviral 
packaging vector), pRSV-Rev (a third-generation lentiviral packaging vector) and pMD2.G (a 
Vesicular Stomatitis Virus glycoprotein (VSV-G)-expressing envelope plasmid). All were gifts from 






A mammalian expression vector with the ampicillin resistance gene and a puromycin selection 
cassette, a gift from the Laboratory of Professor Murray Whitelaw) 
 
pDG458 
A dual-guide RNA (gRNA) Cas9 nuclease plasmid with a green fluorescence protein (GFP) selection 
cassette and the ampicillin resistance gene (Adikusuma et al., 2017), a gift from Chandran Pfitzner 
(Laboratory of Professor Paul Thomas). 
 
2.5.2.2 Plasmids cloned in this thesis 
pENTR1a-dnucTomato-miR30-shPKM2 1572, 1452, 1499 or 1501 
A pENTR1a-dnucTomato-miR30 (Bersten et al., 2015) with shRNA cassettes targeting mouse and 
rat Pkm2 mRNA. Four different plasmids were generated, each with either shPKM2 1572, 1452, 
1499 or 1501 (see section 2.6.1.1). 
 
pLV410-dnucTomato-miR30-shPKM2 1572, 1452, 1499 or 1501  
A pLV410 plasmid with miR30 based shRNA cassettes targeting mouse and rat Pkm2 mRNA. Four 




A pLV410 plasmid with miR30 based shRNA cassettes targeting luciferase (shGL3 1309) (see 
section 2.6.1.2). 
 
pDG458-gRNAs [A1+B1] and pDG458-gRNAs [A2+B2]  
A pDG458 dual-gRNA plasmid (Adikusuma et al., 2017) expressing a pair of gRNAs, one targeting 
the intron between exon 9 and exon 10 of the Pkm gene (gRNA A1 or B1) and the other the intron 
between exon 10 and exon 11 (gRNA A2 or B2). Two plasmids were generated, one expressing 
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gRNAs A1 and B1 (pDG458-gRNAs [A1+B1]), the other gRNAs A2 and B2 (pDG458-gRNAs 
[A2+B2]). The generation of these plasmids is described in section 2.7.1. 
 
2.5.3 Bacterial transformation  
2.5.3.1 Bacterial strains 
Two different E. coli bacterial strains were used: DH5α chemically competent cells for cloning 
experiments and preparation of most plasmids, and DB3.1 chemically competent cells, containing a 
DNA gyrase mutant, used specifically for preparation of empty Gateway cloning destination vectors 
expressing the ccdB gene. The ccdB gene encodes the CcdB protein which is toxic to and would 
inhibit the propagation of DH5α cells.  
 
2.5.3.2 Transformation protocol 
E.coli chemically competent cells were taken out of -80oC storage and thawed on ice. For general 
plasmid preparations, a short transformation protocol was employed. Plasmid DNA (30-100 ng) was 
added to 30-50 µL of competent cells and the mixture incubated on ice for 20 minutes. Next, the 
mixture was incubated (heat shocked) at 42oC for 30 seconds, incubated on ice for a further two 
minutes and plated on a luria broth (LB) agar plate containing appropriate selection antibiotic (100 
µg/mL ampicillin or 50 µg/mL kanamycin).  
 
For ligation, isothermal assembly or gateway reactions, long transformation was performed using the 
same protocol as the short transformation with additional steps before plating. After the two-minute 
incubation on ice, 250 µL Super Optimal broth with Catabolite repression (SOC) medium was added 
to the DNA/competent cells mixture. The mixture was then incubated at 37oC on a shaker for 1-2 
hours and centrifuged at 2400 rpm for 2-3 minutes at room temperature. Next, 200 µL of the 
supernatant was aspirated without disturbing the cell pellet, and the cell pellet was gently 
resuspended in the rest of the supernatant and plated on a LB agar plate containing appropriate 
selection antibiotic. Plates were incubated at 37oC overnight and used to inoculate LB cultures for 




2.5.4 DNA plasmid preparation 
2.5.4.1 Plasmid miniprep 
Five millilitre LB cultures containing a suitable selection antibiotic (final concentrations of 100 µg/mL 
for ampicillin or 50 µg/mL for kanamycin) were inoculated with single colonies picked from 
transformation plates and grown on a shaker at 37oC overnight. Plasmid DNA was purified using a 
QIAprep Spin Miniprep Kit (#27106, Qiagen, Chadstone Centre, VIC, Australia) as per the 
manufacturer’s instructions. Purified DNA concentration was determined by a Nanodrop 
spectrophotometer (Life Technologies) based on the absorbance at 260 nm (A260). Expected 
A260/280 ratio for pure DNA is ~ 1.8. DNA samples were stored at -20oC. 
 
2.5.4.2 Plasmid midiprep 
100-200 mL LB cultures containing a suitable selection antibiotic (final concentrations of 100 µg/mL 
for ampicillin or 50 µg/mL for kanamycin) were inoculated with single colonies picked from 
transformation plates and grown on a shaker at 37oC overnight. Plasmid DNA was purified using a 
NucleoBond Xtra Midi Plus Kit (#740412.50, Macherey Nagel, Düren, Germany) as per the 
manufacturer’s instructions. DNA concentrations were determined by the same method as DNA 
purified from a miniprep kit in section 2.5.4.1. 
 
2.5.5 Restriction digestion 
Digestion reactions for desired restriction enzymes were set up as recommended by New England 
Biolabs (NEB; Ipswich, MA, USA), using 500-2000 µg DNA, 1x NEB buffer, 100 ng/µL BSA (optional 
for some reactions) and 0.2-0.5 µL enzyme per reaction. Reactions were incubated at 37oC and 
analysed on agarose gels. All enzymes used were obtained from NEB. 
 
2.5.6 Gibson’s isothermal assembly and PCR 
Gibson’s isothermal assembly (Gibson et al., 2009) was used to assemble inserts containing shRNA 
sequences and digested vectors with overlapping ends (see also section 2.6.1.1). Products to be 
used as inserts were amplified using Phusion DNA polymerase. PCR primer design was carried out 
as described previously (Gibson et al., 2009) to generate PCR-amplified inserts which contained 40 
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bp of overlapping sequence to the ends of digested vectors. Primers were designed by Dr David 
Bersten (Laboratory of Professor Murray Whitelaw, University of Adelaide, Adelaide, SA, Australia). 
Each PCR reaction was set up as follows: 0.5 µL Phusion DNA polymerase (NEB), 5 µL 5x Phusion 
GC buffer (NEB), 1 µL 10 mM dNTPs, 1 µL 50 mM MgCl2, 1 µL 10 µM forward primer, 1 µL 10 µM 
reverse primer, 100 ng DNA template, and MQ water to a total volume of 25 µL. PCR reactions then 
underwent the following cycling parameters: 98°C for 30 seconds; 35 cycles of 98°C for 10 seconds, 
60°C for 30 seconds, 72°C for 60 seconds; 72°C for 5 minutes; hold at 4°C. 
 
Gibson’s isothermal assembly was carried out as described previously (Gibson et al., 2009), using 
Gibson’s isothermal assembly mix (NEB), containing ligase, polymerase and exonuclease. 
 
2.5.7 Gateway recombination 
Each reaction contained 2 µL LR clonase II enzyme mix (#P/N 56484, Life Technologies Australia), 
1 µL of 300 ng/µL entry vector, 1 µL 150 ng/µL destination vector and 6 µL TE (Tris/EDTA) buffer. 
Reactions were incubated at room temperature for one hour, 2 µL of 2 µg/µL Proteinase K added 
per reaction, further incubated at 37oC for ten minutes, and used for long transformation.  
 
2.5.8 Genomic DNA extraction and PCR 
Genomic DNA (gDNA) and PCR were used to screen PKM2 KO cells (see section 2.7.3). Cells were 
trypsinised and cell suspension centrifuged. Cell pellet was washed with 1x PBS and gDNA extracted 
using a MyTaq Extract-PCR kit (#21126, Bioline Australia, Alexandria, NSW, Australia) according to 
the manufacturer’s instructions. DNA concentration was determined by a Nanodrop 
spectrophotometer based on the absorbance at 260 nm (A260). gDNA was PCR amplified using Taq 
DNA polymerase. Each PCR reaction was set up as follows: 0.25 µL Taq DNA polymerase (NEB), 
5 µL 10x standard Taq buffer (NEB), 1 µL 10 mM dNTPs, 1 µL 10 µM forward primer, 1 µL 10 µM 
reverse primer, 0.5-2 µL gDNA template, 2.5 µL 100% DMSO, and MQ water to a total volume of 50 
µL. PCR reactions then underwent the following cycling parameters: 95°C for 30 seconds; 30 cycles 




2.5.9 DNA analysis on agarose gel 
DNA samples (plasmids, restriction digests, PCR products) and ladder for size determination (1 Kb 
Plus DNA Ladder, #10787-026, Life Technologies Australia) were separated on 1-2% agarose gels 
(depending on expected DNA fragment sizes) by electrophoresis and visualised by in-gel ethidium 
bromide on a UV transilluminator (UVP). Gels were made by dissolving agarose powder in 1x Tris-
Borate-EDTA (TBE) buffer and ethidium bromide added (1 µL per 20 mL 1x TBE buffer). 
 
2.5.10 Gel extraction and purification of DNA fragments 
DNA fragments of interest were excised from the gel using a scalpel blade and purified using a 
QIAquick Gel Extraction Kit (#28706, Qiagen) according to the manufacturer’s protocol. 
 
2.5.11 DNA clean up 
DNA clean up was performed using a QIAquick PCR purification kit (#28106, Qiagen) as per the 
manufacturer’s instruction. 
 
2.5.12 DNA sequencing 
DNA samples were sequenced by Sanger sequencing. Samples were prepared and submitted to the 
Australian Genomics Research Facility (AGRF, Adelaide, SA, Australia) for analysis, either as 
labelled DNA in dried down pellet form or purified DNA.  
 
Labelled DNA in dried down pellet form 
Each sequencing reaction was set up as follows: 1 µL Big Dye Terminator, 3 μl 5x sequencing buffer, 
0.5 µL primer, 400 ng DNA (double stranded plasmids) and MQ water to a total volume of 15 μl. For 
sequencing of pENTR1a plasmids, 1 µL of 15 µM dGTP was also added per reaction. Samples 
underwent the following cycling parameters: 96°C for three minutes and 25 cycles of 96°C for 30 
seconds, 50°C for 15 seconds and 60°C for four minutes. Samples were then cleaned of any free 
bases and precipitated by the following protocol. Each reaction was mixed with 80 µL 75% 
isopropanol and 1 µL glycogen, incubated at room temperature for 30 minutes and centrifuged at 
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13,000 rpm at room temperature for 20 minutes. The supernatant was then removed without 
disturbing the DNA pellet. The pellet was washed with 150 µL 75% isopropanol, air dried at 50 oC 
for approximately ten minutes and submitted to AGRF for analysis. 
 
Purified DNA  
Purified DNA samples were prepared as per AGRF Sample Preparation Guide. Each sample was 
mixed with 1 µL of 10 µM sequencing primer and MQ added to the total volume of 12 µL. Samples 
were submitted to AGRF for Sanger sequencing. Amounts of DNA samples used depended on 
sample type: 600-1500 ng for double stranded plasmids, 70-105 ng for PCR products longer than 
800 bp, 30 ng for 400-600 bp PCR products, and 18 ng for 200-400 bp PCR products.  
  
2.6 Generation and analysis of lentiviral-based shRNA-mediated PKM2 knockdown 
Müller cells 
The miR30 based shRNA system as described previously (Bersten et al., 2015) was employed to 
knock down PKM2 in rat MCs. The system was adapted from that of Dow and colleagues (Dow et 
al., 2012). Firstly, four shRNAs targeting Pkm2 mRNA (shPKM2s) were designed and each cloned 
into a pENTR1a-dnucTomato-miR30 plasmid (Bersten et al., 2015), using Gibson’s isothermal 
assembly, to generate four pENTR1a-dnucTomato-miR30-shPKM2 plasmids. Secondly, the 
dnucTomato-miR30-shPKM2 DNA fragment from each of the four pENTR1a-dnucTomato-miR30-
shPKM2 plasmids was transferred into an empty pLV410 vector (Bersten et al., 2015) by Gateway 
recombination to generate lentiviral mammalian expression pLV410-dnucTomato-miR30-shPKM2 
plasmids, which were introduced into MCs via lentiviral transduction. 
 
2.6.1 Generation of Pkm2-targeting short hairpin RNA constructs 
2.6.1.1 Generation of pENTR1a-dnucTomato-miR30-shPKM2 plasmids  
Four different 22 nucleotide shRNAs targeting Pkm2 mRNA (shPKM2s) (Fig. 2.2A) were originally 
designed against the exclusive exon 10 of mouse Pkm2 mRNA by Stephen Bent (University of 
Adelaide, Adelaide, SA, Australia) using an algorithm as described (Bersten et al., 2015). When 





Figure 2.2. Short hairpin RNAs (shRNAs) targeting exon 10 of Pkm2 mRNA (shPKM2s). (A) Sequences 
of four shPKM2s designed to target exon 10 of mouse Pkm2 mRNA. *Base, the number of the base in the 
mouse Pkm2 mRNA (NCBI Reference Sequence: NM_011099.3) to which the first base on the 3’ end of each 
shPKM2 matches. (B) The nucleotide sequence (the sense strand) of the mouse Pkm2 exon 10 (bases 1436 
to 1602 of mouse Pkm2 mRNA, NCBI Reference Sequence: NM_011099.3) is aligned with the rat Pkm2 exon 
10 (sequence taken from pyruvate kinase M1 and M2 subunit genes, complete coding sequence, GenBank: 
M24359.1), using the NCBI BLAST services. Exon 10 of both the mouse and the rat Pkm2 is 167 bp long. A 
mismatch between the mouse and the rat exon 10 is highlighted in yellow. Positions on exon 10 to which 




the nucleotides targeted by the four shPKM2s. In other words, all nucleotides to which the four 
shPKM2s target are conserved between the two species (Fig. 2.2B), enabling these shPKM2 to 
knock down rat PKM2.  
 
Cloning of shPKM2 into the pENTR1a-dnucTomato-miR30 plasmids was performed as described 
previously (Bersten et al., 2015). The pENTR1a-dnucTomato-miR30 vectors were XhoI/EcoRV-
digested and gel-purified (performed by Dr Jacqueline Fabrizio, Laboratory of Associate Professor 
Dan Peet). Single-stranded 97mer template shRNA oligonucleotides (Ultramer DNA Oligos from 
Integrated DNA Technologies (IDT), Coralville, IA, USA) (table 2.5), each consisting of miR30 context 
flanking each of the 22 nucleotide shPKM2 guide sequences, were amplified using miR30 isothermal 
forward and reverse primers (see section 2.5.1), to generate double-stranded ~190 bp PCR products 
with overlapping sequence to the XhoI/EcoRV-digested pENTR1a-dnucTomato-miR30 plasmids. 
PCR reactions were performed as described in section 2.5.6. Half of the reactions was analysed on 
a 2% agarose gel. If the expected bands were present, the remainder of the PCR reactions were 
cleaned up according to the standard protocol. The PCR products of all shPKM2s were digested by 
XhoI and EcoRV, gel-purified, pooled together (multiplex cloning), mixed with the XhoI/EcoRV-
digested gel-purified pENTR1a-dnucTomato-miR30 vectors and underwent Gibson’s isothermal 
assembly as previously described (Gibson et al., 2009). Assembly reactions were transformed into 
DH5α cells using the long transformation protocol and plates incubated overnight. Single colonies 
were picked, grown in LB overnight, DNA purified (minipreps) and checked with EcoRI restriction 
digestion. Different shPKM2 clones were confirmed by Sanger sequencing using the pENTR1a 





Table 2.5. Single-stranded 97mer template shRNA oligonucleotides  













* commercially sourced from Integrated DNA Technologies (IDT) 
 
2.6.1.2 Generation of pLV410-dnucTomato-miR30-shRNA plasmids  
pLV410-dnucTomato-miR30-shPKM2 plasmids were generated by Gateway recombination (see 
section 2.5.7) to transfer the dnucTomato-miR30-shPKM2 DNA fragment from each of the four 
pENTR1a-dnucTomato-miR30-shPKM2 plasmids into an empty pLV410 vector (Bersten et al., 
2015). Similarly, a pLV410-dnucTomato-miR30-shGL3 plasmid, to be used as a non-targeting 
shRNA control, was generated by Gateway recombination to transfer the dnucTomato-miR30-shGL3 
1309 DNA fragment from the pENTR1a-dnucTomato-miR30-shGL3 1309 plasmid into an empty 
pLV410 vector (Bersten et al., 2015). In the remainder of this thesis the shGL3 is referred to as the 
shControl. Gateway reactions were transformed into DH5α cells using the long transformation 
protocol and plates incubated overnight. Single colonies were picked and grown overnight in LB, and 
plasmids were purified (minipreps) and analysed by FspI restriction digestion. 
 
2.6.2 Lentiviral production 
Firstly, 3 x 106 HEK 293FT cells were seeded in a T75 flask. On the following day, cells were 
transfected with 12.5 µg of one of the five pLV410-dnucTomato-miR30-shRNA plasmids (shPKM2 
1572, 1452, 1499, 1501 or shControl), 7.5 µg pCMV-dvpr 8.2, 6.25 µg pRSV-Rev and 3.75 µg 
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pMD2.G using lipofectamine 2000 (#11668019, Life Technologies Australia). This was performed by 
combining the required plasmids and 70 µL of lipofectamine 2000 in 1 mL culture medium without 
FBS, incubating at room temperature for 20 minutes and adding to the cells. The cells were left for 
one day before the culture medium was removed, the cells washed and fresh medium added. Then 
the cells were left for a further two days and the medium containing lentivirus was harvested, 
centrifuged at 1000 rpm for ten minutes and filtered through a 0.45 µm filter. The lentivirus was used 
for transduction experiments or stored at -80oC until use. 
 
2.6.3 Lentiviral transduction and determination of transduction efficiency 
Primary MCs or rMC-1 cells were seeded into a culture vessel. Approximately 3-4 hours after 
seeding, lentivirus encoding either one of the five pLV410-dnucTomato-miR30-shRNA plasmids 
(shPKM2 1572, 1452, 1499, 1501 or shControl) was added to the cells with polybrene (8 µg/mL final 
concentration). Cell seeding density, type of culture vessel and amount of lentivirus used in each 
experiment are specified in figure legends. Approximately 24 hours later, the cells were washed and 
fresh medium added. Cells were left for approximately 24 or 48 hours (specified in figure legends) 
and then stained with Hoechst 33342 nuclear stain. Fluorescence images were taken with a 
fluorescence microscope (Nikon Eclipse Ti microscope, Nikon Australia), and transduction efficiency 
determined from proportions of transduced cells expressing nuclear Tomato fluorescence to total cell 
numbers indicated by nuclear staining. Cells in each image were counted using the Fiji software 
(Schindelin et al., 2012). 
 
2.6.4 Fluorescence activated cell sorting (FACS) 
Primary MCs were subjected to FACS to enrich for transduced cells. Cells were seeded in a 6-well 
tray (160,000 cells per well) and transduced with lentivirus encoding either one of three pLV410-
dnucTomato-miR30-shRNA plasmids (shPKM2 1572, shPKM2 1452 or shControl). Approximately 
24 hours after transduction, cells were washed and fresh growth medium added. Approximately 48 
hours after transduction, cells were trypsinised, centrifuged and resuspended in sorting buffer (1x 
Hank's Balanced Salt Solution (HBSS), 1 mM EDTA, 25 mM HEPES pH 7.0, 2% FBS). Cells were 
then submitted to and FACS carried out at the Detmold facility (SA Pathology, Adelaide, SA, 
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Australia.). FACS was performed using a Beckman Coulter MoFlo Astrios EQ High Speed Cell Sorter 
running Summit Software version 6.2.4.15830 (Beckman Coulter, Miami, FL, USA) to select cells 
based on Tomato fluorescence protein expression. The cytometer was enclosed within Baker 
SterilGuard BSL Class II Biosafety cabinet (The Baker Company, Sanford, Maine, USA). Sorted cells 
were collected in MEM containing 20% FBS, 25 mM glucose and 2 mM L-glutamine. 
 
2.6.5 Lentiviral-based shRNA-mediated PKM2 knockdown  
rMC-1 cells were seeded and transduced with lentivirus encoding either one of the five pLV410-
dnucTomato-miR30-shRNA plasmids (shPKM2 1572, 1452, 1499, 1501 or shControl) as described 
in section 2.6.3. Cell seeding density, type of culture vessel and amount of lentivirus used in each 
experiment are specified in figure legends. Approximately 48-72 hours (specified in figure legends) 
after transduction, cells were washed and proteins extracted, quantified and analysed by western 
blotting to determine PKM2 and total PKM protein levels. 
 
2.6.6 Metabolic analysis of PKM2 knockdown rMC-1 cells  
rMC-1 cells (3759 cells per well) were seeded in MEM containing 10% FBS, 5.5 mM glucose and 2 
mM L-glutamine (80 µL per well) in a Seahorse 96-well cell culture plate (pre-coated with 0.2% gelatin 
in PBS). The cell plate was allowed to rest at room temperature for 45-60 minutes to promote even 
cell distribution (Lundholt et al., 2003) before being moved to a humidified, 37oC incubator with 5% 
CO2. Approximately 3-4 hours after seeding, cells were transduced with lentivirus encoding either 
one of four pLV410-dnucTomato-miR30-shRNA plasmids (shPKM2 1572, 1452, 1499 or shControl) 
(generated as described in section 2.6.1.2). One day after transduction, cells were washed and fresh 
medium added. Three days after transduction, cells were subjected to lactate and Seahorse assays 
as described in sections 2.2 and 2.3. In each experiment, unless otherwise stated, after the Seahorse 
assay was performed and cell numbers determined, proteins were extracted and analysed by 




2.7 Generation and analysis of CRISPR/Cas9-mediated PKM2 knockout Müller cells 
In order to knock out PKM2 but not PKM1 in MCs, the PKM2-exclusive exon 10 in the Pkm gene 
was targeted using CRISPR/Cas9 technology.  
 
2.7.1 Generation of pDG458 Cas9 nuclease plasmids containing Pkm-targeting guide RNAs 
The strategy to remove exon 10 was to use a pair of guide gRNAs, one targeting the intron between 
exon 9 and exon 10 of the Pkm gene (designated as gRNA [A]) and the other the intron between 
exon 10 and exon 11 (designated as gRNA [B]) (Fig. 2.3). Two different pairs of gRNAs (Table 2.6) 
were used to control for non-specific off-target effects and were designed to target NGG protospacer 
adjacent motif (PAM) sites using an online CRISPR design tool (http://crispr.mit.edu/) with the target 
rat Pkm sequence from the National Center for Biotechnology Information website (NCBI Reference 
Sequence: NC_005107.4). Forward and reverse oligonucleotides for each of the four gRNAs with 
appropriate overhanging ends were designed (Table 2.7), phosphorylated and annealed as 
described previously (Adikusuma et al., 2017). The annealed gRNA A1 oligonucleotides were paired 
with the annealed gRNA B1 oligonucleotides and both ligated into empty pDG458 Cas9 plasmids, 
which are capable of harbouring two gRNAs, using one step cloning as described previously 
(Adikusuma et al., 2017) to generate the pDG458-gRNAs [A1+B1] plasmids. Similarly, the annealed 
gRNA A2 oligonucleotides were paired with the annealed gRNA B2 oligonucleotides and both ligated 
into empty pDG458 Cas9 plasmids to generate the pDG458-gRNAs [A2+B2] plasmids. Ligation 
reactions were transformed into DH5α using the long transformation protocol and plates incubated 
overnight. Single colonies were picked and grown overnight in LB, and plasmids (minipreps) 
analysed by BbSI/EcoRI restriction digestion. Positive clones were verified by Sanger sequencing 





Figure 2.3. The strategy to generate and screen PKM2 knockout (KO) rMC-1 cell lines. (A) Schematic 
diagram illustrating the strategy used to generate PKM2 knockout cells by removing exon (E) 10 from the Pkm 
gene, using CRISPR/Cas9 technology. E10 was removed using a dual-guide RNA expressing Cas9 nuclease 
plasmid (Adikusuma et al., 2017) containing a pair of guide RNAs (gRNAs), one targeting the intron between 
E9 and E10 (gRNA [A]), the other targeting the intron between E10 and E11 (gRNA [B]). (B) Two gRNAs (gRNAs 
A1 and A2) were designed to target the intron between E9 and E10, and another two gRNAs (gRNAs B1 and 
B2) were designed to target the intron between E10 and E11. gRNA A1 was paired with B1 to generate a KO I 
cell population (indicated by blue arrows and text). gRNA A2 was paired with B2 to generate a KO II cell 
population (indicated by green arrows and text). Forward (F) and reverse (R) primers flanking the sites on the 
Pkm gene targeted by the gRNAs were designed to screen for a successful removal of E10. Positions of the 
start of E9 and the end of E11 on chromosome (chr) 8 and the length of each exon are illustrated. Black lines 





Table 2.6. Guide RNA (gRNA) sequences targeting the flanking introns of exon 10 in the Pkm gene 
and NGG protospacer adjacent motif (PAM) sites 
Target area gRNA Target strand on the Pkm gene Sequence (5’ to 3’) PAM 
Intron between 
exons 9 and 10 
A1 sense CAGCCAAGGAGGTCACGATA GGG 
A2 anti-sense GTACCCACTAGGGAATCCTT TGG 
Intron between 
exons 10 and 11 
B1 anti-sense GCCACCTAATCTGGTGTACC TGG 
B2 anti-sense CACCTCTTCTGCCCGAATGC TGG 
 
 
Table 2.7. Forward and reverse oligonucleotides containing the guide RNA (gRNA) sequences 
targeting the Pkm gene with appropriate overhangs for cloning into pDG458 Cas9 plasmids 


















2.7.2 Generation of rMC-1 Müller cells with PKM2 knocked out 
rMC-1 cells in ~80% confluent T75 flasks were co-transfected with the following: 
1) 15 µg of pEF-IRES-Puro6 plasmids (a mammalian expression vector that constitutively 
expresses a puromycin resistance gene)  
2) 15 µg of either one of three Cas9 nuclease plasmids: 
• empty pDG458 without gRNAs targeting the rat Pkm gene, to generate wildtype (WT) 
control cells 
• pDG458-gRNAs [A1+B1]  
pDG458 containing the first pair of gRNAs (A1 and B1) to generate PKM2 KO (KO) I 
cells 
• pDG458-gRNAs [A2+B2]  
pDG458 containing the second pair of gRNAs (A2 and B2) to generate PKM2 KO II 
cells 
These plasmids were mixed with 800 µL MEM without FBS and 90 µL Polyethylenimine (PEI) 
(#23966-1, Polysciences, Warrington, PA, USA), incubated at room temperature for 15 minutes and 
added to the flasks. Approximately 48 hours after transfection, culture medium was changed to 
medium containing 2 µg/mL puromycin to select for transfected cells. After a further 48 hours, 
puromycin was removed and cells left to recover.  
 
2.7.3 Screening of rMC-1 Müller cells with PKM2 knocked out 
After the cells recovered following puromycin selection, they were propagated and gDNA extracted 
(~10 days after transfection) for KO screening by PCR (see section 2.5.8) using PKM2 KO screening 
forward and reverse primers which flank the targeted sites on the Pkm gene (Fig. 2.3). PCR products 
were analysed on 1% agarose gels.  
 
2.7.4 Monoclonal isolation and screening 
Monoclonal isolation of the WT, the PKM2 KO I and the PKM2 KO II cells was performed by limiting 
dilution. Cells were seeded in 96-well trays at a final concentration of 0.5 cells per well. When the 
cells reached confluency (approximately 2 weeks), they were propagated, and gDNA extracted for 
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PCR screening as in section 2.7.3. PCR products were gel-purified and analysed by Sanger 
sequencing using the PKM2 KO screening reverse primer. Proteins were extracted for analysis by 
western blotting to determine PKM2 and total PKM levels.  
 
2.7.5 Metabolic analysis of monoclonal PKM2 knockout rMC-1 cell lines  
One monoclonal line was chosen, based on the screening results, for each of the WT, the PKM2 KO 
I and the PKM2 KO II cells, for lactate and Seahorse assays as described in sections 2.2 and 2.3. 
Cells were seeded at 15,000 cells per well the day before Seahorse assays. 
 
2.8 Data presentation and statistical analysis 
Graphs were generated and statistically significant differences between experimental groups were 
determined using GraphPad Prism Version 8.0.0 software by either unpaired two-tailed student’s t-
tests (comparing between two experimental groups) or one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparison test (comparing between more than two experimental 
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CHAPTER 3:  Characterisation of the novel spontaneously immortalised rat Müller 
cell line SIRMu-1 
3.1 Introduction 
MCs are a crucial and major type of glial cell in the retina, where they provide structural and functional 
support for retinal neurons (reviewed in (Bringmann et al., 2006) (Fig. 1.5). During the course of the 
current study where primary MCs were being utilised for metabolic analyses, a population of 
spontaneously immortalised cells arose from a batch of rat mixed retinal cultures, from which primary 
MC cultures were usually derived. A monoclonal cell line was isolated from these spontaneously 
immortalised cells, named the SIRMu-1 (Spontaneously Immortalised Rat Muller) cell line and 
characterised using western blotting, immunofluorescence, RNA-seq and transfection experiments. 
It was hypothesised that the SIRMu-1 cell line originated from primary MCs and the results were 
consistent with the hypothesis (see Paper 4 (Kittipassorn et al., 2019a) in section 3.3.1). These novel 
SIRMu-1 cells were compared directly to the primary MCs and the SV40-transformed rMC-1 cell line 
(Sarthy et al., 1998).  
 
The work has been published in two publications in peer-review journals. The establishment and 
characterisation of the SIRMu-1 cell line were published in Paper 4 (Kittipassorn et al., 2019a) and 
additional information on RNA-seq data and methodology was published in Paper 5 (Kittipassorn et 
al., 2019b). The SIRMu-1 cell line has been deposited to CellBank Australia and is now available for 
distribution to researchers worldwide (http://www.cellbankaustralia.com/sirmu-1.html). The entire 
RNA-seq dataset has been deposited into NCBI Gene Expression Omnibus (Edgar et al., 2002) and 
is accessible through GEO ID: GSE123161  
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123161). 
 
3.2 Chapter aims 
This chapter addresses Aim 1 of the thesis: to establish and characterise a novel spontaneously 





Detailed introduction, experimental approach, materials and methods, results and discussion are 
presented in the following publications. 
 
3.3.1 Paper 4: Characterization of the novel spontaneously immortalized rat Müller cell line 
SIRMu-1 
Kittipassorn, T., Haydinger, C.D., Wood, J.P.M., Mammone, T., Casson, R.J., and Peet, D.J. (2019a). 
Characterization of the novel spontaneously immortalized rat Muller cell line SIRMu-1. Experimental 






















































Supplementary Fig. S1. Differentially expressed genes in SIRMu-1 and rMC-1 cells, compared to primary (1°) 
MCs. (A) Venn diagram displaying the number of significantly differentially expressed genes at a fold-change 
of greater than 5 in each immortalized cell line compared to 1° MCs. (B) Gene ontology (GO) analysis of RNA-
seq data. Bar graph showing significantly overrepresented (FDR < 0.05) PANTHER GO-Slim Biological Process 
terms among genes differentially expressed in rMC-1 cells relative to primary MCs, compared to the background 
R. norvegicus genome. 
 




3.3.2 Paper 5: RNA sequencing data of cultured primary rat Müller cells, the spontaneously 
immortalized rat Müller cell line, SIRMu-1, and the SV40-transformed rat Müller cell 
line, rMC-1. 
Kittipassorn, T., Haydinger, C.D., Wood, J.P.M., Mammone, T., Casson, R.J., and Peet, D.J. (2019b). 
RNA sequencing data of cultured primary rat Müller cells, the spontaneously immortalized rat Müller 
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CHAPTER 4:  Metabolic characterisation of retinal Müller cells 
4.1 Introduction 
Studies have suggested that the retina displays a preference for undertaking glycolytic metabolism 
even in the presence of an adequate supply of oxygen; this is synonymous with the Warburg effect, 
an unusual form of glucose metabolism (reviewed in Paper 1 (Ng et al., 2015) (Appendix 7.1)) (Cohen 
and Noell, 1960; Tornquist and Alm, 1979; Warburg, 1925; Warburg et al., 1924; Warburg et al., 
1930; Winkler, 1981, 1995). The Warburg effect is commonly found in cancer and other highly 
proliferating cells (Abdel-Haleem et al., 2017; Hsu and Sabatini, 2008; Koppenol et al., 2011; 
Palsson-McDermott and O'Neill, 2013; Rodriguez-Prados et al., 2010; Vander Heiden et al., 2009; 
Warburg, 1956; Warburg et al., 1927), but has also been observed in freshly-isolated guinea pig MCs 
(Poitry-Yamate et al., 1995), cultured primary human MCs (Winkler et al., 2000), and immortalised 
rMC-1 cells (Winkler et al., 2003).  
 
An initial aim of this chapter was to investigate whether cultured primary rat MCs also display the 
Warburg effect similarly to species described above. This investigation included comparison of 
whether the SV40-transformed rMC-1 line (Sarthy et al., 1998) and the novel spontaneously 
immortalised SIRMu-1 line identified and characterised in Chapter 3 (Kittipassorn et al., 2019a) 
display similar glucose metabolism to primary MCs.  
 
Key parameters of glucose metabolism include oxygen consumption or carbon dioxide production 
as indicators of OXPHOS, and lactate production or extracellular acidification as commonly-used 
indicators of glycolytic flux. In the current literature, the Warburg effect is often defined as upregulated 
aerobic glycolysis (Koppenol et al., 2011; Potter et al., 2016; Vander Heiden et al., 2009) but it is 
variable as to what constitutes “upregulation”, i.e. upregulated to what extent. Therefore, in the 
context of this thesis, the Warburg effect is defined as when cells primarily depend on glycolysis 
rather than OXPHOS for ATP production, and hence undergo a high rate of glycolysis, including high 




To investigate whether a cell type displays the Warburg effect, oxygen consumption, extracellular 
acidification and lactate production need to be determined. Firstly, the techniques required for the 
measurement of these parameters were developed and optimised as they had not previously been 
utilised in our laboratory. Secondly, the techniques were used to analyse metabolism of glucose in 
MCs.  
 
4.2 Chapter aims 
This chapter addresses Aim 2 of the thesis: to determine whether cultured rat MCs display the 
Warburg effect, with specific aims as follows: 
 Aim 2.1:  To develop and optimise techniques for metabolic analysis 
 Aim 2.2:  To characterise metabolism of glucose in cultured primary rat MCs  
 Aim 2.3:  To characterise metabolism of glucose in the SV40-transformed rat MC line rMC-1 
and the spontaneously immortalised rat MC line SIRMu-1 compared to primary MCs 
 
4.3 Experimental approach and overview 
To develop techniques to analyse cellular metabolism of glucose, the highly specialised Seahorse 
XF extracellular flux analyser (Agilent Technologies) with Seahorse Cell Mito Stress Test assays to 
measure oxygen consumption and extracellular acidification were employed and optimised. After 
successful optimisation, the Seahorse extracellular flux assays were utilised, together with 
colourimetric plate-based lactate assays to determine lactate production, for analysis of the three 
different rat MCs: primary MCs and the immortalised rMC-1 and SIRMu-1 cell lines. 
 
Metabolic analysis showed that cultured primary rat MCs and rMC-1 cells display the Warburg effect 





4.4.1 Optimisation of metabolic analysis techniques  
Colourimetric plate-based lactate assays (BioVision) were well-established and did not require 
significant optimisation. For oxygen consumption and extracellular acidification, two techniques were 
assessed: fluorescence plate reader-based assays (Luxcel Biosciences) and the Seahorse XFe96 
extracellular flux analyser (Agilent Technologies). These assay systems were chosen as they are 
commonly used in published metabolic studies (Divakaruni et al., 2014; Favre et al., 2010; Hynes et 
al., 2013; Mookerjee et al., 2017; Mookerjee et al., 2015; Papkovsky and Zhdanov, 2015; Zhdanov 
et al., 2011). Both fluorescence plate reader-based assays and the Seahorse extracellular flux 
analyser are high throughput techniques, which enable measurement of samples in a 96-well plate 
format, and do not require large amounts of biological samples. They therefore have advantages 
over classical methods, such as the Clark electrode (Li and Graham, 2012) which is more difficult to 
use and requires a large number of cells that must be able to withstand extended suspension to 
enable measurement of oxygen consumption (Divakaruni et al., 2014). 
 
MitoXpress Xtra oxygen consumption assays (Luxcel Biosciences) and pH-Xtra glycolysis assays 
(Luxcel Biosciences) are multi-well plate-based fluorescence assays that can be used to measure 
oxygen consumption and extracellular acidification, respectively. The MitoXpress Xtra assay utilises 
an oxygen-sensing fluorophore which is quenched by oxygen. Therefore, when the fluorophore is 
added to the culture medium surrounding the cells, the amount of fluorescence emitted is inversely 
proportional to the oxygen concentration within the medium and hence, is directly proportional to the 
oxygen consumption of the cells. The pH-Xtra glycolysis assay utilises a H+-sensing fluorophore. 
When the fluorophore is added to the culture medium surrounding the cell, the amount of 
fluorescence emitted is directly proportional to the level of acidification of the medium. These assays 
were optimised and could be used to measure cellular OCRs and ECARs. However, the assays had 
limited sensitivity with a relatively long time period required to show changes in oxygen consumption 
and extracellular acidification. In addition, OCRs and ECARs had to be measured using two distinct 
assay kits described above, in two different trays of cells. Therefore, OCRs and ECARs of the same 
biological samples could not be measured and directly compared. With these limitations, these 




The Seahorse XF extracellular flux analyser is considered the gold standard for measuring oxygen 
consumption and extracellular acidification in living cells. The Seahorse XFe96 system consists of a 
specialised 96-well cell culture microplate, a sensor cartridge with 96 probes (one probe per well, 
each containing two fluorophores, one sensing changes in oxygen concentration in assay medium 
and the other sensing changes in pH), the actual Seahorse extracellular flux analyser and the Wave 
control software. To perform an assay, cells are seeded into the specialised culture plate in a 
monolayer and placed in the analyser along with a sensor cartridge. Changes in oxygen and pH are 
measured in the assay medium in each well in real time by each of the probes of the sensor cartridge 
for multiple cycles. In each cycle, probes are lowered to 200 µm above the monolayer of cells in the 
cell culture plate, creating a transient micro-chamber within each well, in which changes in oxygen 
concentration and pH are measured simultaneously in the same biological sample and reported as 
OCR and ECAR, respectively. The probes are then lifted and the assay medium in the whole wells 
mixed so that the levels of oxygen and pH are returned to baseline levels. In the next cycle, the 
probes get lowered into the corresponding wells of the cell plate again and the measurements 
repeated. There are also four drug ports surrounding each of the sensor probes in the sensor 
cartridge. The four ports lie above the corresponding well of the cell culture tray during the assay and 
each port can be programmed to inject a drug into the well at a specified time. With these numerous 
advantages, investigation into the ability of the Seahorse analyser to efficiently and accurately 
analyse oxygen consumption and extracellular acidification in cells was undertaken. 
 
4.4.2 Measuring oxygen consumption and extracellular acidification by a Seahorse 
extracellular flux analyser 
The main focus of the thesis is to assess oxygen consumption and extracellular acidification of cells 
in the basal state, particularly OCRs that are due to mitochondrial respiration and ECARbasal. These 
data can be directly obtained from a Seahorse XF Cell Mito Stress Test, which is specifically 
designed for assessing mitochondrial metabolism as well as basal cellular glycolytic activity and 




In a Cell Mito Stress Test, inhibitors targeting the ETC (Fig. 2.1B) are serially injected into wells at 
specific time points to determine cellular responses, generating the typical Seahorse metabolic OCR 
profile (Fig. 2.1A, upper panel). The OCR from the cells prior to treatment represents respiration rate 
in the basal state, i.e. OCRbasal. The first compound, oligomycin, inhibits ATP synthase (complex V) 
(Fig. 2.1B), resulting in a decrease in oxygen consumption (Fig. 2.1A, upper panel). The second 
compound, FCCP, uncouples oxygen consumption from ATP synthesis (Fig. 2.1B), resulting in 
maximal oxygen consumption (Fig. 2.1A, upper panel). The third injection is comprised of rotenone 
and antimycin A (Rot/AA), which inhibit complexes I and III, respectively (Fig. 2.1B), and thereby 
completely inhibit OXPHOS, leaving remaining OCR due to non-mitochondrial respiration (Fig. 2.1A, 
upper panel). Using these inhibitors, several metabolic parameters can be derived, including basal 
mitochondrial respiration (OCRmito), oxygen consumption that is coupled to ATP production 
(OCRcoupled) and non-mitochondrial respiration (OCRnon-mito) (see figure 2.1 and sections 2.3.3.1 and 
2.3.3.4 in Chapter 2). 
 
As the Seahorse analyser measures OCRs and ECARs simultaneously, a kinetic profile of ECARs 
that corresponds to the OCRs can also be obtained (Fig. 2.1A, middle panel). The ECAR from the 
cells prior to treatment represents extracellular acidification in the basal state, i.e. ECARbasal. 
Oligomycin, which inhibits ATP synthase, results in an increase in ECAR, indicating cellular glycolytic 
reserve, i.e. an increased glycolytic activity to compensate for the loss of ATP production from the 
inhibition of OXPHOS (see figure 2.1 and section 2.3.3.2 in Chapter 2). 
 
To get accurate and reliable results from these Seahorse assays, cell-specific optimisation of seeding 
density and concentrations of the mitochondrial inhibitors as well as normalisation factors are 
required. 
 
4.4.2.1 Optimising FCCP concentrations 
High doses of FCCP are required for complete uncoupling of oxygen consumption from ATP 
production, and the concentration required varies significantly between cell types. However, if 
concentrations of FCCP used are too high, this compound becomes toxic to cells leading to a 
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decrease in observed OCR responses. Therefore, FCCP concentrations need to be optimised to 
determine the lowest FCCP concentration that gives the highest response (highest OCR). Therefore, 
initial Cell Mito Stress Tests were performed to determine the optimal FCCP concentrations for 
primary MCs (Fig. 4.1A) and rMC-1 cells (Fig. 4.1B). Assay medium used was a standard media as 
per the manufacturer’s recommendations: Seahorse XF base medium with glucose (10 mM), 
glutamine (2 mM) and sodium pyruvate (1 mM). For both cell populations, the OCRs were elevated 
with increasing concentrations of FCCP from 0.125 up to 0.5 µM, with the 0.5 and 1 µM 
concentrations resulting in similar OCRs, indicating that the response has reached a plateau. Of 
note, in rMC-1 cells 2 µM FCCP was also tested (Fig. 4.1B), and led to a decreased response which 
indicated that when used at 2 µM, FCCP was toxic. As 0.5 µM was the lowest concentration that 
produced the highest response, it was chosen for subsequent experiments.  
 
Importantly, the experiments also show that OCRs and ECARs could be quantitatively and 
simultaneously measured in real time, and responses of the cells to each compound of the Cell Mito 
Stress Tests could be immediately detected (Fig. 4.1). In addition, the responses observed were 
consistent with expected typical Seahorse Cell Mito Stress Test OCR and ECAR profiles (Fig. 2.1A 
upper and middle panels), with OCR decreasing and ECAR increasing after the addition of 
oligomycin, OCR increasing after the addition of FCCP, and OCR decreasing after the addition of 
Rot/AA. 
  
4.4.2.2 Optimising cell seeding density 
Optimal cell seeding density is another important prerequisite for metabolic analysis using the 
Seahorse analyser. Optimal seeding density is one which results in the cells not being completely 
confluent at the time of the assay (resulting in weak or dead cells as well as an unintentionally hypoxic 
environment, all of which could affect metabolism) and which gives OCRbasal and ECARbasal in an 
optimal range (OCRbasal of 20-160 pmol/min and ECARbasal of 10-90 mpH/min, Agilent Technologies 
user manual). In this thesis, the MCs investigated are all adherent cells, so the cells were seeded 
the day before each assay. It is noteworthy that for some cell types there may not be an optimal 
seeding density that fulfils all of the above requirements, as this is dependent on the characteristics 
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of a specific cell population, including culture composition (homogeneous or heterogeneous), cell 
size, proliferation rate, preference for glycolysis or OXPHOS and metabolic activity. 
 
Cell seeding densities for primary MCs (Fig. 4.2A) and rMC-1 cells (Fig. 4.2B) were optimised. After 
it was established and characterised (Paper 4 (Kittipassorn et al., 2019a) in Chapter 3), the novel 
SIRMu-1 cell line was also included in the analysis (Fig. 4.2C). As the ultimate aim was to analyse 
glucose metabolism of MCs, the assay medium used here was Seahorse XF base medium with 10 
mM glucose as the sole substrate. Although 10 mM glucose is above normal blood glucose levels 
(Potter et al., 2016; Wang et al., 1997a, b), it is recommended by the manufacturer to use in the 
assay medium as a saturating concentration is necessary to ensure that cellular metabolism is not 
limited by the amount of the energy substrate. For primary MCs, two cell seeding densities (15,000 
and 20,000 cells/well) were tested, with 15,000 cells/well resulting in the cells being 80-100% 
confluent before the assay and giving OCRbasal and ECARbasal within the desired ranges (Fig. 4.2A). 
This density was then chosen for subsequent experiments. Similar results were obtained with rMC-
1 cells where 15,000 cells/well was found to be the optimal cell seeding density (Fig. 4.2B). For 
SIRMu-1 cells, four cell seeding densities (5000; 10,000; 15,000 and 20,000 cells/well) were 
investigated (Fig 4.2C). The 5000 cell/well seeding density resulted in 95-100% cell confluency but 
both OCRbasal and ECARbasal were lower than the recommended ranges. The other higher seeding 
densities led to OCRbasal being within the range, but the cells appeared overgrown at the time of the 
assay (slightly overgrown in the 10,000 cells/well group and highly overgrown in the other two 
groups). In addition, even with the cells being overgrown, all of the three higher seeding densities 
gave ECARbasal values that were lower than the desired range. Therefore, as there was no seeding 
density that perfectly fit the criteria, the density of 10,000 cells/well was chosen for subsequent 
experiments as it gave optimal OCRbasal and the cells were only slightly overgrown. These results 







Figure 4.1. FCCP concentration optimisation in a Seahorse XF Cell Mito Stress test. Primary (1o) MC (A), 
and rMC-1 (B) cells were seeded in a Seahorse 96-well cell culture plate at 20,000 and 40,000 cells per well 
respectively. On the following day, an XF Cell Mito Stress test was performed where oxygen consumption rates 
(OCRs) and extracellular acidification rates (ECARs) in the presence of glucose (10 mM), glutamine (2 mM) 
and sodium pyruvate (1 mM) were measured simultaneously by the Seahorse XFe96 extracellular flux analyser 
at a basal state and after the addition of oligomycin (2 µM), FCCP (various concentrations as indicated), and 
rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs were measured three times during each of the four 
conditions. Data from one experiment, presented as mean ± SD of each measurement point from a minimum 








Figure 4.2. Cell seeding density optimisation in a Seahorse XF Cell Mito Stress test. Primary (1o) MC (A), 
rMC-1 (B), and SIRMu-1 cells (C) were seeded in a Seahorse 96-well cell culture plate at different densities as 
indicated. On the following day cell confluency of each group was recorded (shown in brackets after a 
corresponding seeding density), and an XF Cell Mito Stress test was performed where oxygen consumption 
rates (OCRs) and extracellular acidification rates (ECARs) in the presence of glucose (10 mM) were measured 
simultaneously by the Seahorse XFe96 extracellular flux analyser at a basal state and after the addition of 
oligomycin (2 µM), FCCP (0.5 µM), and rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs were 
measured three times during each of the four conditions. Data from one experiment, presented as mean ± SD 
of each measurement point from a minimum of six replicate wells per group for the 1o MCs, a minimum of three 




4.4.2.3 Normalising OCR and ECAR data from Seahorse extracellular flux assays 
To accurately interpret and compare cellular metabolic profiles between different cell types or 
treatment groups based on OCR and ECAR data from Seahorse assays, it is crucial to normalise for 
differences in cell number due to differences in seeding densities, proliferation rates, and more 
random differences in cell loss during incubation, washing and treatment. Commonly-used factors 
for normalisation are protein amount and the number of cells per well. Although total protein amount 
is easier to determine, the actual number of cells is arguably a better factor as different cell types or 
groups of the same cell type that have undergone different treatments can have different amounts 
of protein per cell. For normalisation, it is best to determine the number of cells per well at the end 
of an assay, rather than using the original cell seeding density, to account for differences in 
proliferation rates, and cell loss during incubation, washing and treatment. 
 
A number of methods were used to try to accurately and efficiently determine cell numbers after each 
experiment. Firstly, attempts were made to count cells in each well after a Seahorse assay by 
trypsinising the cells and counting them using a hemocytometer or a cell counter. This was shown 
to be inaccurate and inconsistent. For example, there was considerable variation in apparent cell 
numbers when a single well was counted multiple times, or between replicate wells with very similar 
OCRs and ECARs, which could be due to the relatively small number of cells in each well, cell 
clumping, or inconsistencies in the technique. A second method used nuclear labelling of the cells 
followed by imaging using fluorescence microscopy and automated cell counting using the Fiji 
software (Schindelin et al., 2012). This method was more consistent than manual cell counting, 
although it was very inefficient as it required manually taking images of multiple wells. Thus, the 
number of cells for each experimental group was determined using this method from images taken 
from three representative wells in each group. Every well was also observed using a light microscope 
to ensure that the cell confluency of all wells in a group was similar and that wells used for cell 
counting were representative of that group. An average of the number of cells from the three 





We also tested the suitability of an ArrayScan XTI Live High Content Platform (ThermoFisher 
Scientific) which is capable of automatically imaging all the wells in a 96-well cell culture plate in a 
relatively short time while simultaneously counting the numbers of cell in each well. This method of 
determining cell number proved to be accurate, consistent and highly efficient. It also enabled the 
efficient determination of the number of cells in every individual well in each Seahorse assay and the 
ability to normalise OCR and ECAR data from each individual well with the actual number of cells in 
that well, rather than an average from representative wells. This preferred method of determining cell 
number was used for all experiments performed after we gained access to the ArrayScan in 
September 2018. The method by which cell numbers were determined in each Seahorse assay is 
specified in the legend of each subsequent figure. 
 
4.4.2.4 Summary 
With all parameters optimised, the Seahorse analyser was able to efficiently, consistently and 
accurately measure OCRs and ECARs of each type of the cultured MCs in real time. It was also 
capable of rapidly detecting responses of cells to each of the drugs added during the course of the 
experiments. The Cell Mito Stress Tests were also successfully performed, and expected responses 
of OCRs and ECARs to each drug obtained. 
 
4.4.3 Metabolic analysis of primary and immortalised Müller cells 
The optimised Seahorse Cell Mito Stress Test protocol as well as colorimetric lactate assays were 
used to analyse the glucose metabolism of primary MCs, the rMC-1 line and our novel SIRMu-1 line 
(Paper 4 (Kittipassorn et al., 2019a) in Chapter 3) (Fig. 4.3). A key aim was to investigate whether 
primary rat MCs cultured under current conditions displayed the Warburg effect similar to those 
previously reported (Poitry-Yamate et al., 1995; Winkler et al., 2000; Winkler et al., 2003), and to 
determine whether the two immortalised MC lines were metabolically similar to the primary MCs. 
Cervical cancer HeLa cells and primary MEFs were also analysed alongside the MCs. The well-
characterised HeLa cells are known to be highly glycolytic and display the Warburg effect (Reitzer 
et al., 1979; Stanisz et al., 1983), while primary MEFs have been shown to have relatively high OCRs 










Figure 4.3. Metabolic profile of cultured primary and immortalised Müller cells (MCs) in normoxia. 
Primary (1o) MC (15,000 cells/well), rMC-1 (15,000 cells/well), SIRMu-1 (10,000 cells/well), 1o MEF (15,000 
cells/well), and HeLa (10,000 cells/well) cells were seeded in a Seahorse 96-well cell culture plate. On the 
following day, cells were washed and incubated in fresh assay medium (XF base medium with 10 mM glucose) 
for an hour before the medium of each well was collected to use as samples for lactate assays. Cells were then 
subjected to an XF Cell Mito Stress test where oxygen consumption rates (OCRs) and extracellular acidification 
rates (ECARs) in the presence of glucose (10 mM) were measured by the Seahorse XFe96 extracellular flux 
analyser at a basal state and after the addition of oligomycin (2 µM), FCCP (0.5 µM), and rotenone/antimycin A 
(Rot/AA, 0.5 µM). OCRs and ECARs were measured three times during each of the four conditions. Three 
independent experiments (each with a minimum of six replicate wells per group) were performed. In the first 
experiment, cell numbers at the end of the assay could not be determined accurately due to technical problems. 
For the other two experiments, cell numbers were determined by fluorescence microscopy after Hoechst 33342 
nuclear staining. (A) Lactate efflux rates determined from media samples collected before each Cell Mito Stress 
Test was performed, using lactate calorimetric assays, presented as mean ± SD from the three independent 
experiments, each performed using samples from three representative wells per group. (B) Representative 
graphs from one of the three independent experiments showing changes in OCRs, ECARs and proton efflux 
rates (PERs) calculated from the changes in ECARs. Data presented as mean ± SD from at least six replicate 
samples. OCR and ECAR graphs from all three experiments can be found in Appendix 7.6. (C)-(H) Different 
metabolic parameters were determined from the OCR and ECAR readings: (C) basal OCR (OCRbasal), (D) OCR 
due to mitochondrial respiration (OCRmito), (E) OCR coupled to ATP production (OCRcoupled), (F) basal ECAR 
(ECARbasal), (G) basal PER (PER basal), and (H) glycolytic reserve. Data in A and C-H are normalised to cell 
numbers and presented as mean ± SD from two independent experiments with accurate cell counts. Statistical 
significance comparing to 1o MCs was determined by one-way ANOVA followed by Dunnett’s multiple 




4.4.3.1 Lactate production 
Lactate production (indicated by lactate efflux rates in Fig. 4.3A) of the primary MCs is relatively 
similar to the HeLa cells, which are known to display the Warburg effect (Reitzer et al., 1979; Stanisz 
et al., 1983). The rMC-1 cells show very similar rates of lactate production to the primary MCs; 
however, the SIRMu-1 cells display much lower lactate production than primary MCs and all of the 
other cells types. Interestingly, the primary MEFs, which have been reported to have relatively high 
oxidative activity (Bryant et al., 2018; Wu et al., 2009), display the highest lactate production. 
 
4.4.3.2 Oxygen consumption, extracellular acidification and proton efflux 
Kinetic profiles determined for both OCRs and ECARs for all five cell types are shown in the top and 
middle panels in figure 4.3B and in Appendix 7.6. ECARs (mpH/min) indicate changes in the pH level 
in the assay medium and can be converted to absolute changes in H+ or PERs (pmol H+/min) using 
a buffer factor (mM/pH), which is the amount of H+ that changes the pH level in the medium by one 
pH unit as measured in a Seahorse analysis system (see sections 2.3.1 and 2.3.3.3 in Chapter 2). 
The kinetic profiles of PERs are shown in the lower panel in figure 4.3B.  
 
The primary MCs display an expected Cell Mito Stress Test profile (see Fig. 4.3B, compare with Fig. 
2.1A), where OCRs decrease after the addition of oligomycin, increase after the addition of FCCP 
and are completely inhibited after the addition of Rot/AA (Fig. 4.3B). In addition to decreasing OCRs, 
as expected oligomycin leads to an increase in ECARs and PERs (Fig. 4.3B). Looking at the basal 
activity, the primary MCs show relatively high levels of OCRbasal and ECARbasal, which are both higher 
than those of the rMC-1 cells (Fig. 4.3B), suggesting that the primary MCs are more metabolically 
active than the rMC-1 cells. The SIRMu-1 cells display similar OCRs to the primary MCs but much 
lower ECARs, suggesting that the primary MCs are more glycolytic than the SIRMu-1s. For the two 
non-MC cells, the HeLa cells consume very little oxygen while producing noticeable amount of 
extracellular acidification, corresponding to their having a predominantly glycolytic activity, while the 
primary MEFs, similar to the primary MCs, show considerable levels of OCRbasal and ECARbasal, 




From the OCR, ECAR and PER kinetic profiles including responses to the compounds added during 
the assay (Fig. 4.3B), additional important metabolic parameters can be determined using the 
methods as described (Fig. 4.3C-H) (section 2.3.3.4 in Chapter 2). The primary MCs show high levels 
of ECARbasal and PERbasal, relative to OCR parameters (OCRbasal, OCRmito and OCRcoupled), 
suggesting a glycolytic phenotype. The rMC-1 cells also display high levels of ECARbasal and 
PERbasal, relatively to OCR. This suggests that the rMC-1 cells also have a glycolytic phenotype, 
similar to the primary MC. However, the rMC-1 cells show an overall lower trend for all of these 
parameters compared to the primary MCs (Fig. 4.3C-H), suggesting that the rMC-1 cells are less 
energetic than the primary MCs. The SIRMu-1 cells have the highest levels of the OCR parameters, 
but the lowest ECARbasal and PERbasal, among the three MC types (Fig. 4.3C-G). This indicate that 
the SIRMu-1 cells are heavily dependent on OXPHOS, which is a different metabolic phenotype from 
the other two MCs. As expected, the HeLa cells display the lowest OCRs and relatively high 
ECARbasal and PERbasal, consistent with the Warburg effect. Interestingly, while the MEFs do display 
high levels of OCR, they also display relatively high ECARbasal, consistent with the results from the 
lactate assay. Glycolytic reserve (Fig. 4.3H) is higher in the primary MCs and the MEFs than in the 
rMC-1, the SIRMu-1 and the HeLa cells, which have very low glycolytic reserve. Although this is not 
statistically significant, it suggests that the primary MCs and MEFs have a higher capacity to 
upregulate their glycolytic activity when OXPHOS is inhibited. 
 
4.4.3.3 Contribution of glycolysis and respiration to PER 
Extracellular acidification and H+ efflux are commonly used as indicators of glycolysis since the 
conversion of glucose to lactate via glycolysis yields H+ (Divakaruni et al., 2014). However, CO2 
produced from OXPHOS also contributes to extracellular acidification as it can partially hydrate in 
the medium to produce H+ and HCO3- (Mookerjee et al., 2015). Therefore, in order to accurately 
determine the glycolytic activity of cells, it is important to differentiate between acidification which is 
due to glycolysis and acidification which is due to mitochondrial respiration (Mookerjee et al., 2015). 
Based on absolute OCRmito data (the difference between OCRbasal and OCRnon-mito, see Fig. 2.1 and 
section 2.3.3.4 in Chapter 2), the amount of H+ in the medium derived from CO2 can also be 
determined (Mookerjee et al., 2015) (detailed in section 2.3.3.5 in Chapter 2). This is the PERres, and 
the difference between the PERbasal (calculated from ECARbasal) and the PERres is the PERglycol 
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(Mookerjee et al., 2015). Hence, OCRmito data enabled the determination of PERres and consequently 
PERglyco; this was one of the reasons that the Seahorse Cell Mito Stress Tests, in which three 
compounds targeting the ETC and OXPHOS are serially injected, were utilised in this thesis.  
 
Values and % contribution to the PERbasal of PERglyco of the five cell types investigated were 
determined (Fig. 4.4A-B). In primary MCs and HeLa cells, levels of PERglyco are similar (Fig. 4.4A) 
with more than 85% of the PERbasal derived from glycolysis (Fig. 4.4B), consistent with both cell types 
having similar glycolytic activities and displaying the Warburg effect. Although rMC-1 cells have a 
lower absolute value of PERglyco than primary MCs (Fig. 4.4A), they do show a highly similar 
contribution of glycolysis to the total acidification, with also more than 85% of the PERbasal having 
been derived from glycolysis (Fig. 4.4B); this suggests that the rMC-1 cells and the primary MCs 
display similar levels of dependency on glycolysis. On the other hand, SIRMu-1 cells show much 
lower levels of both the value and the % contribution to the PERbasal of the PERglyco, when compared 
to the primary MCs (Fig. 4.4A and B), indicating a clear difference in glycolytic activity between the 
two cell types. Less than 20% of the PERbasal is derived from glycolysis in SIRMu-1 cells, again 
consistent with a much lower relative rate of glycolysis compared with OXPHOS. Of note, on average 
more than 65% of the PERbasal in MEFs is derived from glycolysis, showing a relatively high glycolytic 
activity, similar to primary MCs, rMC-1s and HeLa cells. 
 
4.4.3.4 Contribution of glycolysis and respiration to ATP production and glucose 
consumption 
Cells that exhibit the Warburg effect display high rates of glycolysis and predominantly depend upon 
this pathway for their ATP production, even when exposed to physiological oxygen levels (Hsu and 
Sabatini, 2008; Koppenol et al., 2011; Vander Heiden et al., 2009; Warburg, 1956; Warburg et al., 
1927). Based on OCR and PER data and the type of substrate used in the assays (which was glucose 
in this case), the total amount and relative proportions of ATP produced and glucose consumed that 
were due to either glycolysis or respiration can be calculated (Mookerjee et al., 2017, 2018) (detailed 







Figure 4.4. Metabolic parameters associated with glycolytic activity of cultured primary and 
immortalised Müller cells (MCs) in normoxia. Additional parameters were calculated based on oxygen 
consumption rates (OCRs), extracellular acidification rates (ECARs) and proton efflux rates (PERs) from the 
Cell Mito Stress tests in figure 4.3, where three independent experiments (each with a minimum of six replicate 
wells per group) were performed. The parameters are (A) PER due to glycolysis (PERglyco) in pmol/min/1000 
cells, (B) PERglyco (% contribution to PERbasal in figure 4.3G, (C) % contribution of glycolysis to ATP production, 
and (D) Basal ECAR/OCR ratios. (E) A graph showing a relationship between % contribution of glycolysis to 
ATP production from C and % of metabolised glucose converted to lactate. Data in A are normalised to cell 
numbers and presented as mean ± SD from the two independent experiments. Data in B-E are cell number-
independent and presented as mean ± SD of three independent experiments. Statistical significance comparing 
to 1o MCs was determined by one-way ANOVA followed by Dunnett’s multiple comparison test. *p<0.05, 




ATP is produced from glycolysis, whereas in SIRMu-1s less than 15% is produced from glycolysis 
(Fig. 4.4C and 4.4D). This further supports that primary MCs, rMC-1s and HeLa cells depend on 
glycolysis, while the SIRMu-1 cells depend on OXPHOS. For MEFs, on average less than 50% of 
ATP is generated from glycolysis, confirming that they are more oxidative than glycolytic. The graph 
in figure 4.4D shows a relationship between the contributions of glycolysis to ATP production (data 
from fig. 4.4C) and the proportions of metabolised glucose that are converted into lactate in different 
cell types. The majority of glucose consumed in all cell types, except SIRMu-1 cells, is converted to 
lactate (Fig. 4.4D). In figure 4.4D, the locations on the graph of the primary MC and the rMC-1 data 
points are similar, with the majority of their ATP produced and glucose consumed due to glycolysis, 
further confirming their similar dependency on glycolysis. The graph also shows that HeLa cells are 
highly glycolytic, SIRMu-1 highly oxidative and MEFs intermediate. 
 
Since both glycolysis and respiration contribute to ECARs, the glycolytic activity of cells in the basal 
state can be analysed qualitatively by normalising ECARbasal to OCRbasal, to give ECAR/OCR ratios, 
which are independent of cell number. Among the three MC populations, the primary MCs and the 
rMC-1s show similarly high ECAR/OCR ratios, while that of the SIRMu-1 cells is significantly lower 
compared to the primary MCs (Fig. 4.4E). HeLa cells have the highest ECAR/OCR ratio, indicating 
the highest glycolytic activity among all cell types investigated (Fig. 4.4E). Although slightly lower, 
the ECAR/OCR ratio of MEFs is not statistically significantly different from that of the primary MCs, 
suggesting intermediate glycolytic activity (Fig. 4.4E). The trend of ECAR/OCR ratios (Fig. 4.4E) 
among the five cell types are very similar to the contributions of glycolysis to ATP production (Fig. 
4.4C), confirming that ECAR/OCR ratios are a good indicator of relative glycolytic activity. 
Importantly, again, the SIRMu-1 cells are clearly the most oxidative cell type analysed, with the HeLa 
cells being the most glycolytic and the other MCs intermediate. 
 
4.4.3.5 Summary 
Overall, primary MCs and rMC-1 cells appear to have very similar glucose metabolism. Both cell 
populations show high glycolytic activity, and hence display the Warburg effect, as indicated by 
similar lactate efflux rates, similar contributions of glycolysis to PER and ATP production, similar 
proportions of glucose converted to lactate and similar basal ECAR/OCR ratios (Fig. 4.3 and 4.4). 
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However, there are small differences including lower OCRs (although not statistically significant), 
lower glycolytic reserve (although not statistically significant), lower ECARs and lower PERs in the 
rMC-1 cells compared to the primary MCs (Fig. 4.3C-G). Altogether, this indicates that both the 
primary MCs and the rMC-1 cells display the Warburg effect and predominantly rely on glycolysis for 
ATP production, but the primary MCs are more metabolically active. On the other hand, glucose 
metabolism of the SIRMu-1 cells is very different from the primary MCs in that they are highly 
dependent on OXPHOS, as demonstrated by lower lactate efflux rates (although not statistically 
significant), higher OCRs (although not statistically significant), lower ECARs, lower PERs, lower 
contributions of glycolysis to PER and ATP production, lower proportions of glucose converted to 
lactate and lower basal ECAR/OCR ratios, compared to primary MCs (Fig. 4.3 and 4.4). 
 
4.4.4 Analysing metabolic gene expression in Müller cells based on RNA sequencing data  
To investigate whether the major difference in metabolism between the SIRMu-1 and the primary 
MCs (Fig. 4.3 and 4.4) could be explained by differential gene expression, the relative expression 
levels of 44 key genes involved in glucose metabolism in the SIRMu-1 cells were compared with the 
primary MCs (Table 4.1, Fig. 4.5) using the data from RNA-seq performed and described in Paper 4 
(Kittipassorn et al., 2019a) and Paper 5 (Kittipassorn et al., 2019b) in Chapter 3. rMC-1 data 
compared to primary MCs were also analysed (Table 4.1, Fig. 4.5). Among the 44 genes analysed 
there was no gene that was uniquely differentially expressed in the SIRMu-1 cells compared to the 
primary MCs, even when differential expression was analysed using a minimum two fold-change 
threshold compared to primary MCs (Table 4.1 and the yellow left-hand side area of the Venn 
diagram in Fig. 4.5). There were two genes, Slc2a9 (encoding glucose transporter 9 (GLUT9)) and 
Slc16a3 (encoding monocarboxylate transporter 4, MCT4), that were differentially expressed in the 
SIRMu-1 cells relative to the primary MCs, but these were also differentially expressed in the rMC-1 
cells compared to the primary MCs (Table 4.1 and the green middle area of the Venn diagram in Fig. 
4.5). Therefore, the differential expression of these two genes is likely not an explanation for the 
major difference in glucose metabolism between the SIRMu-1s and the primary MCs, as the rMC-
1s, which display a similar metabolism to primary MCs, also differentially express these genes 




Table 4.1. Differential expression of key genes involved in glucose metabolism in the SIRMu-1 and 








to 1o MC 
SIRMu-1 rMC-1 
Aldoa aldolase, fructose-bisphosphate A 0 0 
Aldoc aldolase, fructose-bisphosphate C 0 0 
Eno1 enolase 1 0 0 
G6pd glucose-6-phosphate dehydrogenase 0 0 
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0 0 
Gpd1 glycerol-3-phosphate dehydrogenase 1 0 1 
Gpi glucose-6-phosphate isomerase 0 0 
Gsr glutathione-disulfide reductase 0 0 
Hk1 hexokinase 1 0 0 
Hk2 hexokinase 2 0 0 
Ldha lactate dehydrogenase A 0 0 
Ldhb lactate dehydrogenase B 0 -1 
Mpc1 mitochondrial pyruvate carrier 1 0 0 
Mpc2 mitochondrial pyruvate carrier 2 0 0 
Pdha1 pyruvate dehydrogenase (lipoamide) alpha 1 0 0 
Pdk1 pyruvate dehydrogenase kinase 1 0 0 
Pdk2 pyruvate dehydrogenase kinase 2 0 0 
Pdk3 pyruvate dehydrogenase kinase 3 0 0 
Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 0 1 
Pfkfb2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 0 0 
Pfkfb3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 0 0 
Pfkl phosphofructokinase, liver type 0 0 
Pfkm phosphofructokinase, muscle 0 0 
Pfkp phosphofructokinase, platelet 0 0 
Pgam1 phosphoglycerate mutase 1 0 0 
Pgd phosphogluconate dehydrogenase 0 0 
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Pgk1 phosphoglycerate kinase 1 0 0 
Pgls 6-phosphogluconolactonase 0 0 
Pkm pyruvate kinase M 0 0 
Rpe ribulose-5-phosphate-3-epimerase 0 0 
Rpia ribose 5-phosphate isomerase A 0 0 
Slc2a1 solute carrier family 2 member 1 0 0 
Slc2a5 solute carrier family 2 member 5 0 0 
Slc2a6 solute carrier family 2 member 6 0 0 
Slc2a8 solute carrier family 2 member 8 0 0 
Slc2a9 solute carrier family 2 member 9 -1 -1 
Slc2a10 solute carrier family 2 member 10 0 -1 
Slc2a12 solute carrier family 2 member 12 0 0 
Slc2a13 solute carrier family 2 member 13 0 -1 
Slc16a1 solute carrier family 16 member 1 0 1 
Slc16a3 solute carrier family 16 member 3 -1 -1 
Slc16a7 solute carrier family 16 member 7 0 0 
Taldo1 transaldolase 1 0 0 
Tkt transketolase 0 0 
 
A fold-change threshold of two was set to analyse differential expression of 44 genes involved in glucose 
metabolism in the SIRMu-1 cells compared to the primary MCs (results shown in the column named “SIRMu-
1”), and in the rMC-1 cells compared to the primary MCs (results shown in the column named “rMC-1”). Genes 
not differentially expressed are denoted by 0, genes downregulated denoted by -1, and genes upregulated 





Figure 4.5. Differentially expressed genes involved in glucose metabolism of SIRMu-1 and rMC-1 cells 
compared to primary (1o) MCs. Venn diagram displays the names of genes significantly differentially 
expressed at a fold-change of greater than two in each immortalised cell line compared to 1o MCs. Differentially 
expressed genes were either upregulated () or downregulated (). Gpd1, glycerol-3-phosphate 
dehydrogenase 1; Ldhb, lactate dehydrogenase B; Pfkfb1, 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1; Slc2a9, solute carrier family 2 member 9; Slc2a10, solute carrier family 2 member 10; Slc2a13, 






As previously discussed, the rMC-1 cells have very similar glucose metabolism to the primary MCs 
although there are small differences with the rMC-1 cells exhibiting lower OCRs, lower ECARs and 
lower PERs (Fig. 4.3 and 4.4). There are only six genes that are uniquely differentially expressed in 
rMC-1 cells under these conditions compared to primary MCs, including Gpd1 (encoding glycerol-3-
phosphate dehydrogenase 1, an enzyme involved in carbohydrate and lipid metabolism), genes 
encoding enzymes involved in the glycolytic pathway (Ldhb encoding LDHB and Pfkfb1 encoding 
phosphofructokinase 2), and genes encoding membrane transporters in the GLUT family (Slc2a10 
encoding GLUT10 and Slc2a13 encoding GLUT13), and Slc16a1 (encoding monocarboxylate 
transporter 1) (Table 4.1 and the blue right-hand area of the Venn diagram in Fig. 4.5), which likely 
contribute to the small metabolic differences between the rMC-1 cells and the primary MCs. 
 
4.5 Discussion 
4.5.1 Metabolic analysis techniques 
Two of the key parameters for the analysis of glucose metabolism in MCs were oxygen consumption 
and extracellular acidification. To analyse these, two techniques were assessed: fluorescence plate 
reader-based assays (Luxcel Biosciences) and the Seahorse XFe96 extracellular flux analyser 
(Agilent Technologies). Although both are high throughput techniques that enable measurement of 
samples in a 96-well plate format and do not require large amounts of cells, the Seahorse 
extracellular flux analyser had a number of advantages over the fluorescence plate reader-based 
assays. With the Seahorse analysis, changes in oxygen concentration (reported as OCR) and pH 
(reported as ECAR) are measured simultaneously in the same biological samples, rapid cellular 
responses can be detected in real time due to a very small volume (about 2 µL) of the transient 
micro-chambers in which changes were measured, drug ports in sensor cartridges enable the 
addition of multiple drugs to the same well over the course of an assay, at specified times, and the 
responses of the same cells to each of the drugs determined, the system has an optimised set of 
protocols for sensitive, consistent and accurate measurements of both OCRs and ECARs, and the 
analysis is quantitative, allowing determination of absolute levels of OCRs and ECARs. This chapter 
presented the optimisation of metabolic assays performed using the Seahorse analyser and 
demonstrated that OCRs and ECARs could be measured efficiently, consistently and accurately. 
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Hence, this technique, together with assays to determine lactate production, were used to investigate 
whether primary MCs display the Warburg effect as previously published (Poitry-Yamate et al., 1995; 
Winkler et al., 2000) and whether the rMC-1 and the SIRMu-1 cells have similar glucose metabolism 
to primary MCs. HeLa cells and MEFs were also analysed alongside MCs. Importantly, these 
experiments enabled glucose metabolism in all cell types to be assessed in the same microplates 
and directly compared. 
 
4.5.2 Interpreting metabolic data and characterising Müller cell glucose metabolism 
The primary MCs display the Warburg effect, similar to HeLa cells but to a lesser degree, as they 
exhibit relatively high values of glycolytic parameters including lactate efflux rates, contribution of 
glycolysis to PER, contribution of glycolysis to ATP production, high proportions of glucose converted 
to lactate and high basal ECAR/OCR ratios (Fig. 4.3 and 4.4). These results are consistent with 
studies published previously in primary MCs of guinea pig (Poitry-Yamate et al., 1995) and of human 
(Winkler et al., 2000). In contrast, other types of primary cells, including normal human dermal 
fibroblasts (NHDF) (Zhang et al., 2012) and rat cortical neurons (Divakaruni et al., 2014), have been 
shown to be predominantly oxidative, confirming the primary MCs as a rare type of primary cells that 
uniquely display the Warburg effect.  
 
Similar to the primary MCs investigated, the rMC-1 cells show high dependence upon glycolysis for 
metabolism, indicating that the rMC-1 cells also display the Warburg effect. This was in line with a 
published report that investigated lactate production by these cells (Winkler et al., 2003). Of note, 
rMC-1 cells show lower OCRs and ECARs than primary MCs, suggesting that although both rMC-1 
cells and primary MCs predominantly depend on glycolysis for ATP production, the latter are more 
metabolically active. Nevertheless, both primary MCs and rMC-1s display the Warburg effect.  
 
For the SIRMu-1 cells, almost all of their metabolic parameters are different from those of the primary 
MCs. Compared to primary MCs, SIRMu-1 cells have a lower PERglyco, a lower contribution of 
glycolysis to ATP production, a lower proportion of glucose converted to lactate, lower basal 
ECAR/OCR ratios, lower ECARbasal, lower lactate efflux rates and higher OCRs. Altogether this 
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indicates that the highly-proliferative SIRMu-1 cells are predominantly oxidative and do not display 
the Warburg effect. This helps to validate the method as it shows that, unlike what has been 
previously suggested (Young, 2013), not all continuously proliferating cell lines appear as glycolytic 
when cultured under these conditions in which sufficient glucose is present, and that predominantly 
oxidative cells do exist in culture. This is also similar to a previously-published finding that the highly-
proliferative human breast cancer MCF-7 cell line seems to be primarily oxidative (Zhang et al., 2012) 
and also supports the less well-known and more recent notions that the Warburg effect might not 
always exist in highly-proliferative cells and that different cell lines from the same tissue origin may 
have different metabolic phenotypes (Giang et al., 2013; Zhang et al., 2012) (reviewed in (Moreno-
Sanchez et al., 2007). Here, the rMC-1 and the SIRMu-1 cell lines both originated from primary rat 
MCs but undertake very different types of glucose metabolism.  
  
The considerable differences between primary MC and SIRMu-1 glucose metabolism are unlikely to 
be due primarily to differential expression of genes involved in glucose metabolism. Analysis of RNA-
seq data on expression levels of 44 key glucose metabolic genes (Table 4.1, Fig. 4.5), including 
genes commonly important in the regulation of the switch between glycolysis and OXPHOS such as 
Pdha1, pdk1 and Ldha (Luo et al., 2011), showed that there was no gene that was uniquely 
differentially expressed in the SIRMu-1 cells compared to the primary MCs. The major differences in 
primary MC and SIRMu-1 glucose metabolism might, instead, be primarily associated with 
differences in expression of genes indirectly involved in glucose metabolism, genes involved in other 
forms of metabolism or, more likely, post-transcriptional mechanisms (Arif et al., 2017). 
 
It is noteworthy that in the SIRMu-1 cells PERglyco contributes less than 20% to the PERbasal, 
calculated from the ECARbasal. Similar results were previously reported including in the MCF-7 cell 
line, the human osteosarcoma Saos-2 cell line and the rat insulinoma INS-1E cell line where only a 
small fraction of the total production of H+ was derived from glycolysis (Giang et al., 2013; Mookerjee 
et al., 2015). This emphasises that it is not ideal to use ECAR obtained from the extracellular flux 
analyser as a sole and direct indicator of cellular glycolytic activity, because in highly oxidative cells 
the majority of ECAR could be the result of H+ released from the hydration of CO2 produced from 
OXPHOS, and not the result of H+ produced from the conversion of glucose to lactate via glycolysis. 
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It also emphasises that in order to accurately use ECAR to represent glycolytic flux, it is crucial to 
determine the proportion of ECAR that is due to glycolysis, or to interpret the ECAR data relative to 
the OCR, as demonstrated in this thesis and in a number of studies by others (Cao et al., 2014; 
Mookerjee et al., 2015; Nicholas et al., 2017; Zhang et al., 2012).  
 
Interestingly, primary MEFs show both a relatively high glycolytic flux (as shown by high lactate efflux 
rates and high ECARs) and a high oxygen consumption, indicating highly metabolically active cells. 
However, they depend slightly more on respiration than glycolysis for ATP production (contribution 
of glycolysis to ATP production was on average less than 50% but not by much and the basal 
ECAR/OCR ratio was relatively low). This shows that a cell type can have a high glycolytic flux, due 
to being highly active cells, without having the majority of ATP being derived from glycolysis, which 
again highlights the importance of considering lactate production, ECAR and OCR altogether when 
analysing glucose metabolism of cells (Divakaruni et al., 2014; Mookerjee et al., 2017, 2018). In 
addition, the MEFs are primary cells and have a population doubling time of approximately seven to 
ten days, similar to the primary rat MCs whose doubling time is approximately seven days 
((Kittipassorn et al., 2019a) in Chapter 3). Despite both cell types being primary cells with similarly 
slow proliferation rates, the primary MCs are more dependent on glycolysis for ATP production than 
the MEFs. On the other hand, although both the MEFs and the SIRMu-1 show dependency on 
OXPHOS (the SIRMu-1 more so than the MEFs), the former are slowly-proliferative cells while the 
latter highly-proliferative. This again demonstrates that proliferative capability does not always 
correlate with a certain metabolic phenotype and also argues against the proposal that the Warburg 
effect exists to facilitate biosynthesis primarily for cellular proliferation (reviewed in (Liberti and 
Locasale, 2016). 
 
Of note, the FCCP concentration used in the above experiments for all five cell types was 0.5 µM, 
selected based on the optimal concentration of FCCP in primary MCs and rMC-1 cells determined 
previously in initial optimisation experiments (Fig. 4.1). After the SIRMu-1 cell line was established, 
it was also included in the metabolic analysis. The FCCP concentrations in SIRMu-1 cells were later 
tested (Appendix 7.7) using the same concentrations (0.125, 0.25, 0.5, 1, 2 µM) as investigated in 
primary MCs and rMC-1 cells (Fig. 4.1). It was found that the highest concentration used (2 µM) still 
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gave a higher OCR response than the second highest concentration (1 µM), demonstrating that the 
optimal FCCP concentration for the SIRMu-1 cells is equal to or higher than 2 µM. This indicates that 
the maximal respiration (illustrated in Fig. 2.1) that can be obtained from the OCR kinetic graphs 
(Fig. 4.3 and Appendix 7.6) in the above experiments of MC metabolic analysis, where 0.5 µM 
concentration of FCCP was used, has to be interpreted cautiously for the SIRMu-1 cells, as they are 
less sensitive to FCCP than the primary MCs and the rMC-1 cells and the FCCP concentration used 
is not the optimal for this cell type, potentially leading to an underestimation of maximal respiration 
in the SIRMu-1 cells. In published studies, the FCCP concentration of 0.5 µM has been used with 
HeLa cells (Boehning et al., 2018; Faccenda et al., 2017) and the concentration of 1 µM has been 
used with MEFs (Bryant et al., 2018; Raini et al., 2017; Wu et al., 2009). Therefore, in a similar 
fashion to SIRMu-1, the OCRFCCP of MEFs in the experiments in this thesis might not be the maximal 
respiration. Interestingly, even with the possibility of an underestimation of maximal respiration, the 
MEFs still have the greatest level of the spare oxidative capacity (the difference between the OCRbasal 
and the OCRFCCP) among all the cell types under the conditions analysed (Fig. 4.3 and Appendix 
7.6). This also shows that while the MEFs are highly active, it does not appear that they have high 
rates of glycolysis because their OXPHOS is at capacity. Importantly, however, the underestimation 
of maximal respiration in the SIRMu-1 cells and MEFs has no impact on the interpretation of the 
results in regard to basal cellular metabolic activity, which is the main focus of this thesis.  
 
An important future experiment would be to incubate MCs with 13C-glucose and track the fate of the 
labelled carbons into intermediates in the glycolytic pathway, the TCA cycle and other pathways, 




The Seahorse extracellular flux analyser was tested and successfully optimised for the measurement 
of oxygen consumption and extracellular acidification, and used for the metabolic characterisation of 
cultured MCs. Metabolic analysis demonstrated that the primary rat MCs display the Warburg effect. 
Of the two immortalised MC lines, the rMC-1s also display the Warburg effect, and were more 
metabolically similar to primary MCs than were the SIRMu-1 cells, which are heavily dependent on 
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OXPHOS and do not display the Warburg effect. Thus, primary MCs and rMC-1 cells were used as 







Role of pyruvate kinase M2 
in the Warburg effect 




CHAPTER 5:  Role of pyruvate kinase M2 in the Warburg effect in retinal Müller cells  
5.1 Introduction 
The non-proliferative mammalian retina displays the Warburg effect (reviewed in Paper 1 (Ng et al., 
2015)) (Cohen and Noell, 1960; Tornquist and Alm, 1979; Warburg, 1925; Warburg et al., 1924; 
Warburg et al., 1930; Winkler, 1981, 1995), whereby cells predominantly utilise glycolysis for ATP 
production regardless of oxygen availability, which is surprisingly similar to proliferating cells 
including cancer cells (Hsu and Sabatini, 2008; Koppenol et al., 2011; Vander Heiden et al., 2009; 
Warburg, 1956; Warburg et al., 1927). Chapter 4 investigates one of the three main hypotheses of 
this thesis that cultured rat MCs display the Warburg effect, and the data support the hypothesis in 
cultured primary rat MCs and the rMC-1 immortalised MC line, consistent with previously published 
reports in freshly-isolated guinea pig MCs (Poitry-Yamate et al., 1995), cultured primary human MCs 
(Winkler et al., 2000), and rMC-1 cells (Winkler et al., 2003). The primary rat MCs and rMC-1 cells 
were therefore chosen as appropriate experimental tools to study the Warburg effect in the retina in 
this thesis. 
 
Not much is known about factors driving the Warburg effect in the retina. On the contrary, a number 
of agents have been implicated in driving the Warburg effect in cancer and other proliferating cells 
(reviewed in (Chaneton and Gottlieb, 2012; Dayton et al., 2016b; Dejure and Eilers, 2017; Semenza, 
2012; Ward and Thompson, 2012)). One such agent is a specific isoform of the glycolytic enzyme 
PK, PKM2 (Christofk et al., 2008a; Clower et al., 2010; Goldberg and Sharp, 2012; Palsson-
McDermott et al., 2015; Siddiqui et al., 2018).  
 
PK is an enzyme that catalyses the conversion of PEP into pyruvate in the glycolytic pathway 
(reviewed in (Mazurek, 2011). There are four PK isoforms, PKM1, PKM2, PKL and PKR, each with 
different tissue expression patterns (see section 1.4.1 in Chapter 1). PKM2 is the specific isoform 
that has been implicated in driving the Warburg effect in a number of cancer and proliferating cells 
(Christofk et al., 2008a; Clower et al., 2010; Goldberg and Sharp, 2012; Palsson-McDermott et al., 
2015; Siddiqui et al., 2018), which is likely facilitated by its function in the nucleus where it acts as a 
coactivator for, among others, the transcription factor HIF-1, leading to upregulation of HIF-1 target 
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genes, many of which are involved in glucose metabolism, and the consequent upregulation of 
glycolysis in concert with an inhibition of OXPHOS (Luo et al., 2011; Palsson-McDermott et al., 2015). 
This function in the nucleus and the contribution to the Warburg effect are unique to PKM2 but not 
its closely-related alternatively-spliced isoform, PKM1, which is encoded by the same gene PKM. 
Alternative splicing results in PKM1 and PKM2 having 11 common exons (exons 1-8, 11 and 12) and 
a mutually-exclusive exon: exon 9 for PKM1 and exon 10 for PKM2 (Noguchi et al., 1986) (Fig. 1.3). 
Exon 9 and exon 10 are of the same length; hence, both isoforms have the same numbers of amino 
acids (531). Each of exons 9 and 10 encodes 56 amino acids (Noguchi et al., 1986). Among these, 
only 22 amino acids are different between PKM1 and PKM2 for human and mouse, and 21 are 
different for rat, resulting in very similar predicted molecular weights between PKM1 and PKM2 in all 
three species (all are approximately 58 kDa; see section 1.4.1 in Chapter 1 for details). The amino 
acid residues in exon 10 of PKM2 that are different from exon 9 in PKM1 form a binding pocket for 
FBP (Dombrauckas et al., 2005; Noguchi et al., 1986), enabling allosteric regulation that is unique 
to PKM2. This implicates PKM2, but not PKM1, in regulating the fate of glucose within the cells (see 
section 1.4.3 in Chapter 1). 
 
With these specific roles of PKM2 and the evidence of PKM2 expression in the mammalian retina 
(Morohoshi et al., 2012), it was hypothesised that PKM2 plays a similar role in driving the Warburg 
effect in MCs as it does in cancer cells, which is explored in this chapter. 
 
5.2 Chapter aims 
This chapter addresses Aim 3 of the thesis: to investigate whether PKM2 drives the Warburg effect 
in MCs. 
 Aim 3.1:  To study the effect of PKM2 knockdown (KD) on the metabolism of glucose in MCs  




5.3 Experimental approach and overview 
PKM expression in cultured MCs was firstly elucidated. Secondly, to determine its specific role in 
MCs, PKM2 was knocked down using a lentiviral shRNA-mediated system and the cells analysed 
for glucose metabolism. Thirdly, to complement and confirm the results of PKM2 KD, PKM2 KO MCs 
were created by employing CRISPR/Cas9 technology, and the KO cells subjected to similar 
metabolic analysis to the KD cells.  
 
The results demonstrated that both cultured primary MCs and immortalised rMC-1 cells express 
PKM2. Attempts were then made to knock down PKM2 in primary MCs but were not successful due 
to low lentiviral transduction efficiency, despite trying different cell seeding densities and different 
batches and amounts of lentivirus. As rMC-1 cells display the Warburg effect, similar to primary MCs, 
they were chosen as the suitable MC cell line for analysis, and PKM2 KD and KO performed. 
Metabolic analyses showed that neither PKM2 KD nor PKM2 KO significantly affected glycolytic 
activity of rMC-1 cells, indicating that PKM2 is not a main driver of the Warburg effect in MCs.  
 
5.4 Results  
5.4.1 Pyruvate kinase M expression in Müller cells 
5.4.1.1 Verifying antibodies 
As PKM1 and PKM2 are encoded by the same gene, PKM, with the only difference being a mutually-
exclusive exon (exon 9 for PKM1 and exon 10 for PKM2) (Noguchi et al., 1986), specific antibodies 
which had been verified in rat tissues were required to investigate expression of these PK isoforms 
in cultured rat MCs by western blotting. A number of commercial antibodies were available, but in 
many cases they had been poorly verified and their specificity was questionable (reviewed in 
(Chaneton and Gottlieb, 2012).  
 
In preliminary studies, two commercially available anti-PKM2 antibodies were tested (Fig. 5.1), a 
polyclonal antibody from Cell Signaling Technology (CS) (#3198S) and a monoclonal antibody from 
Novus Biologicals (N) (#NBP1-48351). These data were presented in the candidate’s Honours thesis 
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(Kittipassorn, 2013) and published during the course of the candidate’s PhD in Paper 2 (Casson et 
al., 2016) (Appendix 7.2). Surprisingly, the two antibodies detected proteins of different sizes in 
human and mouse cell lines (human embryonic kidney HEK293T and mouse embryonic fibroblast 
NIH3T3 cells). The anti-PKM2 antibody from CS was generated using a synthetic peptide 
corresponding to sequences surrounding Serine 406 residue in the region encoded exclusively by 
exon 10 of human PKM2, while the immunogen used to generate the anti-PKM2 antibody from N 
was full length human PKM2 protein, which contains regions encoded by the common exons. In 
addition, CS performed specificity testing that indicated that the antibody only detected PKM2 and 
not PKM1 (personal communication with the manufacturer). It has also been shown independently 
that transfecting cells with a siRNA specific to PKM2 led to a KD of the protein detected by the same 
CS antibody on western blots (Goldberg and Sharp, 2012). Furthermore, this antibody was able to 
detect PKM2 in rat cells (Kittipassorn, 2013). Therefore, given the specificity and verification in rat 
cells of the anti-PKM2 antibody from CS, this antibody was selected for use in all experiments in this 
thesis.  
 
In addition to an antibody specific to PKM2, an antibody specific to PKM1 was also thought to be 
beneficial in determining whether treatments targeting PKM2 also affected PKM1 expression. 
Therefore, three commercially-available anti-PKM1 antibodies were tested: a monoclonal antibody 
from CS (#7067), a polyclonal antibody from Proteintech (PT) (#15821-1-AP), and a polyclonal 
antibody from N (#NBP2-14833). Liver tissues which mainly express PKL (Imamura and Tanaka, 
1972) were used as a negative control, while muscle tissues whose dominant PK isoform is PKM1 
(Imamura and Tanaka, 1972) were used as a positive control. Tissues from both mouse and rat were 
used. None of the three antibodies detected a band of the approximate size of PKM1 (58 kDa) in 
mouse liver, but did all detect bands of approximately 58 kDa, matching the quoted size of this protein 
(see section 1.4.1 in Chapter 1), in mouse muscle samples (Fig. 5.2), as expected. These findings 
suggested that all three antibodies correctly and specifically detected mouse PKM1. However, none 





Figure 5.1. Validating anti-PKM2 antibodies. Western blots of whole cell extracts from HEK293T and NIH3T3 
cell lines grown in hypoxia, probed for PKM2 using two commercially-available antibodies from Cell Signaling 
Technology (CS) (#3198S) and Novus Biologicals (N) (#NBP1-48351). Each of the two sample lanes was cut 
in the middle (dotted lines) and each half probed with each of the two antibodies as indicated. M, molecular 







Figure 5.2. Validating anti-PKM1 antibodies. Western blots of protein extracts from mouse and rat liver and 
muscle tissues, probed for PKM1 using commercially-available antibodies from (A) Cell Signaling Technology 
(#7067), (B) Proteintech (#15821-1-AP), and (C) Novus Biologicals (#NBP2-14833). Expected size of each 
protein is shown in brackets. Arrows indicate target protein bands and asterisks non-specific bands. Each blot 




Immunogens that were used to generate all three antibodies were peptides corresponding to part of 
the human PKM1 protein (Fig. 5.3). In the human PKM1 protein, residues 381-436 are encoded from 
exon 9, the exclusive exon of PKM1. The CS immunogen is a synthetic peptide of undefined length 
corresponding to residues surrounding Alanine 411 which is in the region encoded by exon 9 
(manufacturer’s data sheet). The PT immunogen corresponds to residues 398-417 which are also 
within the region encoded by exon 9 (manufacturer’s data sheet and personal communication with 
the manufacturer). The N immunogen corresponds to a C-terminal region of the human PKM1, 
between residues 350-450 (exact length of immunogen not provided by manufacturer) which span 
regions encoded by exons 8, 9 and 11. The regions of the human PKM1 protein corresponding to 
these immunogens are highly conserved in primary amino acid sequence between human and 
mouse (Fig. 5.3B), but not as well conserved between human and rat (Fig. 5.3C), which could explain 
why none of these antibodies can detect rat PKM1.  
 
Attempts were made to generate custom anti-PKM1 antibodies but these were not successful. Anti-
total PKM antibody (CS #3190S), which detects both isoforms of PKM, was then instead used to 
determine total PKM levels, and by comparison with the anti-PKM2 antibodies the relative level of 
PKM1, as performed previously (Goldberg and Sharp, 2012). The immunogen used to generate this 
pan-specific antibody was a synthetic peptide corresponding to residues around Glycine 200 of 
human PKM2 (manufacturer’s data sheet), which is in a region encoded by a common exon between 
PKM1 and PKM2, and is highly conserved between human and rat (Fig. 5.3C). Figure 5.4 shows 
western blots probed for total PKM (Fig. 5.4A) and PKM2 (Fig. 5.4B) on three different rat tissues: 
liver tissues which mainly express PKL and not PKM (Imamura and Tanaka, 1972) (reviewed in 
(Mazurek, 2011)), muscles which express PKM1 but not PKM2 (Imamura and Tanaka, 1972) 
(reviewed in (Mazurek, 2011)), and retinas that express both isoforms of PKM (Casson et al., 2016; 
Kittipassorn, 2013; Lindsay et al., 2014; Morohoshi et al., 2012). The blot incubated with the 
previously-verified anti-PKM2 antibody only showed positive protein determination in the rat retina 
sample (Fig. 5.4B, lane 3), as expected. The total PKM blot showed a band corresponding to PKM 
in both the rat muscle and the rat retina samples (Fig. 5.4A, lanes 2 and 3). Together these data 
demonstrate that the anti-total PKM antibody is able to detect both rat PKM1 and rat PKM2 proteins, 







Figure 5.3. Immunogens used to generate anti-PKM1 antibodies used in figure 5.1. (A) A schematic 
diagram showing immunogens against human PKM1 protein that were used to generate the three anti-PKM1 
antibodies used in figure 5.1 from Cell Signaling Technology (CS) (#7067), Proteintech (PT) (#15821-1-AP), 
and Novus Biologicals (N) (#NBP2-14833). Data on the CS and the NB immunogens from the manufacturers’ 
data sheets. Data on the PT immunogen from the manufacturers’ data sheets and personal communication with 
the manufacturer. Dashed boxes represent immunogens with length not provided. aa, amino acids. In (B) and 
(C) the amino acid sequence of human PKM1 (NCBI Reference Sequence: NP_872270.1) is aligned with that 
of mouse (NCBI Reference Sequence: NP_001240812.1) and rat (GenBank: AAB93666.1), respectively, using 
the NCBI BLAST services. Exon 9 (residues 381-436) is highlighted in yellow. CS immunogen is a synthetic 
peptide (length not provided) corresponding to residues surrounding Alanine 411 (pink circle). PT immunogen 
is a 20-amino acid-long peptide corresponding to residues 398-417 (green brackets). N immunogen (length not 






Figure 5.4. Anti-total PKM and anti-PKM2 antibodies. Western blots of protein extracts from rat liver, muscle 
and retina tissues, probed for total PKM (A) and PKM2 (B). Expected size of each protein is shown in brackets. 




5.4.1.2 Expression of pyruvate kinase M2 and total pyruvate kinase M in Müller cells 
Using the verified antibodies, the expression of PKM2 and total PKM in three different rat MCs 
(primary, rMC-1 and SIRMu-1) as well as primary MEFs and HeLa cells was investigated (Fig. 5.5). 
These same cells were also used in the subsequent metabolic analyses presented in figures 4.5 and 
4.6.  
 
The western blots demonstrated that all cell types express PKM2, with a very low levels in SIRMu-
1s and MEFs and at least an order of magnitude higher in the other three cell lines (Fig 5.5). A similar 
trend was observed with the levels of total PKM. Interestingly, PKM proteins of human (HeLa), mouse 
(MEF) and rat (three different MCs) all produced bands with small differences in apparent size, but 
all have the same number of amino acids (Fig 5.3). We had previously observed these slight 
differences in size and we hypothesised that they may be due to differences in sequence and/or 
post-translational modifications between species, affecting electrophoretic migration and apparent 
molecular weight. 
 
5.4.2 Effect of pyruvate kinase M2 knockdown on the Warburg effect in Müller cells 
To determine the specific role of PKM2 in glucose metabolism in MCs, we attempted to transiently 
knock down PKM2 protein in primary MCs, using the miR30-based shRNA system as described 
previously (Bersten et al., 2015). The glucose metabolism in these cells with PKM2 knocked down 
could then be analysed using lactate assays and Seahorse Cell Mito Stress Tests, as described in 
Chapter 4. 
 
5.4.2.1 Determining knockdown efficiency of shRNAs targeting pyruvate kinase M2 mRNA 
For the KD of PKM2, four different shRNAs targeting exon 10 of rat PKM2 were designed (shPKM2s 
1572, 1452, 1499 or 1501) and cloned into the pLV410 lentiviral expression vector together with the 
nuclear fluorescent protein Tomato (Bersten et al., 2015) (see section 2.6.1 in Chapter 2). The 
lentiviral system was chosen rather than transient transfection to increase efficiency, specifically for 
use with the primary MCs. As primary MCs are more difficult to grow and transfect, with a short life 





Figure 5.5. PKM2 and total PKM expression in Müller cells (MCs), MEFs and HeLa cells. Western blots of 
whole cell extracts from primary (1o) MEFs, HeLa cells, 1o MCs, rMC-1s and SIRMu-1s, probed for PKM2 and 
total PKM. Expected size of each protein is shown in brackets. Arrows indicate target protein bands and 




shRNAs was performed using the immortalised rMC-1 cell line. High transduction efficiencies of 50-
85% were achieved with the rMC-1 cells at 48 hours after transduction, as determined by 
fluorescence microscopy (see section 2.6.4 in Chapter 2) to quantify the number of cells with the 
constitutive Tomato fluorescent protein expression from the pLV410 expression vector. 
 
To determine the efficiencies of each of the shRNAs, rMC-1 cells transduced with lentivirus encoding 
either a non-targeting shRNA (shControl) or one of four shPKM2s (shPKM2s 1572, 1452, 1499 or 
1501), incubated for 48 hours, and then whole cell extracts analysed by western blotting (Fig. 5.6). 
Although not statistically significant, the results clearly show that shPKM2 1452 was the most efficient 
with an average of 67% decrease in PKM2 protein level compared to the shControl. shPKM2s 1572 
and 1499 were less efficient with an average of 37% and 41% decrease in PKM2 protein levels, 
respectively, compared to the shControl. shPKM2 1501 did not produce a consistent decrease in 
PKM2 levels; hence, shPKM2s 1452, 1572, and 1499 were chosen for subsequent experiments. 
 
5.4.2.2 Transduction efficiency in primary Müller and rMC-1 cells 
After testing the shPKM2s and successfully knocking down PKM2 in rMC-1 cells, similar experiments 
were performed on primary MCs. Figure 5.7 presents representative images taken three days after 
primary MCs (Fig. 5.7B upper panel) and rMC-1 cells (Fig. 5.7A lower panel) were seeded in a 96-
well cell culture plate and transduced with lentivirus encoding a nuclear Tomato fluorescence protein 
and either a non-targeting shRNA (shControl) or one of three shRNAs targeting PKM2 (shPKM2s 
1452, 1572, 1499). Hoechst 33342 nuclear staining indicates the total cell numbers and nuclear 
Tomato-positive cells indicate transduced cells. The representative primary MC images (Fig. 5.7A 
upper panel) are from a well with a 7.3% transduction efficiency, while the average transduction 
efficiencies for all shRNAs ranged from 3 to 14% (Fig. 5.7B). The rMC-1 images (Fig. 5.7A lower 
panel) are from a well with a 64% transduction efficiency while the average transduction efficiencies 
for all shRNAs ranged from 42-74% (Fig. 5.7B). Attempts were made to increase transduction 
efficiency in primary MCs, including employing different cell seeding densities and different batches 
and amounts of lentivirus; however, no experiments showed transduction efficiencies consistently 
above 50% and in most cases transduction efficiencies were less than 25%. These low transduction 




Figure 5.6. Determining knockdown efficiency of short hairpin RNAs (shRNAs) targeting Pkm2 mRNA. 
(A) Western blot of whole cell extracts from rMC-1 cells transduced with lentivirus encoding either shControl 
(non-targeting shRNA) or one of four shRNAs targeting Pkm2 mRNA (shPKM2s 1572, 1452, 1499 or 1501) and 
incubated for 48 hours, probed for PKM2. Blot representative of three independent experiments. In two 
experiments rMC-1 cells were seeded at 100,000 cells per well in a 24-well tray and transduced with 1.2 mL 
lentivirus per well. The third experiment was performed in a 6-well tray with the equivalent cell seeding density 
(500,000 cells per well) and lentivirus amount (6 mL per well). Expected band size of each protein is shown in 
brackets. Arrows indicate target protein bands. (B) A graph showing PKM2 band intensity normalised to the 
loading control actin. The relative PKM2 band intensity of the shControl is set to 100%. Data presented as mean 
± S.D. from three independent experiments, with the mean of each group labelled within each bar.  Statistical 
significance comparing to the shControl group was determined by one-way ANOVA followed by Dunnett’s 





Figure 5.7. Transduction efficiency of primary Müller cells (1o MCs) and rMC-1 cells. 1o MCs (15,000 cells 
per well) and rMC-1 cells (3750 cells per well) were seeded in growth medium (80 µL per well) in a Seahorse 
96-well cell culture plate and transduced with lentivirus (270 µL per well) encoding a nuclear Tomato 
fluorescence protein and either a non-targeting shRNA (shControl) or one of three shRNAs targeting PKM2 
(shPKM2s 1452, 1572, 1499). Three days after transduction, cells were stained with Hoechst 33342 nuclear 
staining and transduction efficiency assessed. (A) Representative fluorescence images from 1o MCs (upper 
panel) and rMC-1 cells (lower panel) transduced with shPKM 1572, showing nuclear Tomato-positive cells (right 
panel), which indicate transduced cells, in comparison to total cell numbers indicated by nuclear staining (left 
panel). Scale bar = 100 µm and applies to all images. (B) Transduction efficiency of each of the four shRNAs in 
1o MCs and rMC-1 cells. Data from one experiment (no statistical test performed) and presented as mean ± SD 
of two replicate wells per groups for 1o MCs and three replicate wells per group for rMC-1 cells, with the mean 
of each group labelled above each bar.  
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(i.e. with the best shRNA at best a 70% KD in 25% of cells could be achieved). Since the transduced 
cells express nuclear Tomato fluorescent protein, an attempt was made to enrich the transduced 
cells in a primary MC population by using FACS. However, the primary MCs were injured and did 
not recover after FACS; this was not unexpected for primary cells, which do not usually tolerate 
stress as well as immortalised cells. Given the difficulties in achieving adequate levels of transduction 
in the primary MCs, and the similarities in glycolytic dependency for ATP production and PKM2 
expression between the primary MCs and the rMC-1 cells, the rMC-1 cells alone were used to 
investigate the role of PKM2 in MCs using shRNA-mediated KD. 
 
5.4.2.3 Effect of pyruvate kinase M2 knockdown in the Warburg effect in rMC-1 cells 
To determine the effect of knocking down PKM2 protein levels on glucose metabolism, rMC-1 cells 
were transduced with lentivirus encoding either a non-targeting shRNA (shControl) or one of the 
three best shPKM2 (shPKM2s 1572, 1452, or 1499), incubated for three days, and then lactate 
assays and Seahorse Cell Mito Stress Tests performed, as described in Chapter 4 (Fig. 5.8). 
Lentivirus for all shRNAs resulted in comparable transduction efficiencies (Fig 5.8A). Western 
blotting (Fig. 5.8B, 5.8C and Appendix 7.8) showed that all shPKM2s produced PKM2 KD but with 
varying efficiencies and consistencies among three independent experiments, with the shPKM2 1452 
being the most efficient and consistent (on average ~80% KD). However, there was no significant 
difference in glycolytic indicators, including lactate efflux rates (Fig. 5.8D), kinetic profiles of ECARs 
and OCRs (Fig. 5.8E and Appendix 7.8), % contribution of glycolysis to ATP production (Fig. 5.8F) 
or basal ECAR/OCR ratios (Fig. 5.8G) between any of the three shRNAs targeting PKM2 and 
shControl. As a comparison, figure 5.8H shows a significantly decreased ECAR/OCR ratio in rMC-1 
cells treated with oxamate, a LDHA inhibitor, demonstrating the loss of the Warburg effect due to 
inhibition of aerobic glycolysis. These results demonstrate that the rMC-1 cells with greatly decreased 
PKM2 levels still display high glycolytic activity, relative to OXPHOS, to the same extent as control 














Figure 5.8. Effect of PKM2 knockdown in the Warburg effect in rMC-1 cells. (A) – (G) rMC-1 (3750 
cells/well) were seeded in a Seahorse 96-well cell culture plate and transduced with lentivirus encoding either 
a non-targeting shRNA (shControl) or one of three shRNAs targeting PKM2 (shPKM2s 1452, 1572, 1499). Three 
days after transduction, cells were washed and incubated in fresh assay medium (XF base medium with 10 mM 
glucose) for an hour before the medium collected for lactate assays. Cells were then subjected to a Seahorse 
XF Cell Mito Stress Test in the presence of glucose (10 mM), using oligomycin (2 µM), FCCP (0.5 µM), and 
rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs were measured three times during each of the four 
conditions. Three independent experiments (each with a minimum of six replicate wells per group) were 
performed. In two experiments, cell numbers and transduction efficiency for each shRNA at the end of the assay 
were determined in three representative wells by fluorescence microscopy after Hoechst 33342 nuclear staining, 
while cells in experimental wells (used for OCR and ECAR readings) were harvested and protein extracted for 
western blot analysis. In the third experiment, cell numbers in all experimental wells were determined by the 
ArrayScan after Hoechst 33342 staining. Proteins for western blot analysis were extracted from a replicate 
Seahorse cell culture plate. Transduction efficiency for each shRNA was determined from a representative well 
in the replicate Seahorse cell culture plate. (A) Transduction efficiency of lentivirus of each shRNAs presented 
as mean ± SD of three independent experiments, with the mean of each shRNA labelled above each bar. (B) 
Western blot, probed for PKM2 and total PKM. Expected band size of each protein is shown in brackets. Arrows 
indicate target protein bands and asterisks non-specific bands. Western blots representative of three 
independent experiments, with other blots shown in Appendix 7.8. (C) PKM2 band intensity normalised to the 
loading control actin. The relative PKM2 band intensity of the shControl is set to 100%. (D) Lactate efflux rates 
determined from media samples collected before each Cell Mito Stress Test, presented as mean ± SD from 
three independent experiments, each performed using samples from three representative wells per group. (E) 
Representative graphs from one of the three independent experiments showing changes in OCRs and ECARs. 
Data presented as mean ± SD from at least six replicate samples. OCR and ECAR graphs from all three 
experiments can be found in Appendix 7.8. (F) % contribution of glycolysis to ATP production and (G) Basal 
ECAR/OCR ratios were determined based on OCR and ECAR readings. Data in A, C, D, F and G are presented 
as mean ± SD from three independent experiments. Statistical significance comparing to the shControl group 
was determined by one-way ANOVA followed by Dunnett’s multiple comparison test. ns, not significant. (H) 
Effect of oxamate treatment on basal ECAR/OCR ratios in rMC-1 cells. Cells were seeded at 15,000 cells per 
well in a Seahorse cell culture plate. On the following day, cells were washed and incubated in fresh assay 
medium (XF base medium with 10 mM glucose) with or without oxamate for approximately three hours, and 
subjected to an XF Cell Mito Stress Test. Data presented as mean ± SD from three independent experiments 
(each with a minimum of two replicate wells per group). Statistical significance comparing to the untreated rMC-
1 cells was determined by an unpaired two-tailed student’s t-test. **p<0.01 
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While the KD did significantly reduce the levels of PKM2, it is important to consider the possibility 
that PKM2 is in excess in these cells, and the residual PKM2 (20-60% on average from the three 
shPKM2) is still able to drive the Warburg effect in MCs. Therefore, to further investigate whether 
PKM2 is required for driving the Warburg effect in MCs, and more specifically whether the residual 
level of PKM2 after the KD was enough to maintain its function, complete PKM2 KO rMC-1 cells 
were generated.  
 
5.4.3 Effect of pyruvate kinase M2 knockout on the Warburg effect in Müller cells 
PKM2 KO rMC-1 cell lines were generated using CRISPR/Cas9 technology and subsequently 
characterised in terms of their glucose metabolism.  
 
5.4.3.1 Generating rMC-1 cell lines with pyruvate kinase M2 knocked out using 
CRISPR/Cas9 
PKM2 and its splice variant PKM1 are encoded from the same gene Pkm (Noguchi et al., 1986). 
With alternative splicing, Pkm2 mRNA contains the exclusive exon 10 and Pkm1 contains the 
exclusive exon 9 (Fig. 1.3) (Chaneton and Gottlieb, 2012; Noguchi et al., 1986). A strategy was 
devised to generate PKM2 KO rMC-1 cells by removing exon 10 from the Pkm gene while keeping 
exon 9 intact, so that a complete loss of the PKM2 protein could be achieved without affecting PKM1.  
 
To use CRISPR/Cas9 technology to remove exon 10 of the Pkm gene, a strategy was employed 
where a pair of gRNAs were used: one targeting the intron between exon 9 and exon 10 and the 
other the intron between exon 10 and exon 11 (Fig. 5.9A) (see also Fig. 2.3 and section 2.7.1 in 
Chapter 2). Cas9 nuclease would cause a double stranded break at both sites targeted by the two 
gRNAs and the portion between the two cut sites, which contains exon 10, could be removed during 
subsequent repair. To control for non-specific off-target effects, two different pairs of gRNAs were 
designed, and each used to generate distinct lines of PKM2 KO cells. Two gRNAs (gRNAs A1 and 
A2) were designed to target the intron between exon 9 and exon 10, and another two gRNAs (gRNAs 
B1 and B2) were designed to target the intron between exon 10 and exon 11 (Fig. 5.9A). gRNA A1 
was paired with B1 to generate a PKM2 KO I cell population, and gRNA A2 was paired with B2 to 
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generate a PKM2 KO II population (Fig. 5.9A). A primer pair that flanks the cut sites of the gRNAs 
was designed for use in PCR screening of KO cells.  
 
5.4.3.2 Screening and verifying pyruvate kinase M2 knockout rMC-1 cell lines  
rMC-1 cells were co-transfected with a plasmid encoding a puromycin resistance gene for selection, 
and a dual-gRNA expressing Cas9 nuclease plasmid (Adikusuma et al., 2017) containing either no 
gRNAs (an empty vector (EV) to generate a WT control pool of cells), gRNAs A1 and B1 (to generate 
the KO I pool), or gRNAs A2 and B2 (to generated the KO II pool). Transfected cells of each pool 
(EV, KO I or KO II) were selected with puromycin for 48 hours, and the gDNA extracted from surviving 
cells and screened by PCR (Fig 5.9B, the lanes labelled “Pool”). Amplified gDNA from the EV pool 
shows an unmodified WT PCR product of approximately 1100 base pairs (bp) as expected, the same 
as a sample from parent rMC-1 cells (untreated). The KO I pool produced a WT band of 
approximately 1100bp, an expected KO I PCR product of approximately 580 bp, and an additional 
band of approximately 850 bp (Fig. 5.9A and B), suggesting that there are both WT (cells that were 
successfully transfected but the Cas9-mediated deletion was unsuccessful) and KO alleles mixed 
within the pool. Similar results were found with the KO II pool which produced a WT band of 
approximately 1100bp, an expected KO II PCR product of approximately 470 bp, and another band 
of approximately 800 bp (Fig. 5.9A and B). Note that the additional bands in both KO I and KO II 
pools may be due to the loss of only part of exon 10 during the DNA repair process. Importantly, the 
bands corresponding to the expected KO products were clear, indicating successful and relatively 
efficient loss of exon 10 in each pool of cells. 
 
Prior to further analysis, monoclonal lines were generated from each pool and propagated. gDNA of 
15 monoclonal lines from each KO pool was extracted and screened by PCR (Fig. 5.9B, the lanes 
labelled “monoclones”). Monoclonal lines were also generated from the WT control EV pool and five 
lines also screened by PCR. All EV monoclonal lines showed a WT band of approximately 1100 bp 
as expected. Importantly, a number of the KO I and KO II monoclonal lines produced bands of 
approximately 580 and 470 bp, respectively, consistent with the loss of exon 10. Three lines each 
from KO I and KO II were selected, first based on the absence of a band corresponding to the WT 







Figure 5.9. Generating and screening PKM2 knockout (KO) rMC-1 cell lines. (A) Schematic diagram 
illustrating a strategy to generate PKM2 KO cells by removing exon (E) 10 from the Pkm gene, using 
CRISPR/Cas9 technology. E10 was removed using a dual-guide RNA expressing Cas9 nuclease plasmid 
(Adikusuma et al., 2017) containing a pair of guide RNA (gRNAs). Two gRNAs (gRNAs A1 and A2) were 
designed to target the intron between E9 and E10, and another two gRNAs (gRNAs B1 and B2) were designed 
to target the intron between E10 and E11. gRNA A1 was paired with B1 to generate a KO I cell population 
(indicated by blue arrows and text). gRNA A2 was paired with B2 to generate a KO II population (indicated by 
green arrows and text). Distance between the two cut sites for each pair of gRNAs is shown. Forward (F) and 
reverse (R) primers were designed to screen for removal of E10, with PCR products of wildtype (WT) and KO 
indicated. Positions of the start of E9 and the end of E11 on chromosome (chr) 8 and the length of each exon 
are also illustrated. Black lines between exons indicate introns. bp, base pairs. The diagram is not to scale. (B) 
and (C) rMC-1 cells were co-transfected with a plasmid encoding a puromycin resistant gene for selection and 
one of three Cas9 nuclease plasmids: an empty vector (EV) without gRNA (to generate a WT control pool of 
cells), a vector with gRNAs A1 and B1 (to generate the KO I pool), or a vector with gRNAs A2 and B2 (to 
generated the KO II pool). Approximately 48 hours after transfection, transfected cells were selected with 
puromycin. gDNA was extracted from the three pools of cells and PCR performed (B). Five monoclonal lines 
were then isolated from the WT pool (EV) and 15 monoclonal lines from each of the KO pools. gDNA were 
extracted from these lines and used for PCR (B). Selected lines based on the PCR results (circled in red in C) 
were grown and proteins extracted and subjected to western blotting, probed for PKM2 and total PKM (C). 





 or smaller, if additional deletions had occurred during repair. The selected cell lines were lines 2, 4, 
12 for the KO I pool and lines 1, 2, 11 for the KO II (Fig. 5.9B). Three EV cell lines were randomly 
selected (lines 1, 2 and 4), and there was no obvious change in growth rate between the six KO lines 
compared to the EV lines.   
 
Whole cell extracts were made from each of these selected cell lines and subjected to western 
blotting (Fig. 5.9C). With the exception of the KO I line 2, PKM2 was not detected in any of the KO 
lines, consistent with the KO of PKM2. All of the KO cell lines displayed varying levels of total PKM, 
corresponding to PKM1, and these levels were lower than the total PKM in the EV control lines, also 
consistent with the KO of PKM2.  
 
The monoclonal line from each of the KO pools that displayed the most similar level of total PKM to 
the EV control lines (line 12 for KO I, line 1 for KO II) was chosen, and the amplified DNA analysed 
by Sanger sequencing. Figure 5.10 schematically illustrates the modified alleles, based on 
sequencing results, of the monoclonal PKM2 KO I line 12 and the monoclonal PKM2 KO II line 1. 
One allele of the KO I line 12 has lost 524 bp and the other 569 bp (Fig. 5.10). For the KO II line 1, 
one allele has lost 771 bp and the other 633 bp (Fig. 5.10). Both alleles of each cell line have exon 
10 completely removed, and the 3’ end of exon 9 remains intact, confirming the complete KO of 
PKM2.  
 
These two monoclonal PKM2 KO lines, and the corresponding EV control line, were then analysed 
metabolically using lactate assays and Seahorse Cell Mito Stress Tests. In the remainder of this 
thesis, the KO I line 12 is referred to as the KO I line, and the KO II line 1 is referred to as the KO II 







Figure 5.10. Modified Pkm alleles of selected monoclonal PKM2 knockout (KO) rMC-1 cell lines. 
Schematic diagrams showing the modified alleles of the KO I line 12 and the KO II line 1 based on Sanger 
sequencing results. Triangles and text underneath indicate the portion of each allele that was removed and its 




5.4.3.3 Effect of pyruvate kinase M2 knockout on the Warburg effect in rMC-1 cells 
Lactate assays and Seahorse Cell Mito Stress Tests were performed on the two distinct PKM2 KO 
rMC-1 cell lines in comparison to the WT line (Figure 5.11). Western blots confirmed that the two KO 
lines lacked PKM2, and had reduced total PKM, compared to the WT control (Fig. 5.11A). 
Parameters indicative of glycolytic activity, namely lactate efflux rates (Fig. 5.11B), ECAR and OCR 
kinetic profiles (Fig. 5.11C and Appendix 7.9), % contribution of glycolysis to ATP production (Fig. 
5.11D), and basal ECAR/OCR ratios (Fig. 5.11E), were not significantly changed in either the KO I 
line or the KO II line compared to the WT cells, and similar to previous observations with untreated 
rMC-1 and primary MCs (Fig. 4.6 and 4.7). While there was a small apparent change in lactate 
production, this is not statistically significant and did not alter either the contribution of glycolysis to 
ATP production or the basal ECAR/OCR ratio, which were very similar to the WT cells. Thus, any 
effects on metabolism with the loss of PKM2 are subtle, and the Warburg effect is essentially similar 
to the WT cells. These data are consistent with the PKM2 KD results (Fig. 5.8), and support the 
conclusion that PKM2 is not a major driver of the Warburg effect in rMC-1 cells. Of note, the KO I 
line had a small but statistically significant lower OCRbasal, OCRFCCP and OCRcoupled compared to the 
WT cells, but these results were not consistent with those of the other PKM2 KO line (KO II) in which 
there was either no significant change (for OCRbasal and OCRFCCP) or an increase (OCRcoupled) 
compared to the WT, suggesting that these are likely off-target effects (Appendix 7.9B and C). 
Importantly, the inconsistencies of these results between the two KO lines indicate that these 
changes are not specific to PKM2 KO. 
 
5.5 Discussion 
5.5.1 Pyruvate kinase M2 expression in cultured Müller cells and correlation with glycolytic 
dependency 
Firstly, PKM2 expression in different cultured rat MCs was determined using a verified PKM2-specific 
antibody (Kittipassorn, 2013) (Paper 2 (Casson et al., 2016) (Appendix 7.2)) (Fig. 5.4B). The 
specificity of the antibody is particularly crucial as PKM2 and PKM1 have very similar amino acid 
sequences and predicted molecular weights (See section 1.4.1 in Chapter 1). This issue also exists 
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in published studies that used anti-PKM2 antibodies that have not been verified, the results of which 
have to be interpreted with caution (reviewed in (Chaneton and Gottlieb, 2012)).  
 
Using the verified antibody, this thesis shows that the three MCs (primary, rMC-1 and SIRMu-1), 
primary MEFs and HeLa cells all express PKM2 but to different degrees (Fig. 5.5). PKM2 expression 
in primary rat MCs is consistent with the results of western blotting and immunocytochemistry 
presented in the candidate’s Honours thesis (Kittipassorn, 2013) and with PKM2 expression in 
cultured primary mouse MCs (Lindsay et al., 2014). PKM2 expression in rMC-1 and HeLa cells is 
also in agreement with published reports (Bluemlein et al., 2011; Christofk et al., 2008a; Lindsay et 
al., 2014). This thesis adds to that knowledge by showing that the SIRMu-1 cells also express PKM2 
and that each of the five cell types investigated expresses PKM2 to a different degree. SIRMu-1 cells 
and primary MEFs express PKM2 at a level at least ten times lower than the other three cell types. 
Interestingly, PKM2 protein levels correlate with the cellular dependency on glycolysis for ATP 
production as presented in Chapter 4 (Fig. 4.4). HeLa cells, rMC-1 cells and primary MCs with higher 
PKM2 levels are more dependent on glycolysis for ATP production than on OXPHOS (on average 
over 50% of ATP is derived from glycolysis). MEFs and SIRMu-1 cells that have much lower levels 
of PKM2 are oxidative and on average less than 50% of ATP is derived from glycolysis. This agrees 
with a previously published finding where activated CD4 and CD8 T cells were shown to be more 
glycolytic and express higher levels of PKM2 than resting T cells (Cao et al., 2014). This correlation 
suggests that PKM2 might be involved in the control of glycolytic activity in cells. However, it does 
not indicate a causal relationship and further investigations are required.  
 
In addition to PKM2 expression, it was also of interest to determine corresponding PKM1 expression. 
Unfortunately, a verified PKM1-specific antibody that works with rat PKM1 was not available (Fig. 
5.2), consistent with that described in a collaborative study (Paper 2 (Casson et al., 2016)) (Appendix 
7.2). A verified anti-total PKM antibody was instead used, similar to that used previously by others 
(Goldberg and Sharp, 2012). This antibody targets a common area of PKM1 and PKM2 proteins and 
can detect both isoforms (Fig. 5.4). Total PKM expression is higher in HeLa cells, rMC-1 cells and 
primary MCs than in MEFs and SIRMu-1 cells, following the same trend as PKM2 levels. Total PKM 







Figure 5.11. Effect of PKM2 knockout (KO) on the Warburg effect in rMC-1 cells. Experiments were 
performed on three rMC-1 monoclonal cell lines: WT (the empty vector EV1 line), PKM2 KO I (the KO I line 12) 
and PKM2 KO II (the KO II line 1). (A) Western blot of whole cell extracts probed for PKM2 and total PKM. 
Results representative of three independent experiments. Expected size of each protein is shown in brackets. 
Arrows indicate target protein bands and asterisks non-specific bands. (B) – (E) The WT, the PKM2 KO I and 
the PKM2 KO II rMC-1 cell lines were seeded at 15,000 cells/well in a Seahorse 96-well cell culture plate. On 
the following day, cells were washed and incubated in fresh assay medium (XF base medium with 10 mM 
glucose) for an hour before the medium of each well was collected to use as samples for lactate assays. Cells 
were then subjected to an XF Cell Mito Stress test using oligomycin (2 µM), FCCP (0.5 µM), and 
rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs were measured three times during each of the four 
conditions. Three independent experiments (each with a minimum of eight replicate wells per group) were 
performed. Cell numbers from all three experiments were determined by the ArrayScan after Hoechst 33342 
nuclear staining. (B) Lactate efflux rates determined from media samples collected before each Cell Mito Stress 
Test was performed, presented as mean ± SD from the three independent experiments, each performed using 
samples from three representative wells per group. (C) Representative graphs from one of the three 
independent experiments showing changes in OCRs and ECARs. Data presented as mean ± SD from at least 
eight replicate samples. OCR and ECAR graphs from all three experiments can be found in Appendix 7.9. (D) 
% contribution of glycolysis to ATP production and (E) Basal ECAR/OCR ratios were determined based on OCR 
and ECAR readings. Data in B, D and E are presented as mean ± SD from the three independent experiments. 
Statistical significance comparing to WT was determined by one-way ANOVA followed by Dunnett’s multiple 




(Kittipassorn et al., 2019a) and Paper 5 (Kittipassorn et al., 2019b) in Chapter 3. Unlike the clear 
difference in the protein levels, even when the stringency of the analysis was reduced to just a two-
fold difference in expression levels, there was no significant difference in the expression of the PKM 
transcripts between SIRMu-1 cells and primary MCs (Table 4.1), which could be due to post-
transcriptional regulation. A similar observation has previously been demonstrated with glutamine 
synthetase (GS), where the difference in its mRNA level in SIRMu-1 cells compared with primary 
MCs was of a lower degree than the difference in protein levels (data presented and discussed in 
Paper 4 (Kittipassorn et al., 2019a) in Chapter 3). Quantification of the amounts of each isoform 
could not be determined from the RNA-seq data. 
 
5.5.2 Role of pyruvate kinase M2 in the Warburg effect in cultured Müller cells  
To investigate the role of PKM2 in the Warburg effect in MCs (Aim 3 of the thesis), PKM2 KD and 
KO were performed. Methods and agents that specifically target PKM2 but not PKM1 were critical 
as the two isoforms are closely related. Although there were varying KD efficiencies (on average 
~40-80%), metabolic analysis of the rMC-1 cells with PKM2 knocked down clearly demonstrated that 
the KD did not significantly affect the glycolytic activity of rMC-1 cells as shown by no statistically 
significant changes in any of the glycolytic parameters (lactate efflux rates, % contribution of 
glycolysis to ATP production and basal ECAR/OCR ratios) between the KD cells and the control (Fig. 
5.8), suggesting that PKM2 is not a main driver of the Warburg effect in cultured MCs.  
 
Next, rMC-1 cells with PKM2 knocked out were generated in order to differentiate between two 
possibilities: that PKM2 is not a major driver of the Warburg effect in MCs or that the residual amount 
of PKM2 (on average ~20-60%) was adequate to maintain its function of promoting the Warburg 
effect. A study has shown that a 90% decrease in PKM2 levels is required to illicit a 50% decrease 
in cell viability in HCT116 cells (Goldberg and Sharp, 2012)). Although cell viability is not the same 
biological effect as that being investigated in this thesis, given that the average KDs achieved were 




Two distinct monoclonal lines of rMC-1 cells with PKM2 knocked out were generated by removing 
the PKM2-specific exon 10 from the Pkm gene disturbing the PKM1-specific exon 9. Both lines had 
a complete loss of PKM2 protein and similar levels of total PKM (Fig. 5.9 and 5.11). The levels of 
total PKM in both KO lines were lower than that of the WT control line but were still present. As PKM2 
was completely lost, the presence of the total PKM bands in the KO lines shows that the knocking 
out of PKM2 by manipulating the Pkm gene did not stop the expression of PKM1. 
 
The KO lines were subjected to metabolic analysis (Fig. 5.11). PKM2 KO did not significantly affect 
the glycolytic activity of the rMC-1 cells, similar to the results of the PKM2 KD cells, confirming that 
PKM2 is not a main driver of the Warburg effect in cultured MCs. This also suggests that the 
correlation between PKM2 protein levels and glycolytic dependency of cells is not a causal 
relationship. It is possible that PKM2 does play a subtle role in glucose metabolism that cannot be 
detected in this series of experiments, but clearly not the major role it is postulated to play in some 
cancer and other proliferating cells that display the Warburg effect (Christofk et al., 2008a; Clower et 
al., 2010; Goldberg and Sharp, 2012; Palsson-McDermott et al., 2015) (reviewed in (Chaneton and 
Gottlieb, 2012; Dayton et al., 2016b)). 
 
Although it is unlikely that PKM1 expression levels were decreased in the PKM2 KD and KO cells as 
the materials and methods used to knock down and knock out PKM2 were highly specific, a limitation 
of this thesis is that it cannot be directly shown that PKM1 expression levels were not reduced with 
the KD and the KO of PKM2 due to the unavailability of PKM1-specfic antibodies. Nevertheless, 
since neither PKM2 KD nor KO affects the Warburg effect in rMC-1 cells, and the changes in PKM2 
protein levels (a decrease for the KD and an absence for the KO) were conclusively verified, it is 
clear that PKM2 is not a main driver of the Warburg effect in these cells in vitro.  
 
5.5.3 Pyruvate kinase M2 expression in Müller cells in vivo  
At the commencement of this PhD project, there was limited information on PKM2 expression in 
different cell types of the retina in situ or in vivo. More recent studies have addressed this matter by 
immunohistochemical analysis of retinal sections (Paper 2 (Casson et al., 2016) (Appendix 7.2)) 
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(Lindsay et al., 2014; Rueda et al., 2016). Unlike the cultured rat MCs depicted in this thesis, there 
is no discernible expression of PKM2 in MCs in mouse and rat retinal sections (Paper 2 (Casson et 
al., 2016) (Appendix 7.2)) (Lindsay et al., 2014; Rueda et al., 2016). On the contrary, there is some 
expression of PKM2 in MCs in human and marmoset retinas, indicating differences between species 
(Paper 2 (Casson et al., 2016) (Appendix 7.2)). Interestingly, PKM2 is strongly expressed in 
photoreceptors in all four species (Paper 2 (Casson et al., 2016) (Appendix 7.XX)) (Chinchore et al., 
2017; Lindsay et al., 2014; Rajala et al., 2018a; Rajala et al., 2016; Rueda et al., 2016). For PKM1, 
there is expression in photoreceptors but no discernible expression in MCs in mouse retinas (Paper 
2 (Casson et al., 2016) (Appendix 7.2)) (Lindsay et al., 2014; Rueda et al., 2016). PKM1 is also 
expressed in photoreceptors in marmosets and humans, while PKM1 localisation in rat retinas 
remains largely unknown due to the unavailability of verified antibodies (Paper 2 (Casson et al., 
2016) (Appendix 7.2)). Detailed data on PKM1 and PKM2 expression and localisation in the retina 
are presented and discussed in Paper 2 (Casson et al., 2016) (Appendix 7.2). Interestingly, analysing 
microarray gene expression data from a previously published study (Roesch et al., 2008), Lindsay 
et al. reported that freshly isolated mouse MCs express a low level of Pkm transcripts while 
photoreceptors express a much higher level (Lindsay et al., 2014). The mouse MCs were freshly 
isolated and had not been in culture before the gene expression study was performed and therefore 
were highly relevant to MCs in situ (Roesch et al., 2008). This not only suggests that photoreceptors 
strongly express PKM, in agreement with the immunohistochemical data (Paper 2 (Casson et al., 
2016) (Appendix 7.2)) (Lindsay et al., 2014; Rueda et al., 2016), but it also shows that there is some 
PKM expression in freshly isolated rodent MCs and this indicates the possibility that the absence of 
discernible PKM expression in MCs in retinal sections of rodents shown by immunohistochemistry 
(Casson et al., 2016; Lindsay et al., 2014; Rueda et al., 2016) could be because the levels are too 
low to be detected by this method. However, it has to be kept in mind that it could also be due to a 
poor correlation between mRNA and the protein levels because of post-transcriptional regulation, 
and the possibility that freshly isolated MCs are still not exactly the same as MCs in situ. 
Nevertheless, rat MCs in situ do not strongly express PKM2 in contrast to the cultured rat MCs shown 
in this thesis. Of note, there are very limited data on expression analysis of Pkm transcripts in the 
retina by in situ hybridisation; one study has shown in mouse retinas that PKM2 is expressed in the 
photoreceptor layer and that PKM1 is expressed in the INL, in which MC bodies are usually located. 
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(Chinchore et al., 2017). In addition, the same study has shown by PCR analysis that Pklr transcripts 
are not expressed in the retina (Chinchore et al., 2017). 
 
Changes in protein expression in MCs after a period of being cultured have been shown previously 
although PKM2 expression was not directly assessed (Hauck et al., 2003). The difference in PKM2 
expression in MCs in situ from published studies (Paper 2 (Casson et al., 2016) (Appendix 7.2)) 
(Lindsay et al., 2014; Rueda et al., 2016) and in culture as demonstrated in this thesis could be 
because cultured cells adopt PKM2 expression for a survival advantage in vitro. It could be argued 
that this is the case for the rMC-1 cells and the primary MCs. The rMC-1 cells proliferate effectively 
indefinitely and although primary MCs are short-lived, they do survive in culture for a period of time 
(typically four to eight weeks) (Paper 4 (Kittipassorn et al., 2019a) in Chapter 3). However, the 
SIRMu-1 cells, which also proliferate essentially indefinitely and are resilient in culture, and primary 
MEFs, which have a short life span but also survive in culture, express a much lower level of PKM2; 
this does not entirely support the above argument that PKM2 expression provides survival or 
proliferation advantages.  
 
This is in part similar to a study by Israelsen et al. where cell lines were generated from mammary 
tumours of Pkm2fl/fl mice with a conditional deletion of PKM2 in the tumours by Cre recombinase-
mediated exon 10 excision (Israelsen et al., 2013). These cell lines unexpectedly retain at least one 
Pkm2fl allele and express high levels of PKM2 protein even though PKM2 deletion was observed in 
the parent tumours. The study then suggests that transition of cells from in vivo to tissue culture 
preferably selects for the few cells in which both Pkm alleles had not undergone recombination. 
However, upon deleting the remaining Pkm2fl allele in the cell lines in vitro, they found that the loss 
of PKM2 did not change oxygen consumption or gene expression induced by hypoxia or β-catenin 
and concluded that these functions or in vitro proliferation were not the basis of the selection for the 
few PKM2-expressing cells during the generation of the tumour cell lines.  
 
Overall, whether or not PKM2 expression correlates with or provides an advantage for cell survival 
in vitro requires further investigation, similar to the topic of the conflicting roles of PKM2 in cellular 
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proliferation in vivo and tumourigenesis discussed in the literature (Christofk et al., 2008a; Dayton et 
al., 2016a; Goldberg and Sharp, 2012; Israelsen et al., 2013). Furthermore, to conclusively determine 
the role of PKM2 in MCs in vivo, MC-specific PKM2 KO mice could be generated by crossing mice 
that specifically express Cre recombinase in MCs with floxed Pkm2 mice, and the retinas analysed 
for MC functions. 
 
5.5.4 Cultured Müller cells as a model to study the Warburg effect in the retina and beyond  
The apparent difference in PKM2 expression between MCs in situ and in culture has made cultured 
rat MCs a less physiologically relevant model for the study of the role of PKM2 in the Warburg effect 
in the retina. It does not indicate, however, that cultured MCs are not a useful tool for the study of 
the Warburg effect in the retina at all, as they may have other qualities that are similar to MCs in vivo 
which remain to be determined. Furthermore, primary MCs are still one of the very few cell types that 
are slowly-proliferative and yet display the Warburg effect, rendering them a unique system for the 
study of both the Warburg effect in general, and the reasons behind the existence of this 
phenomenon that are independent of the proliferation demands of the cells. 
 
Importantly, this thesis adds to the body of knowledge in the field of glucose metabolism and shows 
that the role of PKM2 in the Warburg effect might not be as universal as previously postulated 
(Christofk et al., 2008a; Clower et al., 2010; Goldberg and Sharp, 2012; Palsson-McDermott et al., 
2015) (reviewed in (Chaneton and Gottlieb, 2012; Dayton et al., 2016b)) and that it might be cell 
type-dependent. In addition, it would still be beneficial to determine why PKM2 does not play a crucial 
role in driving the Warburg effect in primary MCs, such as determining the predominant allosteric 
form (tetrameric, dimeric or monomeric), the state of PKM2 phosphorylation and other post-
translational modifications, and the interaction of PKM2 with HIF-1 and PHD3 in the primary MCs, 
which would all contribute to the knowledge of PKM2 function. As PKM2 has been reported to 
contribute to the Warburg effect in cancer and proliferating cells by acting as a coactivator of HIF-1 
and upregulating glycolysis (Luo et al., 2011; Palsson-McDermott et al., 2015), PKM2 not significantly 
affecting the Warburg effect in cultured MCs described here could be either because HIF-1 also does 
not play a crucial role in the Warburg effect, or because PKM2 does not interact and/or is not acting 
as a coactivator of HIF-1 in this system. The former could be investigated by assessing metabolic 
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changes in rMC-1 cell lines with HIF-1 knocked out, which will be carried out as part of future work 
in our laboratory. If HIF-1 KO does lead to significant changes in the Warburg effect in rMC-1 cells, 
the next step will be to determine whether PKM2 interacts with HIF-1 in cultured MCs. Being a unique 
cell type that proliferates slowly and displays the Warburg effect, it would also be beneficial to use 
cultured MCs to investigate the role in the Warburg effect of other potential drivers that have been 
implicated in cancer cells, including the PI3K pathway (Makinoshima et al., 2015; Ward and 
Thompson, 2012) and Myc (Dejure and Eilers, 2017).  
 
In terms of the study of the Warburg effect in the retina in vivo and the role of PKM2, photoreceptors 
might be a more physiologically relevant model as they strongly express PKM2 in situ (Paper 2 
(Casson et al., 2016) (Appendix 7.2)) (Lindsay et al., 2014; Rajala et al., 2018a; Rajala et al., 2016; 
Rueda et al., 2016), have recently been shown to be a major source of lactate production in the retina 
(Lindsay et al., 2014), make up the majority of cells in the retina (Jeon et al., 1998; Macosko et al., 
2015) and are arguably the most important cell types being the light-sensing cells. In fact, recent 
studies have investigated the role of PKM2 in the Warburg effect and other biological aspects in 
photoreceptors (Chinchore et al., 2017; Rajala et al., 2018a; Rajala et al., 2018b; Rajala et al., 2016). 
This will be further discussed in Chapter 6. 
 
5.5.5 Conclusions 
Cultured primary MCs, rMC-1 and HeLa cells, which depend on glycolysis for ATP production, 
strongly express PKM2. MEFs and SIRMu-1 cells, which predominantly use OXPHOS, also express 
PKM2 but at much lower levels. This suggests a correlation between PKM2 protein levels and the 
glycolytic dependency of cells. PKM2 KD and KO do not significantly affect the Warburg effect in 
rMC-1 cells. This is not consistent with one of the main hypotheses of this thesis that PKM2 drives 
the Warburg effect in cultured MCs, and it also indicates that the role of PKM2 in the Warburg effect 
may be cell-type dependent. Unlike cultured rat MCs, there is no discernible PKM2 expression in rat 
MCs in situ (Paper 2 (Casson et al., 2016) (Appendix 7.2)) (Lindsay et al., 2014; Rueda et al., 2016). 
This makes cultured MCs a less physiologically relevant model for the study of the role of PKM2 in 
the Warburg effect in the retina. However, cultured MCs could still be a good experimental tool to 
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study the role of factors other than PKM2 in the Warburg effect in the retina as well as to investigate 











CHAPTER 6:  Final discussion and future perspectives 
The hypotheses examined in this PhD project were 1) that the SIRMu-1 cell line originated from 
primary MCs, 2) that cultured rat MCs displayed the Warburg effect, and 3) that PKM2 drove the 
Warburg effect in cultured MCs. These hypotheses logically defined the aims of the thesis to be 1) 
to establish and characterise the novel spontaneously immortalised rat MC line SIRMu-1, 2) to 
determine whether cultured rat MCs displayed the Warburg effect, and 3) to investigate whether 
PKM2 drove this Warburg effect in MCs. All aims were successfully addressed. For Aim 1, the 
SIRMu-1 cell line was established and verified to originate from primary MCs (Chapter 3). For Aim 2 
(Chapter 4), metabolic analysis, consisting of lactate assays and Seahorse extracellular flux analyser 
assays which measured OCRs and ECARs, showed that cultured primary rat MCs and immortalised 
rMC-1 cells do predominantly use glycolysis to produce ATP, even in the presence of abundant 
oxygen, and hence, do indeed display the Warburg effect (Fig. 4.3 and 4.4), supporting the second 
hypothesis. Note that in contrast, the SIRMu-1 cells unexpectedly did not display the Warburg effect 
and are highly oxidative (Fig. 4.3 and 4.4), and therefore only the primary MCs and rMC-1 cells were 
used to explore the role of PKM2 in the Warburg effect in MCs (Chapter 5). The results for Aim 3, 
however, demonstrated that PKM2 KD and KO did not significantly affect the glycolytic activity of 
rMC-1 cells (Fig. 5.8 and 5.11), and it was thus concluded that PKM2 does not act as a main driver 
of the Warburg effect in cultured MCs. 
 
6.1 The novel spontaneously-immortalised SIRMu-1 Müller cell line as an 
experimental tool for ophthalmology research and other fields 
The SIRMu-1 cells were verified to originate from primary MCs but exhibit characteristics of 
immortalised cells, including rapid proliferation, an effectively indefinite life span and relatively high 
transfection efficiency (Paper 4 (Kittipassorn et al., 2019a) in Chapter 3). Therefore, they are a useful 
experimental tool for MC research. The SIRMu-1 cell line has a more similar overall transcriptome 
to primary MCs than does the rMC-1 line (Sarthy et al., 1998), another well-established immortalised 
MC line (Paper 4 (Kittipassorn et al., 2019a) in Chapter 3). This suggests that in general the SIRMu-
1 cells are a more suitable experimental model for gene expression studies in MCs. For specific 
genes, however, it has to be verified which cell line expresses the genes of interest at a more similar 
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level to the primary MCs and MCs in vivo. While the SIRMu-1 cells have very similar morphology to 
primary MCs, the rMC-1 cells are morphologically different from the primary MCs. This indicates that 
the SIRMu-1 cells may be a more appropriate experimental tool for the study of MC morphology and 
cytoskeleton (Scaife and Langdon, 2000). Furthermore, the SIRMu-1 cells were shown to be derived 
from a male rat, while the rMC-1 are female rat-derived cells (Paper 4 (Kittipassorn et al., 2019a) in 
Chapter 3); both can be useful and complementary for gender-specific ophthalmologic studies. 
 
As a corollary, the SIRMu-1 cells spontaneously became immortalised without having been 
intentionally transformed with exogenous reagents. Thus, these cells can theoretically be used to 
study spontaneous cellular immortalisation, and more specifically, underlying mechanisms and 
differential gene expression related to this event (e.g. using RNA seq data from this study, described 
in Paper 4 (Kittipassorn et al., 2019a) and Paper 5 (Kittipassorn et al., 2019b) in Chapter 3). 
Underlying mechanisms of spontaneous immortalisation were not investigated in this thesis as they 
did not fall under the original remit of the study.  
 
This thesis also showed that the immortalised, highly-proliferative SIRMu-1 cells exhibit a relative 
preference for oxidative metabolism, which is vastly different from the short-lived, slowly-proliferative, 
highly-glycolytic primary MCs from which they originated (Fig. 4.3 and 4.4). Although this indicates 
that the SIRMu-1 cells are not a suitable experiment tool to represent cultured primary MCs in the 
study of glucose metabolism as discussed in this thesis, it suggests another potential use for the 
SIRMu-1 cells as a valuable model for other aspects of cellular metabolism research. They can be 
used to study if and how OXPHOS is related to proliferation, or how cells can switch between 
glycolytic dependency to more oxidative metabolism, especially when their overall transcriptome is 
very similar to that of primary MCs from which they originated (Paper 4 (Kittipassorn et al., 2019a)) 
and when there was no significant difference in the expression of key genes involved in glucose 
metabolism (Table 4.1 and Fig 4.8). For example, it would be informative to assess the number of 
mitochondria per cell in SIRMu-1 cells compared with that of primary MCs to determine whether the 




6.2 Investigating cellular metabolism  
Cells that display the Warburg effect have upregulated aerobic glycolysis and common phenotypes 
are high lactate production, low oxygen consumption and high extracellular acidification (Hsu and 
Sabatini, 2008; Koppenol et al., 2011; Vander Heiden et al., 2009; Warburg, 1956; Warburg et al., 
1927). It is important to determine all the characteristic parameters together to obtain a 
comprehensive profile of metabolism of the cell type of interest because cells that have a high lactate 
production might not always primarily depend on glycolysis for ATP production, as seen with the 
primary MEFs in this thesis (Fig. 4.3 and 4.4). 
 
When analysing and drawing conclusions from metabolic studies of glucose, both in this thesis and 
beyond, the experimental conditions and their relevance to in vivo conditions needs to be taken into 
account. For example, one key condition is the concentration of glucose used. Low glucose 
concentrations in culture medium can cause issues with attachment of cells in primary mixed retinal 
cultures, from which the primary MCs are derived, and hence we and others use media containing 
25 mM glucose to promote cell attachment in primary neuron/glial cultures and primary MC cultures 
(Eide and McMurray, 2005; Wood et al., 2005) (Paper 4 (Kittipassorn et al., 2019a) in Chapter 3). All 
other cell types that were used for experiments alongside primary MCs were also maintained in 
medium containing 25 mM glucose to keep the growth conditions consistent with primary MCs. 
However, all cells were cultured in medium with 5.5 mM glucose, which is more physiologically 
relevant (Potter et al., 2016; Wang et al., 1997a, b) and recommended for use by the Seahorse 
analyser’s manufacturer, or at least 24 hours before being seeded for Seahorse assays, which is at 
least 40 hours before the start of the assay. During the Seahorse assays 10 mM glucose, a saturating 
concentration, was used in the assay medium as recommended by the manufacturer to ensure that 
cellular metabolism was not restricted by the amount of substrate. Of note, in the current study cells 
cultured in 5.5 mM glucose showed no obvious difference in cellular morphology or proliferation 
compared to cells cultured in 25 mM glucose. However, a study has reported that cultured rMC-1 
cells grown in a high glucose concentration (30 mM) for seven days show reduced basal OCR, 
maximal OCR and basal ECAR, as well as changes in mitochondrial morphology, compared to cells 
grown in 5 mM glucose (Tien et al., 2017). A limitation of this thesis is that it is not known whether 
the use of 25 mM glucose also affected cellular metabolism in our system and if so, whether culturing 
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the cells in 5.5 mM glucose for at least 40 hours before the start of the Seahorse assays was long 
enough to re-adjust the cells to an arguably more physiological state. An informative follow-up 
experiment would be to maintain the cells in 5.5 mM glucose, with the caution of the cell attachment 
issues in the primary cultures, subject them to Seahorse assays and compared the results with those 
of this thesis to determine the influence of glucose concentration in the media on glucose 
metabolism. Importantly, the use of 25 mM glucose in media does not affect the validity of the findings 
in this thesis. The primary MCs and the rMC-1 cells clearly display the Warburg effect in the culture 
and experimental conditions of this thesis and therefore are a suitable model for the study of the 
Warburg effect. 
 
6.3 Investigating retinal metabolism 
The second hypothesis of this thesis was that cultured rat MCs displayed the Warburg effect. 
Metabolic analyses showed that the cultured primary MCs and rMC-1 cells do display the Warburg 
effect, consistent with the hypothesis (Fig. 4.3 and 4.4). This also further supports the well-
characterised notion that MCs in vitro display the Warburg effect, as demonstrated previously in 
freshly-isolated guinea pig MCs (Poitry-Yamate et al., 1995), cultured primary human MCs (Winkler 
et al., 2000), and rMC-1 cells (Winkler et al., 2003). Unexpectedly, the expression of the glycolytic 
enzyme PKM2 in cultured rodent MCs shown in this thesis (Fig. 5.5) and in work by others (Lindsay 
et al., 2014) is in contrast to the absence of discernible expression of PKM2 in rodent MCs in situ 
(Paper 2 (Casson et al., 2016) (Appendix 7.2)) (Lindsay et al., 2014; Rueda et al., 2016). This 
suggests that the metabolism of MCs in culture and in vivo could be different, at least in some 
aspects, and metabolic properties of MCs in vivo remain to be further elucidated.  
 
Lindsay et al. demonstrated that cultured primary mouse MCs do not incorporate 13C from glucose 
into lactate as fast as whole intact retinas (Lindsay et al., 2014). In the same study, using mouse 
retinas with an inherent photoreceptor degeneration caused by deficiency of the photoreceptor-
specific gene Aryl hydrocarbon interacting protein like 1 (Aipl1) (Ramamurthy et al., 2004), they 
showed that lactate production was reduced by 74% in AIPL1-/- retinas compared to retinas from 
control mice (Lindsay et al., 2014). They concluded that these results were consistent with 
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photoreceptors, and not MCs, being the major source of lactate production, and hence the Warburg 
effect, in the retina in vivo (Lindsay et al., 2014).  
 
This alone does not indicate that MCs do not display the Warburg effect at all; they might do so but 
to a lesser degree than photoreceptors, and it is also worth considering that the photoreceptors make 
up a much larger proportion of the retina by cell number than the MCs. Another possibility is that 
photoreceptors are not the direct primary source of lactate production but rather their degeneration 
affected other retinal cell types, including MCs, which could have affected their metabolism. 
Abnormal changes to MCs have been reported in retinal diseases associated with photoreceptor cell 
death, such as retinal detachment (reviewed in (Bringmann et al., 2006)). Therefore, investigating 
metabolism of MCs in vivo is important and could be performed by comparing lactate production in 
retinal explants from a transgenic mouse model with inducible MC ablation, as described previously 
(Shen et al., 2012), with those from control mice. Even if photoreceptors are the major source of 
lactate production in the retina as suggested by Lindsay et al. (Lindsay et al., 2014), it is still possible 
that MCs contribute to the other 26% of lactate production and display the Warburg effect in vivo. 
 
However, studies have shown that MCs in the rodent retina have low or no expression levels of 
glycolytic enzymes, including PKM1, PKM2, hexokinase 2 (HK2), and LDHA, as well as a low LDH 
activity (Paper 2 (Casson et al., 2016) (Appendix 7.2)) (Lindsay et al., 2014; Rueda et al., 2016), 
which suggests a limited capacity of MCs for glycolysis and argues against MCs displaying the 
Warburg effect in vivo. In addition, MCs in the rodent retina have a low expression level of 
cytochrome c oxidase subunit IV (COX IV) and a low COX activity, suggesting a limited capacity for 
OXPHOS (Rueda et al., 2016). If MCs really do have limited capacities for glycolysis and OXPHOS 
as suggested by these studies on enzyme expression and activity, the question is, how do MCs in 
vivo fulfill their energy requirements?  
 
With low or no expression of either PKM1 or PKM2, MCs may produce pyruvate to fuel their 
mitochondria via an alternative PK-independent reaction, where PEP donates its phosphate to 
phosphoglycerate mutase (PGM) resulting in a production of pyruvate (Vander Heiden et al., 2010b). 
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It has also been proposed that MCs take up lactate produced by photoreceptors via MCT4 and 
convert it into pyruvate (Lindsay et al., 2014). Expression of MCT4 protein and/or mRNA in MCs has 
been shown previously (Chidlow et al., 2005), and supported by the RNA-seq analysis in this thesis 
(Table 4.1 in Chapter 4 and Supplementary table S1 from (Kittipassorn et al., 2019a) in Appendix 
7.5). In addition, MCs may depend on the TCA cycle to produce guanosine triphosphate (GTP), and 
depend on high-energy phosphate transferring kinases to produce ATP. They express relatively high 
levels of enzymes involved in the TCA cycle, including oxoglutarate/alpha-ketoglutarate 
dehydrogenase (OGDH) and succinate thiokinase (STK), and high-energy phosphate transferring 
kinases, including nucleoside-diphosphate kinase (NDPK) and adenylate kinase 1 (AK1) (Rueda et 
al., 2016). MCs also highly express glutamate dehydrogenase (Rueda et al., 2016) and may use it 
to convert glutamate to α-ketoglutarate which can feed the TCA cycle. Moreover, as MCs express 
mitochondrial fatty acid β-oxidation enzymes (Atsuzawa et al., 2010), they may utilise fatty acid β-
oxidation to produce acetyl CoA for the TCA cycle. Of note, in contrast to MCs in the rodent retina, 
MCs in the marmoset and the human retina show a discernible expression of PKM2 (Paper 2 
(Casson et al., 2016) (Appendix 7.2)), suggesting that the glycolytic capacity of MCs in vivo varies 
between species. It would also be interesting to determine whether cultured primary human MCs and 
immortalised human MC cells, such as the MIO-M1 line (Limb et al., 2002), express PKM2 like the 
human MCs in situ (Paper 2 (Casson et al., 2016) (Appendix 7.2)).  
 
More recently, the focus of retinal metabolism research has shifted from MCs to photoreceptors. As 
light-sensing cells, they are arguably the most crucial cell types in the retina. There are two main 
types of photoreceptors, rods and cones, and together they make up the majority of cell populations 
in the retina. Using microscopy techniques, Jeon et al. reported that photoreceptors comprise 82% 
(rods 79.9%, cones 2.1%) of all cells in the mouse retina (Jeon et al., 1998). Similarly, Macosko et 
al. reported that photoreceptors comprise 69.8% (rods 65.6%, cones 4.2%) of all cells in mouse 
retinas by single cell RNA-seq (Macosko et al., 2015).  
 
As mentioned, photoreceptors have been proposed to be the major source of lactate production, and 
hence the Warburg effect, in the retina (Lindsay et al., 2014). In support of this, photoreceptors show 
abundant expression of glycolytic enzymes, especially the isoforms that have been shown to promote 
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the Warburg effect, including PKM2, HK2 and LDHA, indicating that they have a high capacity for 
glycolysis (Paper 2 (Casson et al., 2016) (Appendix 7.2)) (Chinchore et al., 2017; Lindsay et al., 
2014; Rajala et al., 2018a; Rajala et al., 2016; Reidel et al., 2011; Rueda et al., 2016). Photoreceptors 
also have abundant mitochondria (Stone et al., 2008) and express considerable levels of COX IV 
and enzymes involved in the TCA cycle, including OGDH and STK, indicating that they also 
potentially have a high capacity for OXPHOS (Rueda et al., 2016). Thus, given their abundance, 
their major contribution to retinal lactate production in vivo, and the expression levels of key metabolic 
enzymes, photoreceptors are an appropriate focus for the study of retinal metabolism.  
 
6.4 The role of PKM2 in the Warburg effect in the mammalian retina 
The third aim of this thesis was to investigate whether PKM2 drove the Warburg effect in MCs, using 
cultured rat MCs as an experimental tool. The results showed that while PKM2 is expressed in 
cultured rat MCs, it is not a key driver of the Warburg effect (Chapter 5). As mentioned, recent studies 
have shown that there is no discernible PKM2 expression in MCs but there is strong PKM2 
expression in photoreceptors in the rodent retina (Paper 2 (Casson et al., 2016) (Appendix 7.2)) 
(Chinchore et al., 2017; Lindsay et al., 2014; Rajala et al., 2018a; Rajala et al., 2016; Rueda et al., 
2016).  
 
While not commonly expressed in MCs, a number of studies support a role for PKM2 in the Warburg 
effect in rod photoreceptor cells in mammalian retinas. Chinchore and colleagues demonstrated that 
freshly-isolated retinas of mice with a rod-specific conditional deletion of Pkm2 exhibit a small but 
significant reduction in lactate production compared to control mice (Chinchore et al., 2017). Rajala 
et al. showed that the amount of carbon from glucose that was incorporated into pyruvate and lactate 
in isolated retinas of rod-specific PKM2 KO mice was less than in the controls, while there was an 
accumulation of PEP (Rajala et al., 2018a).  
 
In addition to metabolism, PKM2 has also been shown to play a role in the viability, structure and 
function of photoreceptors. Rod-specific PKM2 KO, with aging, leads to photoreceptor cell death, 
reduced thickness of photoreceptor end tips, reduced GLUT1 expression, and reduced 
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electroretinography (ERG) responses (Rajala et al., 2018a). Similarly, cone-specific PKM2 KO 
results in cone degeneration and function loss in aged mice (Rajala et al., 2018b). Furthermore, 
shRNA-mediated PKM2 KD led to photoreceptors with shorter outer segments, a phenotype which 
could be rescued with dark rearing, possibly because there is less outer segment shedding in the 
dark (LaVail, 1980) and less biogenesis is required (Chinchore et al., 2017).  
 
Interestingly, it has been reported that there are IgG antibodies recognising PKM2 in the serum of 
patients with dry and wet age-related macular degeneration (AMD) with a higher reactivity in wet 
than dry AMD, but it is unknown whether these directly contribute to, or are secondary products of 
AMD (Morohoshi et al., 2012). The authors proposed that anti-PKM2 IgG could be used as a 
biomarker for the progression of AMD (Morohoshi et al., 2012).  
 
With mounting evidence for a role for PKM2 in the retina, it is worth noting that novel cancer 
treatments targeting PKM2 (reviewed in (Tennant et al., 2010)) might adversely affect the retina.   
 
6.5 Investigating other potential drivers of the Warburg effect in the mammalian 
retina 
In addition to PKM2, various other factors have been implicated in driving the Warburg effect in 
cancer and proliferating cells, such as LDHA, HK2, HIF-1, and the PI3K signalling pathway (reviewed 
in (Upadhyay et al., 2013; Vander Heiden et al., 2009)), some of which have been recently studied 
in photoreceptors and MCs. 
 
Photoreceptors strongly express LDHA and HK2 (Paper 2 (Casson et al., 2016) (Appendix 7.2) 
(Chinchore et al., 2017; Petit et al., 2018; Rueda et al., 2016). A rod-specific LDHA KO resulted in a 
reduced retinal lactate production, indicating a role of LDHA in the Warburg effect in rod 
photoreceptors (Chinchore et al., 2017). A shRNA-mediated LDHA KD led to a decrease in 
photoreceptor outer segment length which could be partially rescued with dark rearing, in which less 
outer segment shedding (LaVail, 1980) and biogenesis may be required, similar to the effect of PKM2 
KD in the same study described above (Chinchore et al., 2017). Rod-specific HK2 KO resulted in 
175 
 
decreased retinal lactate production and reduced expression of LDHA and PKM2, suggesting a 
decrease in the Warburg effect (Petit et al., 2018). In addition, HK2 loss in rod cells did not impact 
photoreceptor structure or survival but did affect rod ERG function, indicating a possible role for the 
Warburg effect in rod function (Petit et al., 2018). Unlike rods, HK2 KO in cones did not affect cellular 
function but its impact on the Warburg effect here is not known, as cones only make up 3% of 
photoreceptors which make it difficult to observe cone-dependent changes when measuring lactate 
in whole retinas (Petit et al., 2018). 
 
HIF-1 and other HIFs (HIF-2 and HIF-3) play an important role in retinal development, physiology 
and disease (reviewed in Paper 3 (Peet et al., 2017) (Appendix 7.3)). A potential role for HIF-1 in 
establishing the Warburg effect in the retina is supported by the report of HIF-1α expression in 
normoxic human and rat retinas shown by immunohistochemistry and western blotting (Hughes et 
al., 2010), although this result has to be approached with caution as it is not uncommon for anti-HIF-
1α antibodies to cross-react non-specifically. Interestingly, both the rod-specific KO of HIF-2α alone 
or of HIF-2α and HIF-1α combined did not affect photoreceptor development, morphology and ERG 
functions in mouse (Kast et al., 2016). Metabolic changes were not directly assessed in this study, 
but the data may imply that either the loss of the HIFs do not affect the Warburg effect in rod 
photoreceptors, or the presence of the Warburg effect is not essential for rod survival and function 
(reviewed in Paper 3 (Peet et al., 2017) (Appendix 7.3)). This is, in part, surprising as a number of 
downstream target genes of HIF-1, such as LDHA, PKM2, and HK2, when lost, lead to a decrease 
in retinal lactate production and changes in photoreceptor structure or function (Chinchore et al., 
2017; Petit et al., 2018). However, there is an additional possibility. In another report, a mouse model 
with a rod-specific loss of VHL, in which HIF-1 and HIF-2 are chronically activated, has an 
upregulation of Pdk1 and Glut1 in the retina, and a slowly progressing retinal degeneration that can 
be alleviated by expression of shRNA targeting Hif-1α (Barben et al., 2018). This does not 
conclusively demonstrate that the HIFs drive the Warburg effect in rods, but if they do, it may mean 
that a chronic activation of the HIFs lead to a chronically-upregulated Warburg effect which could 
impact rod cell survival, while a HIF KO (such as in (Kast et al., 2016)) may result in a decreased 
Warburg effect which would not affect rod survival. Nevertheless, this suggests that the role of the 
HIFs in photoreceptor metabolism, structure and function is complex, and is likely tightly-regulated. 
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It remains to be elucidated whether the HIFs are involved in driving the Warburg effect in 
photoreceptors. 
 
A conditional deletion of Hif-1α has also been reported in MCs; it did not cause apparent 
morphological or functional defects under normal conditions, but in mice with oxygen-induced 
retinopathy the deletion of Hif-1α in MCs led to reduced retinal inflammation and vascular leakage 
(Lin et al., 2011). However, metabolic changes were not determined. In this study by Lin et al., the 
mouse model with HIF-1α KO in MCs was generated by crossing floxed Hif-1α mice with mice that 
express Cre recombinase in MCs as described previously (Ueki et al., 2009). These MC Cre mice 
were generated using a 3.0-kb human vitelliform macular dystrophy-2 (VMD2) promoter (Ueki et al., 
2009). VMD2 is usually preferentially expressed in RPE (Esumi et al., 2004), and Ueki et al. aimed 
to generate RPE-specific Cre mice but unexpectedly obtained a transgenic line with prominent Cre 
activity in MCs. In this line, Cre activity in RPE was nearly absent, while there was some Cre activity 
in some neurons in the INL and some photoreceptors. This suggests that the results reported by Lin 
et al. above need to be interpreted cautiously as the effects seen may have been the consequence 
of Hif-1α deletion in cell types other than MCs. In addition, further studies using this Cre mouse line 
to investigate the role of other agents in MC metabolism and function have to be designed and 
performed carefully due to the non-MC Cre activity. Alternatively, Rlbp1-CreER, a mouse model with 
inducible MC-specific Cre expression (Shen et al., 2012), generated using a part of the regulatory 
region of the retinaldehyde binding protein 1 gene (Rlbp1), is a valuable and, perhaps, a more 
suitable tool for MC-specific gene editing to study the role of genes of interest in MCs. 
 
Another pathway of interest in driving the Warburg effect in retinas is the PI3K signalling pathway. 
Loss of PI3K in cones leads to a reduced expression of genes encoding GLUT1, HK2, PKM2, and 
HIF-1α, possibly implying a decrease in the Warburg effect (Rajala et al., 2016). 
 
In addition to investigating the drivers of the Warburg effect in the mammalian retina, it is also 
important to elucidate why the mammalian retina displays the Warburg effect. Despite suggestions 
being mooted (Casson et al., 2012; Ng et al., 2015), this is still unknown. One commonly-postulated 
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explanation is that the Warburg effect is required to accommodate the high biosynthetic demand 
associated with the constant renewal of photoreceptor outer segments (reviewed in Paper 1 (Ng et 
al., 2015) (Appendix 7.1)) (Chinchore et al., 2017). An interesting experiment would be to determine 
whether glucose directly contributes to biosynthesis as a carbon source. This could be performed by 
following the incorporation of labelled carbon from glucose into the retina, and determining if and 
how much of the carbon is directly incorporated into the visual pigment rhodopsin and outer segment 
structures.   
 
6.6 Implications for retinal diseases and cancer treatment research 
There may not yet be a direct link between the disruption of the Warburg effect in the retina and 
retinal diseases in human, but it is clear that photoreceptors are metabolically demanding (Ames et 
al., 1992) and that the loss or degeneration of photoreceptors are the basis of many blinding retinal 
diseases, such as AMD and retinitis pigmentosa. In addition, although MC metabolism in vivo 
remains to be elucidated, it is well established that MCs play an important role in retinal diseases 
(reviewed in (Bringmann et al., 2006)) and MC loss or damage has been shown to lead to 
photoreceptor apoptosis and vascular pathologies (Dubois-Dauphin et al., 2000; Shen et al., 2012). 
Therefore, the regulation of photoreceptor and MC metabolism is crucial to retinal health. 
Furthermore, various factors that have been studied in regard to retinal metabolism also play 
important roles in other aspects of retinal physiology. For example, HIF-1 has been shown to regulate 
key metabolic genes, but HIF-1 and other HIFs have also been shown to play crucial roles in the 
formation and maintenance of retinal vasculature (reviewed in Paper 3 (Peet et al., 2017) (Appendix 
7.3)). Altogether this highlights a complex interconnected relationship between potential drivers of 
the Warburg effect, their other roles in the retina, retinal metabolism and retinal diseases, as well as 
indicates that to manipulate one agent to treat one aspect of a condition it might adversely affect 
others. For instance, in diabetic retinopathy, if HIF-1 is to be inhibited to decrease VEGF expression 
and hence reduce neovascularisation, it may at the same time decrease LDHA, PKM2 and HK2 
expression and hence affect photoreceptor metabolism, structure or function (Chinchore et al., 2017; 




Moreover, if factors that play a role in retinal and cancer metabolism are conserved, treatments 
targeting cancer metabolism, both directly and indirectly, may adversely affect the retina. For 
example, cetuximab is a drug that, in combination with chemotherapy and/or radiotherapy, is 
approved for treating patients with colorectal cancers and head and neck cancers (Bonner et al., 
2006; Cunningham et al., 2004) and has been shown to down-regulate HIF-1α and LDHA (Lu et al., 
2013; Luwor et al., 2005), calling into question whether the drug could have unknown long-term 
adverse effects on the retina. This highlights the importance of understanding the mechanisms and 
reasons behind the Warburg effect in the retina in addition to the association with retinal diseases, 
as they could contribute to awareness of possible adverse effects of metabolism-targeting cancer 
treatments and to developing novel diagnostic and therapeutic strategies for retinal diseases. 
 
6.7 Final conclusions 
This thesis describes a useful novel SIRMu-1 MC cell line, highlights the importance of 
comprehensive metabolic analyses that cover various parameters in addition to lactate production, 
verifies that cultured primary rat MCs and rMC-1 cells display the Warburg effect, enhances our 
understanding of MC metabolism and demonstrates that the role of PKM2 in the Warburg effect is 
likely cell type-dependent. Furthermore, it emphasises the notion that cultured cells have both similar 
and different aspects compared to their in vivo counterparts and therefore, multiple established cell 
lines derived from the same cell type and species of origin may not always retain the same properties 










CHAPTER 7:  Appendices 
7.1 Paper 1: Cancer-like metabolism of the mammalian retina 
Ng, S.K., Wood, J.P., Chidlow, G., Han, G., Kittipassorn, T., Peet, D.J., and Casson, R.J. (2015). 












































7.2 Paper 2: M-Type Pyruvate Kinase Isoforms and Lactate Dehydrogenase A in the 
Mammalian Retina: Metabolic Implications 
Casson, R.J., Wood, J.P., Han, G., Kittipassorn, T., Peet, D.J., and Chidlow, G. (2016). M-Type 
Pyruvate Kinase Isoforms and Lactate Dehydrogenase A in the Mammalian Retina: Metabolic 




























































7.3 Paper 3: HIF signalling: The eyes have it  
Peet, D.J., Kittipassorn, T., Wood, J.P., Chidlow, G., and Casson, R.J. (2017). HIF signalling: The 




























7.4 HeLa cell identification testing  
HeLa cells were trypsinised and centrifuged and gDNA extracted using a QIAamp DNA Blood Mini 
kit (Qiagen) by the candidate. The sample was submitted to CellBank Australia for human cell line 
authentication testing by Emily Button (Laboratory of Professor Murray Whitelaw, University of 









7.5 Paper 4: Supplementary table S1 
Supplementary table S1. Differentially expressed genes (DEGs) in SIRMu-1 cells and/or rMC-1 
cells relative to primary (1o) MCs. Reproduced from (Kittipassorn et al., 2019a), the main article of 
which can be found in section 3.3.1 in Chapter 3. 
 
(A) DEGs in both the SIRMu-1 and the rMC-1 cell lines relative to 1o MCs. 
Gene symbol Gene ENTREZID Gene name 
DEGs compared to 1o 
MC 
SIRMu-1 rMC-1 
Rab6b 363123 RAB6B, member RAS oncogene family 1 1 
Meis2 311311 Meis homeobox 2 1 1 
Kif26a 314473 kinesin family member 26A -1 1 
Serpina3n 24795 serine (or cysteine) peptidase inhibitor, clade A, member 3N -1 1 
Olr59 170816 olfactory receptor 59 1 -1 
Grem1 50566 gremlin 1, DAN family BMP antagonist -1 -1 
Glb1l 301525 galactosidase, beta 1-like -1 -1 
Serpine2 29366 serpin family E member 2 -1 -1 
Ccnd2 64033 cyclin D2 -1 -1 
Apoe 25728 apolipoprotein E -1 -1 
Sod3 25352 superoxide dismutase 3, extracellular -1 -1 
Ctsk 29175 cathepsin K -1 -1 
C1qtnf5 315598 C1q and tumor necrosis factor related protein 5 -1 -1 
Pvrl1 NA NA -1 -1 
38231 287606 septin 4 -1 -1 
Scn1b 29686 sodium voltage-gated channel beta subunit 1 -1 -1 
Fndc1 308099 fibronectin type III domain containing 1 -1 -1 
Acvrl1 25237 activin A receptor like type 1 -1 -1 
Ly6e 362934 lymphocyte antigen 6 complex, locus E -1 -1 
Scamp5 65171 secretory carrier membrane protein 5 -1 -1 
Cpxm1 296156 carboxypeptidase X (M14 family), member 1 -1 -1 
Ociad2 100361733 OCIA domain containing 2 -1 -1 
Rarres1 310486 retinoic acid receptor responder 1 -1 -1 
Fgfr1 79114 Fibroblast growth factor receptor 1 -1 -1 
Olfm1 93667 olfactomedin 1 -1 -1 
Smpdl3a 294422 sphingomyelin phosphodiesterase, acid-like 3A -1 -1 
Thy1 24832 Thy-1 cell surface antigen -1 -1 
Mgp 25333 matrix Gla protein -1 -1 
Ttc9 500689 tetratricopeptide repeat domain 9 -1 -1 
Tspan12 362326 tetraspanin 12 -1 -1 
Gng2 80850 G protein subunit gamma 2 -1 -1 
Stk26 317589 serine/threonine protein kinase 26 -1 -1 
Cpeb1 293056 cytoplasmic polyadenylation element binding protein 1 -1 -1 
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Map3k9 500690 mitogen-activated protein kinase kinase kinase 9 -1 -1 
Zbtb7c 679155 zinc finger and BTB domain containing 7C -1 -1 
Lrp3 89787 LDL receptor related protein 3 -1 -1 
Ccdc125 499518 coiled-coil domain containing 125 -1 -1 
Lrfn3 308495 leucine rich repeat and fibronectin type III domain containing 3 -1 -1 
Dchs1 308912 dachsous cadherin-related 1 -1 -1 
Pamr1 311252 peptidase domain containing associated with muscle regeneration 1 -1 -1 
Slc16a3 80878 solute carrier family 16 member 3 -1 -1 
Rbpjl 362268 recombination signal binding protein for immunoglobulin kappa J region-like -1 -1 
Acp5 25732 acid phosphatase 5, tartrate resistant -1 -1 
St3gal6 304023 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 -1 -1 
Ttbk1 316229 tau tubulin kinase 1 -1 -1 
Rai2 501555 retinoic acid induced 2 -1 -1 
Fbxo44 500587 F-box protein 44 -1 -1 
Lpl 24539 lipoprotein lipase -1 -1 
RGD1563349 502727 similar to RIKEN cDNA 9330182L06 -1 -1 
Zfp641 300197 zinc finger protein 641 -1 -1 
Cpz 83575 carboxypeptidase Z -1 -1 
Car3 54232 carbonic anhydrase 3 -1 -1 
Colec12 361289 collectin sub-family member 12 -1 -1 
Sat2 360547 spermidine/spermine N1-acetyltransferase family member 2 -1 -1 
Layn 500996 layilin -1 -1 
Gfpt2 360518 glutamine-fructose-6-phosphate transaminase 2 -1 -1 
Gpc3 25236 glypican 3 -1 -1 
Pde2a 81743 phosphodiesterase 2A -1 -1 
Ndn 308690 necdin, MAGE family member -1 -1 
Kirrel3 315546 kin of IRRE like 3 (Drosophila) -1 -1 
Egflam 365691 EGF-like, fibronectin type III and laminin G domains -1 -1 
Nefm 24588 neurofilament, medium polypeptide -1 -1 
Pla2g7 301265 phospholipase A2 group VII -1 -1 
Erc2 259269 ELKS/RAB6-interacting/CAST family member 2 -1 -1 
Ric3 687147 RIC3 acetylcholine receptor chaperone -1 -1 
Eya2 156826 EYA transcriptional coactivator and phosphatase 2 -1 -1 
Astn1 304900 astrotactin 1 -1 -1 
Epb41l4b 500464 erythrocyte membrane protein band 4.1 like 4B -1 -1 
Plcb1 24654 phospholipase C beta 1 -1 -1 
Slc22a18 309131 solute carrier family 22, member 18 -1 -1 
Ntng2 311836 netrin G2 -1 -1 
Plagl1 25157 PLAG1 like zinc finger 1 -1 -1 
Reln 24718 reelin -1 -1 
Serpinb2 60325 serpin family B member 2 -1 -1 
Unc79 314401 unc-79 homolog (C. elegans) -1 -1 
Map7d3 317614 MAP7 domain containing 3 -1 -1 
Prkcz 25522 protein kinase C, zeta -1 -1 
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Panx2 362979 pannexin 2 -1 -1 
Tmem200a 498987 transmembrane protein 200A -1 -1 
Pik3ap1 294048 phosphoinositide-3-kinase adaptor protein 1 -1 -1 
Cnrip1 364208 cannabinoid receptor interacting protein 1 -1 -1 
Pcdha13 116742 protocadherin alpha 13 -1 -1 
Frem2 310418 Fras1 related extracellular matrix protein 2 -1 -1 
Cfh 155012 complement factor H -1 -1 
Tmem117 500921 transmembrane protein 117 -1 -1 
Zfp286a 497923 zinc finger protein 286A -1 -1 
Dok6 498898 docking protein 6 -1 -1 
Shroom2 317435 shroom family member 2 -1 -1 
Actn2 291245 actinin alpha 2 -1 -1 
Pcdha11 394223 protocadherin alpha 11 -1 -1 
RGD1566401 500717 similar to GTL2, imprinted maternally expressed untranslated -1 -1 
Enpp5 316249 ectonucleotide pyrophosphatase/phosphodiesterase 5 -1 -1 
Zfp423 94188 zinc finger protein 423 -1 -1 
Tfpi2 286926 tissue factor pathway inhibitor 2 -1 -1 
Pde7b 140929 phosphodiesterase 7B -1 -1 
Limch1 305332 LIM and calponin homology domains 1 -1 -1 
Lrrc15 246296 leucine rich repeat containing 15 -1 -1 
Sfrp1 84402 secreted frizzled-related protein 1 -1 -1 
Tyrp1 298182 tyrosinase-related protein 1 -1 -1 
Rbm46 310548 RNA binding motif protein 46 -1 -1 
Opcml 116597 opioid binding protein/cell adhesion molecule-like -1 -1 
Ina 24503 internexin neuronal intermediate filament protein, alpha -1 -1 
Mal2 362911 mal, T-cell differentiation protein 2 -1 -1 
Amtn 689404 amelotin -1 -1 
Chrm2 81645 cholinergic receptor, muscarinic 2 -1 -1 
Tmem179 314472 transmembrane protein 179 -1 -1 
Bace2 288227 beta-site APP-cleaving enzyme 2 -1 -1 
Cpne8 362988 copine 8 -1 -1 
Entpd1 64519 ectonucleoside triphosphate diphosphohydrolase 1 -1 -1 
Rab38 252916 RAB38, member RAS oncogene family -1 -1 
Dcaf12 313296 DDB1 and CUL4 associated factor 12 -1 -1 
Car2 54231 carbonic anhydrase 2 -1 -1 
Hoga1 293949 4-hydroxy-2-oxoglutarate aldolase 1 -1 -1 
RGD1562726 498060 similar to Putative protein C21orf62 homolog -1 -1 
Rgs6 54295 regulator of G-protein signaling 6 -1 -1 
Cyp7b1 25429 cytochrome P450, family 7, subfamily b, polypeptide 1 -1 -1 
Rspo3 498997 R-spondin 3 -1 -1 
Gucy1a2 66012 guanylate cyclase 1 soluble subunit alpha 2 -1 -1 
Lrrn2 289020 leucine rich repeat neuronal 2 -1 -1 
Pnmal2 308393 paraneoplastic Ma antigen family-like 2 -1 -1 
Ryr2 689560 ryanodine receptor 2 -1 -1 
Plcl2 301173 phospholipase C-like 2 -1 -1 
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Gabra2 289606 gamma-aminobutyric acid type A receptor alpha2 subunit -1 -1 
Sobp 309860 sine oculis binding protein homolog -1 -1 
Mctp2 308742 multiple C2 and transmembrane domain containing 2 -1 -1 
Acss1 296259 acyl-CoA synthetase short-chain family member 1 -1 -1 
 
Differentially expressed genes (DEGs) by a fold-change of at least 5, relative to primary MCs, in the SIRMu-1 cells compared 
to the primary MCs (results shown in the column named “SIRMu-1”), and in the rMC-1 cells compared to the primary MCs 
(results shown in the column named “rMC-1”). Downregulation is indicated by -1, upregulation by 1. 
 
(B) DEGs only in the SIRMu-1 cell line relative to 1o MCs. 




to 1o MC 
Lrp2 29216 LDL receptor related protein 2 1 
Flt1 54251 FMS-related tyrosine kinase 1 1 
Avil 79253 advillin 1 
Ddx3 1E+08 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 1 
Tek 89804 TEK receptor tyrosine kinase 1 
Eif2s3y 1E+08 eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked 1 
Dmrt3 293976 doublesex and mab-3 related transcription factor 3 1 
Mageb4 317271 melanoma antigen family B, 4 1 
Tbx1 360737 T-box 1 1 
Adprhl1 290880 ADP-ribosylhydrolase like 1 1 
Bpgm 296973 bisphosphoglycerate mutase -1 
Adcy7 84420 adenylate cyclase 7 -1 
Sirpa 25528 signal-regulatory protein alpha -1 
Npdc1 296562 neural proliferation, differentiation and control, 1 -1 
Prkag2 373545 protein kinase AMP-activated non-catalytic subunit gamma 2 -1 
Shroom3 305230 shroom family member 3 -1 
Prkar1b 25521 protein kinase cAMP-dependent type 1 regulatory subunit beta -1 
Ephx2 65030 epoxide hydrolase 2 -1 
Rnf130 652955 ring finger protein 130 -1 
Myh14 308572 myosin heavy chain 14 -1 
Cacna1a 25398 calcium voltage-gated channel subunit alpha1 A -1 
Ctsc 25423 cathepsin C -1 
Ppm1h 314897 protein phosphatase, Mg2+/Mn2+ dependent, 1H -1 
Gspt2 501582 G1 to S phase transition 2 -1 
Oasl2 304549 2'-5' oligoadenylate synthetase-like 2 -1 
Mb21d2 498100 Mab-21 domain containing 2 -1 
Fam83h 362937 family with sequence similarity 83, member H -1 
Bcl3 680611 B-cell CLL/lymphoma 3 -1 
RGD1309676 361118 similar to RIKEN cDNA 5730469M10 -1 
Plce1 114633 phospholipase C, epsilon 1 -1 
Tlr3 364594 toll-like receptor 3 -1 
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Psmb8 24968 proteasome subunit beta 8 -1 
Lifr 81680 leukemia inhibitory factor receptor alpha -1 
Mboat2 313997 membrane bound O-acyltransferase domain containing 2 -1 
Tnfrsf21 316256 TNF receptor superfamily member 21 -1 
Trpv4 66026 transient receptor potential cation channel, subfamily V, member 4 -1 
Ptp4a3 362930 protein tyrosine phosphatase type IVA, member 3 -1 
Nsg1 25247 neuron specific gene family member 1 -1 
Adra1d 29413 adrenoceptor alpha 1D -1 
Cx3cl1 89808 C-X3-C motif chemokine ligand 1 -1 
Elmo1 361251 engulfment and cell motility 1 -1 
Slc6a17 613226 solute carrier family 6 member 17 -1 
Homer2 29547 homer scaffolding protein 2 -1 
Irgm 303090 immunity-related GTPase M -1 
Cdh6 25409 cadherin 6 -1 
Htr1b 25075 5-hydroxytryptamine receptor 1B -1 
Creg1 289185 cellular repressor of E1A-stimulated genes 1 -1 
LOC500956 500956 hypothetical protein LOC500956 -1 
Cyp27a1 301517 cytochrome P450, family 27, subfamily a, polypeptide 1 -1 
Rtn1 116644 reticulon 1 -1 
Jam2 619374 junctional adhesion molecule 2 -1 
Hdac11 297453 histone deacetylase 11 -1 
Rragd 297960 Ras-related GTP binding D -1 
Nap1l2 317247 nucleosome assembly protein 1-like 2 -1 
Phyhipl 309901 phytanoyl-CoA 2-hydroxylase interacting protein-like -1 
Khdrbs3 64015 KH RNA binding domain containing, signal transduction associated 3 -1 
Slc7a4 303787 solute carrier family 7, member 4 -1 
Sema4d 306790 semaphorin 4D -1 
Stox2 306459 storkhead box 2 -1 
Zfhx4 310250 zinc finger homeobox 4 -1 
Hand2 64637 heart and neural crest derivatives expressed 2 -1 
Begain 79146 brain-enriched guanylate kinase-associated -1 
Svip 499157 small VCP interacting protein -1 
RGD1310110 361032 similar to 3632451O06Rik protein -1 
Mpp7 307035 membrane palmitoylated protein 7 -1 
Sorl1 300652 sortilin related receptor 1 -1 
Mafb 54264 MAF bZIP transcription factor B -1 
Fam49a 298890 family with sequence similarity 49, member A -1 
Slc35g1 294072 solute carrier family 35, member G1 -1 
Kcnc3 117101 potassium voltage-gated channel subfamily C member 3 -1 
Grik2 54257 glutamate ionotropic receptor kainate type subunit 2 -1 
Elovl7 361895 ELOVL fatty acid elongase 7 -1 
Car13 499566 carbonic anhydrase 13 -1 
Mmp13 171052 matrix metallopeptidase 13 -1 
 
Differentially expressed genes (DEGs) by a fold-change of at least 5 in the SIRMu-1 cells, relative to primary MCs. 
Downregulation is indicated by -1, upregulation by 1. 
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(C) DEGs only in the rMC-1 cell line relative to 1o MCs. 




to 1o MC 
Rrm1 685579 ribonucleotide reductase catalytic subunit M1 1 
Smc4 295107 structural maintenance of chromosomes 4 1 
Tmpo 25359 thymopoietin 1 
Psat1 293820 phosphoserine aminotransferase 1 1 
Dek 306817 DEK proto-oncogene 1 
Smc2 362519 structural maintenance of chromosomes 2 1 
Pcna 25737 proliferating cell nuclear antigen 1 
Top2a 360243 topoisomerase (DNA) II alpha 1 
H2afz 58940 H2A histone family, member Z 1 
Mcm2 312538 minichromosome maintenance complex component 2 1 
Fam111a 499322 family with sequence similarity 111, member A 1 
Hmgn2 114637 high mobility group nucleosomal binding domain 2 1 
Mki67 291234 marker of proliferation Ki-67 1 
Mcm4 29728 minichromosome maintenance complex component 4 1 
Atad2 314993 ATPase family, AAA domain containing 2 1 
Nasp 298441 nuclear autoantigenic sperm protein 1 
Prc1 308761 protein regulator of cytokinesis 1 1 
Cenpf 257649 centromere protein F 1 
Cdkn1b 83571 cyclin-dependent kinase inhibitor 1B 1 
Prim1 246327 primase, DNA, polypeptide 1 1 
Psip1 313323 PC4 and SFRS1 interacting protein 1 1 
Aif1l 362107 allograft inflammatory factor 1-like 1 
Dnajc9 364240 DnaJ heat shock protein family (Hsp40) member C9 1 
Mcm7 288532 minichromosome maintenance complex component 7 1 
Usp1 313387 ubiquitin specific peptidase 1 1 
Tpx2 311546 TPX2, microtubule nucleation factor 1 
Mcm6 29685 minichromosome maintenance complex component 6 1 
Kif23 315740 kinesin family member 23 1 
Ezh2 312299 enhancer of zeste 2 polycomb repressive complex 2 subunit 1 
Incenp 293733 inner centromere protein 1 
Kif20a 361308 kinesin family member 20A 1 
Cdk1 54237 cyclin-dependent kinase 1 1 
Slfn13 303378 schlafen family member 13 1 
Kntc1 304477 kinetochore associated 1 1 
Stmn1 29332 stathmin 1 1 
Kif11 171304 kinesin family member 11 1 
Mcm3 316273 minichromosome maintenance complex component 3 1 
Nup85 287830 nucleoporin 85 1 
Arhgap11a 296060 Rho GTPase activating protein 11A 1 
Amer1 501584 APC membrane recruitment protein 1 1 
Ect2 361921 epithelial cell transforming 2 1 
Lmnb2 299625 lamin B2 1 
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Bub1 296137 BUB1 mitotic checkpoint serine/threonine kinase 1 
Myrf 293736 myelin regulatory factor 1 
Timeless 83508 timeless circadian clock 1 
Pola1 85241 DNA polymerase alpha 1, catalytic subunit 1 
Mcm5 291885 minichromosome maintenance complex component 5 1 
Casp2 64314 caspase 2 1 
Lmnb1 116685 lamin B1 1 
Tk1 24834 thymidine kinase 1 1 
Pole 304573 DNA polymerase epsilon, catalytic subunit 1 
Iqgap3 310621 IQ motif containing GTPase activating protein 3 1 
Kif20b 309523 kinesin family member 20B 1 
Ccnb1 25203 cyclin B1 1 
Tacc3 360962 transforming, acidic coiled-coil containing protein 3 1 
Cdk2 362817 cyclin dependent kinase 2 1 
Wdhd1 305827 WD repeat and HMG-box DNA binding protein 1 1 
Fen1 84490 flap structure-specific endonuclease 1 1 
Hmmr 25460 hyaluronan-mediated motility receptor 1 
Dlgap5 289997 DLG associated protein 5 1 
Fads2 83512 fatty acid desaturase 2 1 
Ccna2 114494 cyclin A2 1 
Rrm2 362720 ribonucleotide reductase regulatory subunit M2 1 
Plk1 25515 polo-like kinase 1 1 
Spag5 252918 sperm associated antigen 5 1 
Foxm1 58921 forkhead box M1 1 
Mad2l1 297176 MAD2 mitotic arrest deficient-like 1 (yeast) 1 
Zfp367 306695 zinc finger protein 367 1 
Mdm1 314859 Mdm1 nuclear protein 1 
Cdc20 64515 cell division cycle 20 1 
Rpa2 59102 replication protein A2 1 
Plk4 310344 polo-like kinase 4 1 
Fancd2 312641 Fanconi anemia, complementation group D2 1 
Rfc3 288414 replication factor C subunit 3 1 
Uhrf1 316129 ubiquitin-like with PHD and ring finger domains 1 1 
Siva1 362791 SIVA1, apoptosis-inducing factor 1 
Bub1b 171576 BUB1 mitotic checkpoint serine/threonine kinase B 1 
Crip2 338401 cysteine-rich protein 2 1 
Cdca8 500545 cell division cycle associated 8 1 
Mybl2 296344 myeloblastosis oncogene-like 2 1 
Brca1 497672 BRCA1, DNA repair associated 1 
Brca2 360254 BRCA2, DNA repair associated 1 
Kifc1 294286 kinesin family member C1 1 
Espl1 315330 extra spindle pole bodies like 1, separase 1 
Exosc2 366017 exosome component 2 1 
Chek1 140583 checkpoint kinase 1 1 
Ccne2 362485 cyclin E2 1 
Cks2 498709 CDC28 protein kinase regulatory subunit 2 1 
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Nusap1 311336 nucleolar and spindle associated protein 1 1 
Mms22l 313108 MMS22-like, DNA repair protein 1 
Rfc4 288003 replication factor C subunit 4 1 
Aurkb 114592 aurora kinase B 1 
Orc6 291927 origin recognition complex, subunit 6 1 
Hmgb2 29395 high mobility group box 2 1 
Rbl1 680111 RB transcriptional corepressor like 1 1 
Cdca2 305984 cell division cycle associated 2 1 
Nuf2 304951 NUF2, NDC80 kinetochore complex component 1 
Ube2c 296368 ubiquitin-conjugating enzyme E2C 1 
Racgap1 315298 Rac GTPase-activating protein 1 1 
Nup43 683983 nucleoporin 43 1 
Tcf19 406195 transcription factor 19 1 
Knstrn 311325 kinetochore-localized astrin/SPAG5 binding protein 1 
Cdh3 116777 cadherin 3 1 
Rfc5 304528 replication factor C subunit 5 1 
Kif18b 303575 kinesin family member 18B 1 
Pola2 85242 DNA polymerase alpha 2, accessory subunit 1 
Rad18 362412 RAD18 E3 ubiquitin protein ligase 1 
Mtbp 500870 MDM2 binding protein 1 
Ttk 315852 Ttk protein kinase 1 
Casc5 NA NA 1 
Kif15 353302 kinesin family member 15 1 
Aurka 261730 aurora kinase A 1 
Skp2 294790 S-phase kinase-associated protein 2, E3 ubiquitin protein ligase 1 
Kif2c 171529 kinesin family member 2C 1 
Exosc8 295050 exosome component 8 1 
Spc25 295661 SPC25, NDC80 kinetochore complex component 1 
Slc38a1 170567 solute carrier family 38, member 1 1 
Krt8 25626 keratin 8 1 
Ndc80 301701 NDC80 kinetochore complex component 1 
Cenpn 361416 centromere protein N 1 
Cep55 294074 centrosomal protein 55 1 
Cbx2 303730 chromobox 2 1 
Hspa4l 294993 heat shock protein 4-like 1 
Mcm10 307126 minichromosome maintenance 10 replication initiation factor 1 
Cenpi 25448 centromere protein I 1 
Fbxo5 292263 F-box protein 5 1 
Pmf1 681050 polyamine-modulated factor 1 1 
Tube1 361856 tubulin, epsilon 1 1 
Melk 362510 maternal embryonic leucine zipper kinase 1 
Cdca3 297594 cell division cycle associated 3 1 
Rad51ap1 689055 RAD51 associated protein 1 1 
Cdkn2c 54238 cyclin-dependent kinase inhibitor 2C 1 
Troap 300219 trophinin associated protein 1 
Hjurp 316602 Holliday junction recognition protein 1 
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Depdc1 295538 DEP domain containing 1 1 
Pbk 290326 PDZ binding kinase 1 
Cdc6 360621 cell division cycle 6 1 
Birc5 64041 baculoviral IAP repeat-containing 5 1 
Ska3 361047 spindle and kinetochore associated complex subunit 3 1 
Gmnn 291137 geminin, DNA replication inhibitor 1 
Tprn 499749 taperin 1 
Cdc45 287961 cell division cycle 45 1 
Cdt1 292071 chromatin licensing and DNA replication factor 1 1 
Ddias 499204 DNA damage-induced apoptosis suppressor 1 
Kif18a 362186 kinesin family member 18A 1 
Mcm8 296178 minichromosome maintenance 8 homologous recombination repair factor 1 
Chaf1b 288242 chromatin assembly factor 1 subunit B 1 
Xrcc2 499966 X-ray repair cross complementing 2 1 
Pkmyt1 287101 protein kinase, membrane associated tyrosine/threonine 1 1 
Dhfr 24312 dihydrofolate reductase 1 
Recql4 300057 RecQ like helicase 4 1 
Mtfr2 1.01E+08 mitochondrial fission regulator 2 1 
Cenpk 294712 centromere protein K 1 
Asf1b 304648 anti-silencing function 1B histone chaperone 1 
LOC498265 498265 similar to hypothetical protein FLJ10706 1 
Gins2 292058 GINS complex subunit 2 1 
Ns5atp9 300795 NS5A (hepatitis C virus) transactivated protein 9 1 
Cenpt 307805 centromere protein T 1 
Celsr2 83465 cadherin, EGF LAG seven-pass G-type receptor 2 1 
Depdc7 295971 DEP domain containing 7 1 
Pttg1 64193 pituitary tumor-transforming 1 1 
Fanca 361435 Fanconi anemia, complementation group A 1 
Tonsl 366953 tonsoku-like, DNA repair protein 1 
Trip13 292206 thyroid hormone receptor interactor 13 1 
Gins3 307639 GINS complex subunit 3 1 
Dbf4 312046 DBF4 zinc finger 1 
Bard1 64557 BRCA1 associated RING domain 1 1 
Clspn 298534 claspin 1 
Ccnb2 363088 cyclin B2 1 
Parpbp 1E+08 PARP1 binding protein 1 
Nsl1 498310 NSL1, MIS12 kinetochore complex component 1 
Dscc1 299933 DNA replication and sister chromatid cohesion 1 1 
Cenpw 689399 centromere protein W 1 
Ercc6l 317252 ERCC excision repair 6 like, spindle assembly checkpoint helicase 1 
Fam83d 311598 family with sequence similarity 83, member D 1 
Stard10 293150 StAR-related lipid transfer domain containing 10 1 
Prr11 360591 proline rich 11 1 
RGD1306227 310377 similar to 4833420G17Rik protein 1 
Scd1 NA NA 1 
Pard6b 362279 par-6 family cell polarity regulator beta 1 
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Rad51 499870 RAD51 recombinase 1 
Ska1 291441 spindle and kinetochore associated complex subunit 1 1 
Lhx2 296706 LIM homeobox 2 1 
Cenpm 315164 centromere protein M 1 
Cdca7 311742 cell division cycle associated 7 1 
Cenpq 363198 centromere protein Q 1 
Cenpu 306464 centromere protein U 1 
Exo1 305000 exonuclease 1 1 
Polq 288079 DNA polymerase theta 1 
Gins1 499914 GINS complex subunit 1 1 
E2f7 314818 E2F transcription factor 7 1 
Rad54l 298429 RAD54 like (S. cerevisiae) 1 
Sass6 310807 SAS-6 centriolar assembly protein 1 
Psrc1 691380 proline and serine rich coiled-coil 1 1 
Fancb 501552 Fanconi anemia, complementation group B 1 
Nek2 114482 NIMA-related kinase 2 1 
Orc1 313479 origin recognition complex, subunit 1 1 
Exnef 309036 exonuclease NEF-sp 1 
Pole2 299112 DNA polymerase epsilon 2, accessory subunit 1 
Traip 367167 TRAF-interacting protein 1 
Sapcd2 680531 suppressor APC domain containing 2 1 
Ube2t 360847 ubiquitin-conjugating enzyme E2T 1 
Rab15 299156 RAB15, member RAS oncogene family 1 
Gpr19 312787 G protein-coupled receptor 19 1 
Igsf9 304982 immunoglobulin superfamily, member 9 1 
Depdc1b 310074 DEP domain containing 1B 1 
Cep70 367153 centrosomal protein 70 1 
Mxd3 252915 Max dimerization protein 3 1 
Cenpa 298850 centromere protein A 1 
Msh5 294252 mutS homolog 5 1 
Arrb2 25388 arrestin, beta 2 1 
Rad54b 313063 RAD54 homolog B (S. cerevisiae) 1 
Cdca5 684771 cell division cycle associated 5 1 
Tst 25274 thiosulfate sulfurtransferase 1 
LOC303566 303566 E2F1-inducible gene 1 
Psmb9 24967 proteasome subunit beta 9 1 
Dctpp1 192252 dCTP pyrophosphatase 1 1 
Atp2c2 171496 ATPase secretory pathway Ca2+ transporting 2 1 
Srd5a1 24950 steroid 5 alpha-reductase 1 1 
L1cam 50687 L1 cell adhesion molecule 1 
Eme1 287634 essential meiotic structure-specific endonuclease 1 1 
Nup210 58958 nucleoporin 210 1 
Lmo1 245979 LIM domain only 1 1 
Gatm 81660 glycine amidinotransferase 1 
Ccsap 307926 centriole, cilia and spindle-associated protein 1 
Cd24 25145 CD24 molecule 1 
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Tmem173 498840 transmembrane protein 173 1 
Fignl1 289777 fidgetin-like 1 1 
Ppl 302934 periplakin 1 
Xk 497078 X-linked Kx blood group 1 
Neil3 290729 nei-like DNA glycosylase 3 1 
Tfcp2l1 304741 transcription factor CP2-like 1 1 
Lsr 64355 lipolysis stimulated lipoprotein receptor 1 
Rhox5 24631 reproductive homeobox 5 1 
Slc29a4 288499 solute carrier family 29 member 4 1 
Mecom 294924 MDS1 and EVI1 complex locus 1 
Slc16a14 316578 solute carrier family 16, member 14 1 
Efna2 84358 ephrin A2 1 
Efcab11 500705 EF-hand calcium binding domain 11 1 
Mlf1 310483 myeloid leukemia factor 1 1 
Padi3 29520 peptidyl arginine deiminase 3 1 
Apold1 444983 apolipoprotein L domain containing 1 1 
B4galnt4 309105 beta-1,4-N-acetyl-galactosaminyl transferase 4 1 
Smpd3 94338 sphingomyelin phosphodiesterase 3 1 
Pard6a 307799 par-6 family cell polarity regulator alpha 1 
Pde3b 29516 phosphodiesterase 3B 1 
Rps6ka6 317203 ribosomal protein S6 kinase A6 1 
Mab21l1 688394 mab-21 like 1 1 
Asb12 503446 ankyrin repeat and SOCS box-containing 12 1 
Them6 300015 thioesterase superfamily member 6 1 
Rfx2 301121 regulatory factor X2 1 
Gchfr 171128 GTP cyclohydrolase I feedback regulator 1 
Lck 313050 LCK proto-oncogene, Src family tyrosine kinase 1 
Lrr1 685860 leucine rich repeat protein 1 1 
Sptb 314251 spectrin, beta, erythrocytic 1 
Ybx2 303250 Y box binding protein 2 1 
Cxcl10 245920 C-X-C motif chemokine ligand 10 1 
Bst2 378947 bone marrow stromal cell antigen 2 1 
Tjp3 314640 tight junction protein 3 1 
Sall1 307740 spalt-like transcription factor 1 1 
Foxn1 287469 forkhead box N1 1 
Mir25 1E+08 microRNA 25 1 
RT1-CE6 415073 RT1 class I, locus CE6 1 
Hoxc4 24459 homeo box C4 1 
Gper1 171104 G protein-coupled estrogen receptor 1 1 
Dapp1 362046 dual adaptor of phosphotyrosine and 3-phosphoinositides 1 1 
Fcho1 290639 FCH domain only 1 1 
Phactr1 306844 phosphatase and actin regulator 1 1 
B3gnt5 116740 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 1 
Cdhr5 171554 cadherin-related family member 5 1 
Cdx2 66019 caudal type homeo box 2 1 
Krt15 287700 keratin 15 1 
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Tspan8 171048 tetraspanin 8 1 
MAST1 353118 microtubule associated serine/threonine kinase 1 1 
Foxa2 25099 forkhead box A2 1 
Dennd2d 310772 DENN domain containing 2D 1 
Hist3h2ba 303175 histone cluster 3, H2ba 1 
Dok7 305448 docking protein 7 1 
Runx3 156726 runt-related transcription factor 3 1 
Grhl2 299979 grainyhead-like transcription factor 2 1 
Hnf1b 25640 HNF1 homeobox B 1 
Hoxa2 1.04E+08 homeo box A2 1 
Apol3 315108 apolipoprotein L, 3 1 
Hpgd 79242 hydroxyprostaglandin dehydrogenase 15 (NAD) 1 
Slc17a7 116638 solute carrier family 17 member 7 1 
Usp44 314746 ubiquitin specific peptidase 44 1 
Hhex 79237 hematopoietically expressed homeobox 1 
Oasl 304545 2'-5'-oligoadenylate synthetase-like 1 
Defb29 641519 defensin beta 29 1 
Gata4 54254 GATA binding protein 4 1 
Inhbe 83711 inhibin beta E subunit 1 
C5ar2 445269 complement component 5a receptor 2 1 
Cecr2 500308 CECR2, histone acetyl-lysine reader 1 
Hoxb9 287647 homeo box B9 1 
Slc9b1 365946 solute carrier family 9 member B1 1 
Hoxc10 315338 homeo box C10 1 
Ifit1 56824 interferon-induced protein with tetratricopeptide repeats 1 1 
Mpp3 114202 membrane palmitoylated protein 3 1 
S1pr5 60399 sphingosine-1-phosphate receptor 5 1 
Htr5b 79247 5-hydroxytryptamine (serotonin) receptor 5B 1 
Bnc1 365299 basonuclin 1 1 
Tal1 313507 TAL bHLH transcription factor 1, erythroid differentiation factor 1 
Hoxc9 368178 homeobox C9 1 
Hoxb3 303488 homeo box B3 1 
Fabp12 499570 fatty acid binding protein 12 1 
Hmx3 293537 H6 family homeobox 3 1 
Tex101 207113 testis expressed 101 1 
Mak 25677 male germ cell-associated kinase 1 
R3hdml 366245 R3H domain containing-like 1 
Nr0b2 117274 nuclear receptor subfamily 0, group B, member 2 1 
Col1a1 29393 collagen type I alpha 1 chain -1 
Fn1 25661 fibronectin 1 -1 
Thbs1 445442 thrombospondin 1 -1 
Sparc 24791 secreted protein acidic and cysteine rich -1 
Col3a1 84032 collagen type III alpha 1 chain -1 
Bgn 25181 biglycan -1 
Fat1 83720 FAT atypical cadherin 1 -1 
Col4a1 290905 collagen type IV alpha 1 chain -1 
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Fbn1 83727 fibrillin 1 -1 
Tpm2 500450 tropomyosin 2, beta -1 
Ltbp2 59106 latent transforming growth factor beta binding protein 2 -1 
Postn 361945 periostin -1 
Pdgfrb 24629 platelet derived growth factor receptor beta -1 
Ccng1 25405 cyclin G1 -1 
Lamp1 25328 lysosomal-associated membrane protein 1 -1 
Pam 25508 peptidylglycine alpha-amidating monooxygenase -1 
Htra1 65164 HtrA serine peptidase 1 -1 
Col8a1 304021 collagen type VIII alpha 1 chain -1 
Adam19 303068 ADAM metallopeptidase domain 19 -1 
Itm2c 301575 integral membrane protein 2C -1 
Mmp14 81707 matrix metallopeptidase 14 -1 
Map1a 25152 microtubule-associated protein 1A -1 
Flnc 362332 filamin C -1 
Sulf1 171396 sulfatase 1 -1 
Npc2 286898 NPC intracellular cholesterol transporter 2 -1 
Cpe 25669 carboxypeptidase E -1 
Bc1 29294 brain cytoplasmic RNA 1 -1 
Pdlim1 54133 PDZ and LIM domain 1 -1 
Cdkn1a 114851 cyclin-dependent kinase inhibitor 1A -1 
Akap12 83425 A-kinase anchoring protein 12 -1 
Myl9 296313 myosin light chain 9 -1 
Fkbp10 360627 FK506 binding protein 10 -1 
Nucb2 59295 nucleobindin 2 -1 
Adamts12 294809 ADAM metallopeptidase with thrombospondin type 1 motif, 12 -1 
Nid2 302248 nidogen 2 -1 
Itga11 315744 integrin subunit alpha 11 -1 
Mmp2 81686 matrix metallopeptidase 2 -1 
Igfbp7 289560 insulin-like growth factor binding protein 7 -1 
Hmox1 24451 heme oxygenase 1 -1 
Fam198b 310540 family with sequence similarity 198, member B -1 
Lbh 683626 limb bud and heart development -1 
Fbln5 29158 fibulin 5 -1 
Ehbp1l1 309169 EH domain binding protein 1-like 1 -1 
Chpf 316533 chondroitin polymerizing factor -1 
Fam129a 63912 family with sequence similarity 129, member A -1 
Tp53inp2 362246 tumor protein p53 inducible nuclear protein 2 -1 
Serpinf1 287526 serpin family F member 1 -1 
Emilin1 298845 elastin microfibril interfacer 1 -1 
Npr3 25339 natriuretic peptide receptor 3 -1 
Gpr176 117257 G protein-coupled receptor 176 -1 
Gpc4 317322 glypican 4 -1 
Wisp2 29576 WNT1 inducible signaling pathway protein 2 -1 
P3h3 297595 prolyl 3-hydroxylase 3 -1 
Anxa3 25291 annexin A3 -1 
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Dkk3 171548 dickkopf WNT signaling pathway inhibitor 3 -1 
Pdzrn3 312607 PDZ domain containing RING finger 3 -1 
Pragmin 306506 pragma of Rnd2 -1 
Smim14 364154 small integral membrane protein 14 -1 
Hist1h2bh 306945 histone cluster 1, H2bh -1 
Spp1 25353 secreted phosphoprotein 1 -1 
Lmcd1 494021 LIM and cysteine-rich domains 1 -1 
Scara5 305974 scavenger receptor class A, member 5 -1 
Nkd2 308068 naked cuticle homolog 2 -1 
Tll1 678743 tolloid-like 1 -1 
Aebp1 305494 AE binding protein 1 -1 
Sulf2 311642 sulfatase 2 -1 
Marveld1 309375 MARVEL domain containing 1 -1 
Nexn 246172 nexilin (F actin binding protein) -1 
Jam3 315509 junctional adhesion molecule 3 -1 
Tfpi 29436 tissue factor pathway inhibitor -1 
Rin2 311494 Ras and Rab interactor 2 -1 
Sat1 302642 spermidine/spermine N1-acetyl transferase 1 -1 
Mmp19 304608 matrix metallopeptidase 19 -1 
Cdh11 84407 cadherin 11 -1 
Wfdc1 171112 WAP four-disulfide core domain 1 -1 
Npr2 116564 natriuretic peptide receptor 2 -1 
Gpnmb 113955 glycoprotein nmb -1 
Tcn2 64365 transcobalamin 2 -1 
Ptprn 116660 protein tyrosine phosphatase, receptor type, N -1 
Wfs1 83725 wolframin ER transmembrane glycoprotein -1 
Grb10 498416 growth factor receptor bound protein 10 -1 
Aen 361594 apoptosis enhancing nuclease -1 
Rasl11b 305302 RAS-like family 11 member B -1 
Cd59 25407 CD59 molecule -1 
Itga8 364786 integrin subunit alpha 8 -1 
Ddah2 294239 dimethylarginine dimethylaminohydrolase 2 -1 
Mrvi1 308899 murine retrovirus integration site 1 homolog -1 
Cnn1 65204 calponin 1 -1 
Il1r1 25663 interleukin 1 receptor type 1 -1 
Pcsk6 25507 proprotein convertase subtilisin/kexin type 6 -1 
Ehd3 192249 EH-domain containing 3 -1 
Tgfb1i1 84574 transforming growth factor beta 1 induced transcript 1 -1 
Lmod1 304816 leiomodin 1 -1 
Nfatc4 305897 nuclear factor of activated T-cells 4 -1 
Dsel 297865 dermatan sulfate epimerase-like -1 
Scara3 364405 scavenger receptor class A, member 3 -1 
Cdh13 192248 cadherin 13 -1 
Nbl1 50594 neuroblastoma 1, DAN family BMP antagonist -1 
Plxdc2 361282 plexin domain containing 2 -1 
C1qtnf6 315114 C1q and tumor necrosis factor related protein 6 -1 
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Zfp36l1 29344 zinc finger protein 36, C3H type-like 1 -1 
Grb14 58844 growth factor receptor bound protein 14 -1 
Neu1 24591 neuraminidase 1 -1 
Tgfa 24827 transforming growth factor alpha -1 
Plekhh2 313866 pleckstrin homology, MyTH4 and FERM domain containing H2 -1 
Ckb 24264 creatine kinase B -1 
Cyba 79129 cytochrome b-245 alpha chain -1 
Tmem119 304581 transmembrane protein 119 -1 
Flrt2 299236 fibronectin leucine rich transmembrane protein 2 -1 
Pla2g16 24913 phospholipase A2, group XVI -1 
Flvcr2 314323 feline leukemia virus subgroup C cellular receptor family, member 2 -1 
Fam214b 298201 family with sequence similarity 214, member B -1 
Abca1 313210 ATP binding cassette subfamily A member 1 -1 
Prss35 315866 protease, serine, 35 -1 
Ptprk 360302 protein tyrosine phosphatase, receptor type, K -1 
Dact3 499088 dishevelled-binding antagonist of beta-catenin 3 -1 
Fgfr2 25022 fibroblast growth factor receptor 2 -1 
Timp3 25358 TIMP metallopeptidase inhibitor 3 -1 
Abcb1b 24646 ATP-binding cassette, subfamily B (MDR/TAP), member 1B -1 
Pcdh7 360942 protocadherin 7 -1 
Cobl 305497 cordon-bleu WH2 repeat protein -1 
Rnase4 56759 ribonuclease A family member 4 -1 
Ephx1 25315 epoxide hydrolase 1 -1 
Nav3 314814 neuron navigator 3 -1 
Itga1 25118 integrin subunit alpha 1 -1 
Arhgef6 363509 Rac/Cdc42 guanine nucleotide exchange factor 6 -1 
Cpt1c 308579 carnitine palmitoyltransferase 1c -1 
Cacna1c 24239 calcium voltage-gated channel subunit alpha1 C -1 
Qsox1 84491 quiescin sulfhydryl oxidase 1 -1 
Sdc3 116673 syndecan 3 -1 
Pdgfrl 290771 platelet-derived growth factor receptor-like -1 
Tmem150a 245966 transmembrane protein 150A -1 
Slc8a1 29715 solute carrier family 8 member A1 -1 
Fam101b NA NA -1 
Palmd 310811 palmdelphin -1 
Jph2 296345 junctophilin 2 -1 
Stk39 54348 serine threonine kinase 39 -1 
Tfap2b 301285 transcription factor AP-2 beta -1 
Igf2bp2 303824 insulin-like growth factor 2 mRNA binding protein 2 -1 
Srpx2 317181 sushi-repeat-containing protein, X-linked 2 -1 
Aldh1l2 299699 aldehyde dehydrogenase 1 family, member L2 -1 
Arnt2 25243 aryl hydrocarbon receptor nuclear translocator 2 -1 
Spry2 306141 sprouty RTK signaling antagonist 2 -1 
Pla2g4a 24653 phospholipase A2 group IVA -1 
Npl 304860 N-acetylneuraminate pyruvate lyase -1 
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Acad11 315973 acyl-CoA dehydrogenase family, member 11 -1 
Trim2 361970 tripartite motif-containing 2 -1 
Trib2 313974 tribbles pseudokinase 2 -1 
Mme 24590 membrane metallo-endopeptidase -1 
Gpx7 298376 glutathione peroxidase 7 -1 
Ctsh 25425 cathepsin H -1 
Tmem223 690285 transmembrane protein 223 -1 
Arhgap24 305156 Rho GTPase activating protein 24 -1 
Dhrs3 313689 dehydrogenase/reductase 3 -1 
Prkg1 54286 protein kinase, cGMP-dependent, type 1 -1 
Cntn2 25356 contactin 2 -1 
Fblim1 362650 filamin binding LIM protein 1 -1 
Sema4g 361764 semaphorin 4G -1 
Pappa 313262 pregnancy-associated plasma protein A -1 
Baiap2l1 304282 BAI1-associated protein 2-like 1 -1 
Prickle2 312563 prickle planar cell polarity protein 2 -1 
Nkain4 296469 Na+/K+ transporting ATPase interacting 4 -1 
RGD1311756 362769 similar to hypothetical protein FLJ20950 -1 
Shroom4 317391 shroom family member 4 -1 
Papss2 294103 3'-phosphoadenosine 5'-phosphosulfate synthase 2 -1 
Avpr1a 25107 arginine vasopressin receptor 1A -1 
RGD1562618 501007 similar to RIKEN cDNA 6030419C18 gene -1 
Bend6 363212 BEN domain containing 6 -1 
Gria3 29628 glutamate ionotropic receptor AMPA type subunit 3 -1 
Nudt18 361068 nudix hydrolase 18 -1 
Prrx1 266813 paired related homeobox 1 -1 
Lims2 361303 LIM zinc finger domain containing 2 -1 
Gpr153 619550 G protein-coupled receptor 153 -1 
Nfia 25492 nuclear factor I/A -1 
Uchl1 29545 ubiquitin C-terminal hydrolase L1 -1 
Cybrd1 295669 cytochrome b reductase 1 -1 
Dlg3 58948 discs large MAGUK scaffold protein 3 -1 
Ntm 50864 neurotrimin -1 
Smarca1 317575 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 -1 
Pitx2 54284 paired-like homeodomain 2 -1 
Adm 25026 adrenomedullin -1 
Rab27a 50645 RAB27A, member RAS oncogene family -1 
Aff3 363220 AF4/FMR2 family, member 3 -1 
Trpv2 29465 transient receptor potential cation channel, subfamily V, member 2 -1 
Gnb4 294962 G protein subunit beta 4 -1 
Apc2 299611 APC2, WNT signaling pathway regulator -1 
Sdk2 360652 sidekick cell adhesion molecule 2 -1 
Ppt2 54398 palmitoyl-protein thioesterase 2 -1 
Rftn1 501095 raftlin lipid raft linker 1 -1 
Unc13a 64829 unc-13 homolog A -1 
Scn2a 24766 sodium voltage-gated channel alpha subunit 2 -1 
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C2 24231 complement C2 -1 
Ptprv 64576 protein tyrosine phosphatase, receptor type, V -1 
Mgmt 25332 O-6-methylguanine-DNA methyltransferase -1 
Galt 298003 galactose-1-phosphate uridylyltransferase -1 
Ptgs1 24693 prostaglandin-endoperoxide synthase 1 -1 
Scube3 294297 signal peptide, CUB domain and EGF like domain containing 3 -1 
Itpr2 81678 inositol 1,4,5-trisphosphate receptor, type 2 -1 
Il1rl2 171106 interleukin 1 receptor-like 2 -1 
Itpkb 54260 inositol-trisphosphate 3-kinase B -1 
Galnt13 311039 polypeptide N-acetylgalactosaminyltransferase 13 -1 
Dhtkd1 361272 dehydrogenase E1 and transketolase domain containing 1 -1 
Sox9 140586 SRY box 9 -1 
Clmp 286939 CXADR-like membrane protein -1 
Peg3 1.04E+08 paternally expressed 3 -1 
Cd48 245962 Cd48 molecule -1 
Ctsz 252929 cathepsin Z -1 
Efs 290212 embryonal Fyn-associated substrate -1 
Cyp4f6 266689 cytochrome P450, family 4, subfamily f, polypeptide 6 -1 
Armcx6 363496 armadillo repeat containing, X-linked 6 -1 
Cdc42ep5 361505 CDC42 effector protein 5 -1 
Mapkapk3 315994 mitogen-activated protein kinase-activated protein kinase 3 -1 
C1qtnf2 497886 C1q and tumor necrosis factor related protein 2 -1 
Ror2 306782 receptor tyrosine kinase-like orphan receptor 2 -1 
Slc2a10 366251 solute carrier family 2 member 10 -1 
Triqk 500413 triple QxxK/R motif containing -1 
Manba 310864 mannosidase beta -1 
Rhoj 299145 ras homolog family member J -1 
Slc2a13 171147 solute carrier family 2 member 13 -1 
Trim16 303214 tripartite motif-containing 16 -1 
Dmd 24907 dystrophin -1 
Gatsl3 360969 GATS protein-like 3 -1 
Rorb 309288 RAR-related orphan receptor B -1 
Usp13 310306 ubiquitin specific peptidase 13 -1 
Def6 309642 DEF6 guanine nucleotide exchange factor -1 
Dcn 29139 decorin -1 
Zfp521 307579 zinc finger protein 521 -1 
Asah2 114104 N-acylsphingosine amidohydrolase 2 -1 
Mks1 287612 Meckel syndrome, type 1 -1 
Fbxl7 361907 F-box and leucine-rich repeat protein 7 -1 
Paqr7 313615 progestin and adipoQ receptor family member 7 -1 
Prickle3 317380 prickle planar cell polarity protein 3 -1 
Shc2 314612 SHC adaptor protein 2 -1 
Pde10a 63885 phosphodiesterase 10A -1 
Wnt5a 64566 wingless-type MMTV integration site family, member 5A -1 
Tnfrsf10b 364420 tumor necrosis factor receptor superfamily, member 10b -1 
Rbpms 498642 RNA binding protein with multiple splicing -1 
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Col15a1 298069 collagen type XV alpha 1 chain -1 
Phactr2 308291 phosphatase and actin regulator 2 -1 
Nr2f1 81808 nuclear receptor subfamily 2, group F, member 1 -1 
Pparg 25664 peroxisome proliferator-activated receptor gamma -1 
Zmym6 362602 zinc finger MYM-type containing 6 -1 
Epb41l3 116724 erythrocyte membrane protein band 4.1-like 3 -1 
Slc9a9 363115 solute carrier family 9 member A9 -1 
Ghr 25235 growth hormone receptor -1 
Smim1 500595 small integral membrane protein 1 -1 
Mycbpap 494192 Mycbp associated protein -1 
Adcy5 64532 adenylate cyclase 5 -1 
Dync2li1 298767 dynein cytoplasmic 2 light intermediate chain 1 -1 
Tmem204 287129 transmembrane protein 204 -1 
Csgalnact1 306375 chondroitin sulfate N-acetylgalactosaminyltransferase 1 -1 
Plag1 297804 PLAG1 zinc finger -1 
Cyp4v3 266761 cytochrome P450, family 4, subfamily v, polypeptide 3 -1 
Procr 362248 protein C receptor -1 
Plac9 361105 placenta-specific 9 -1 
Tox 362481 thymocyte selection-associated high mobility group box -1 
Enpep 64017 glutamyl aminopeptidase -1 
Efhc1 301295 EF-hand domain containing 1 -1 
Hecw2 316395 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 -1 
Nap1l3 170914 nucleosome assembly protein 1-like 3 -1 
Ppfia4 140592 PTPRF interacting protein alpha 4 -1 
Fam46a 300870 family with sequence similarity 46, member A -1 
Tmsbl1 286978 thymosin beta-like protein 1 -1 
Abtb2 171440 ankyrin repeat and BTB domain containing 2 -1 
Ebpl 361054 emopamil binding protein-like -1 
LOC100909539 1.01E+08 uncharacterized LOC100909539 -1 
Htr2a 29595 5-hydroxytryptamine receptor 2A -1 
Rgs7bp 294715 regulator of G-protein signaling 7 binding protein -1 
Figf NA NA -1 
Il17rd 498576 interleukin 17 receptor D -1 
Nudt22 293703 nudix hydrolase 22 -1 
Rps6ka2 117269 ribosomal protein S6 kinase polypeptide 2 -1 
Rgs16 360857 regulator of G-protein signaling 16 -1 
Mageh1 367767 MAGE family member H1 -1 
Cd80 25408 Cd80 molecule -1 
Mansc1 690606 MANSC domain containing 1 -1 
Pak3 29433 p21 (RAC1) activated kinase 3 -1 
Rasl10b 303382 RAS-like, family 10, member B -1 
Cys1 690489 cystin 1 -1 
Irx2 306657 iroquois homeobox 2 -1 
Nudt7 361413 nudix hydrolase 7 -1 
Nlrp3 287362 NLR family, pyrin domain containing 3 -1 
Emx2 499380 empty spiracles homeobox 2 -1 
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Kcnd3 65195 potassium voltage-gated channel subfamily D member 3 -1 
Thsd7a 500032 thrombospondin type 1 domain containing 7A -1 
Rims1 84556 regulating synaptic membrane exocytosis 1 -1 
Nipal2 362899 NIPA-like domain containing 2 -1 
Stc1 81801 stanniocalcin 1 -1 
S1pr1 29733 sphingosine-1-phosphate receptor 1 -1 
LOC690276 690276 hypothetical protein LOC690276 -1 
Pde3a 50678 phosphodiesterase 3A -1 
Fam173a 287150 family with sequence similarity 173, member A -1 
Pcdha4 116741 protocadherin alpha 4 -1 
Rcan2 140666 regulator of calcineurin 2 -1 
Gnai1 25686 G protein subunit alpha i1 -1 
Ly96 448830 lymphocyte antigen 96 -1 
Tram1l1 310846 translocation associated membrane protein 1-like 1 -1 
Camk2n1 287005 calcium/calmodulin-dependent protein kinase II inhibitor 1 -1 
Tspyl4 309828 TSPY-like 4 -1 
Zrsr1 498425 zinc finger (CCCH type), RNA binding motif and serine/arginine rich 1 -1 
Ache 83817 acetylcholinesterase -1 
Nalcn 266760 sodium leak channel, non-selective -1 
Pth1r 56813 parathyroid hormone 1 receptor -1 
Pln 64672 phospholamban -1 
B3gnt7 316583 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 -1 
Inpp4b 116699 inositol polyphosphate-4-phosphatase type II B -1 
Ogdhl 290566 oxoglutarate dehydrogenase-like -1 
Pde4a 25638 phosphodiesterase 4A -1 
Tmem246 362518 transmembrane protein 246 -1 
Eda 302424 ectodysplasin-A -1 
Hspb7 50565 heat shock protein family B (small) member 7 -1 
Tmem30b 314224 transmembrane protein 30B -1 
Peg12 308692 paternally expressed 12 -1 
Lyn 81515 LYN proto-oncogene, Src family tyrosine kinase -1 
Fndc5 260327 fibronectin type III domain containing 5 -1 
Alx4 296511 ALX homeobox 4 -1 
Fam58b 303321 family with sequence similarity 58, member B -1 
Cdo1 81718 cysteine dioxygenase type 1 -1 
Ptafr 58949 platelet-activating factor receptor -1 
Apobec3b 315137 apolipoprotein B mRNA editing enzyme catalytic subunit 3B -1 
Fut4 60670 fucosyltransferase 4 -1 
Itgb3 29302 integrin subunit beta 3 -1 
Tbx3 353305 T-box 3 -1 
Adam23 301460 ADAM metallopeptidase domain 23 -1 
Gda 83585 guanine deaminase -1 
Ophn1 312108 oligophrenin 1 -1 
Ppp1r3d 689995 protein phosphatase 1, regulatory subunit 3D -1 
Ttc12 300696 tetratricopeptide repeat domain 12 -1 
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Tmem220 287405 transmembrane protein 220 -1 
Dock11 313438 dedicator of cytokinesis 11 -1 
Dcxr 171408 dicarbonyl and L-xylulose reductase -1 
Celf4 307540 CUGBP, Elav-like family member 4 -1 
Ppapdc3 NA NA -1 
Rgs8 54297 regulator of G-protein signaling 8 -1 
Ndst3 295430 N-deacetylase and N-sulfotransferase 3 -1 
Gal3st4 498166 galactose-3-O-sulfotransferase 4 -1 
Stxbp6 362734 syntaxin binding protein 6 -1 
Adora2b 29316 adenosine A2B receptor -1 
Hic1 303310 hypermethylated in cancer 1 -1 
Lpcat2 1E+08 lysophosphatidylcholine acyltransferase 2 -1 
Mbp 24547 myelin basic protein -1 
Magi2 113970 membrane associated guanylate kinase, WW and PDZ domain containing 2 -1 
Pcdhga2 498846 protocadherin gamma subfamily A, 2 -1 
Six2 366542 SIX homeobox 2 -1 
Smoc2 292401 SPARC related modular calcium binding 2 -1 
Clec2g 362447 C-type lectin domain family 2, member G -1 
Tmem14a 363206 transmembrane protein 14A -1 
Gpc2 171517 glypican 2 -1 
Cln3 293485 ceroid-lipofuscinosis, neuronal 3 -1 
Vstm4 361112 V-set and transmembrane domain containing 4 -1 
Tbx15 295315 T-box 15 -1 
Nova1 298992 NOVA alternative splicing regulator 1 -1 
Calcrl 25029 calcitonin receptor-like -1 
Tmod2 58814 tropomodulin 2 -1 
Klhl31 315833 kelch-like family member 31 -1 
Fgf10 25443 fibroblast growth factor 10 -1 
Tbx2 303398 T-box 2 -1 
Acyp2 364224 acylphosphatase 2 -1 
Vsnl1 24877 visinin-like 1 -1 
Kcng1 296395 potassium voltage-gated channel modifier subfamily G member 1 -1 
Zfp385d 305691 zinc finger protein 385D -1 
Lpar4 302378 lysophosphatidic acid receptor 4 -1 
Zfp37 115768 zinc finger protein 37 -1 
Plscr1 117540 phospholipid scramblase 1 -1 
Scube1 315174 signal peptide, CUB domain and EGF like domain containing 1 -1 
Epm2a 114005 epilepsy, progressive myoclonus type 2A -1 
Nipal4 303070 NIPA-like domain containing 4 -1 
Tmem86a 308602 transmembrane protein 86A -1 
Ica1 81024 islet cell autoantigen 1 -1 
Cdyl2 292044 chromodomain Y-like 2 -1 
Nr3c2 25672 nuclear receptor subfamily 3, group C, member 2 -1 
St6galnac3 29758 ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 -1 
Cd302 295629 CD302 molecule -1 
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Hdac9 687001 histone deacetylase 9 -1 
LOC501110 501110 similar to Glutathione S-transferase A1 (GTH1) (HA subunit 1) (GST-epsilon) (GSTA1-1) (GST class-alpha) -1 
Hrasls5 293711 HRAS-like suppressor family, member 5 -1 
Cacnb2 116600 calcium voltage-gated channel auxiliary subunit beta 2 -1 
Rab27b 84590 RAB27B, member RAS oncogene family -1 
Matn4 296358 matrilin 4 -1 
Atp6v1c2 362802 ATPase H+ transporting V1 subunit C2 -1 
Rnf180 685384 ring finger protein 180 -1 
Amz1 304317 archaelysin family metallopeptidase 1 -1 
Fez1 81730 fasciculation and elongation protein zeta 1 -1 
Cds1 81925 CDP-diacylglycerol synthase 1 -1 
Negr1 59318 neuronal growth regulator 1 -1 
Cap2 116653 CAP, adenylate cyclase-associated protein, 2 (yeast) -1 
Aard 246323 alanine and arginine rich domain containing protein -1 
Slc25a27 85262 solute carrier family 25, member 27 -1 
Pcdhb3 291656 protocadherin beta 3 -1 
Nme4 685679 NME/NM23 nucleoside diphosphate kinase 4 -1 
Nostrin 311111 nitric oxide synthase trafficking -1 
Drp2 66027 dystrophin related protein 2 -1 
Dusp15 362238 dual specificity phosphatase 15 -1 
Apbb1ip 307171 amyloid beta precursor protein binding family B member 1 interacting protein -1 
Prrt1 406167 proline-rich transmembrane protein 1 -1 
Grip1 84016 glutamate receptor interacting protein 1 -1 
Syndig1 362235 synapse differentiation inducing 1 -1 
Trpc4 84494 transient receptor potential cation channel, subfamily C, member 4 -1 
Grm8 60590 glutamate metabotropic receptor 8 -1 
Thnsl2 297332 threonine synthase-like 2 -1 
Nox1 114243 NADPH oxidase 1 -1 
Sema6d 311384 semaphorin 6D -1 
Fbxo41 312504 F-box protein 41 -1 
Sdsl 360816 serine dehydratase-like -1 
Pcdhb2 498843 protocadherin beta 2 -1 
Rarres2 297073 retinoic acid receptor responder 2 -1 
Brinp1 140610 BMP/retinoic acid inducible neural specific 1 -1 
Exo5 313563 exonuclease 5 -1 
Ptpru 116680 protein tyrosine phosphatase, receptor type, U -1 
Slc16a4 295356 solute carrier family 16, member 4 -1 
Adcy8 29241 adenylate cyclase 8 -1 
Fmo5 246248 flavin containing monooxygenase 5 -1 
Pycard 282817 PYD and CARD domain containing -1 
Fam217b 311692 family with sequence similarity 217, member B -1 
Mdfi 501097 MyoD family inhibitor -1 
Tmem35 308134 transmembrane protein 35 -1 
Hs6st3 364476 heparan sulfate 6-O-sulfotransferase 3 -1 
Erbb4 59323 erb-b2 receptor tyrosine kinase 4 -1 
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Zfp583 499068 zinc finger protein 583 -1 
Pclo 56768 piccolo (presynaptic cytomatrix protein) -1 
Col1a2 84352 collagen type I alpha 2 chain -1 
Epha3 29210 Eph receptor A3 -1 
Ccdc19 NA NA -1 
Msx2 25483 msh homeobox 2 -1 
Sgcd 497892 sarcoglycan, delta -1 
Mir214 1E+08 microRNA 214 -1 
Glrb 25456 glycine receptor, beta -1 
Gramd1b 300644 GRAM domain containing 1B -1 
Cmklr1 60669 chemerin chemokine-like receptor 1 -1 
Mrgpre 404660 MAS related GPR family member E -1 
Dgkg 25666 diacylglycerol kinase, gamma -1 
Susd2 294335 sushi domain containing 2 -1 
Hspa12a 307997 heat shock protein family A (Hsp70) member 12A -1 
Heyl 313575 hes-related family bHLH transcription factor with YRPW motif-like -1 
Spa17 85244 sperm autoantigenic protein 17 -1 
Hsd11b1 25116 hydroxysteroid 11-beta dehydrogenase 1 -1 
Plcd4 140693 phospholipase C, delta 4 -1 
Atp8b1 291555 ATPase phospholipid transporting 8B1 -1 
Slc35f1 502421 solute carrier family 35, member F1 -1 
Tmem202 691306 transmembrane protein 202 -1 
Rem1 366232 RRAD and GEM like GTPase 1 -1 
Cnksr2 59322 connector enhancer of kinase suppressor of Ras 2 -1 
Lrrtm3 294380 leucine rich repeat transmembrane neuronal 3 -1 
Adcy10 59320 adenylate cyclase 10 (soluble) -1 
Plcl1 84587 phospholipase C-like 1 -1 
Gsap 311984 gamma-secretase activating protein -1 
Agmo 362732 alkylglycerol monooxygenase -1 
Cacna1d 29716 calcium voltage-gated channel subunit alpha1 D -1 
Tmem45a 680866 transmembrane protein 45A -1 
Prr16 361327 proline rich 16 -1 
B3galt1 366064 Beta-1,3-galactosyltransferase 1 -1 
Park2 56816 parkin RBR E3 ubiquitin protein ligase -1 
Nkd1 364952 naked cuticle homolog 1 -1 
Mgat4a 367252 mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A -1 
Clcnkb 79430 chloride voltage-gated channel Kb -1 
Zfp3 497944 zinc finger protein 3 -1 
Sema5b 303901 semaphorin 5B -1 
Myrip 360034 myosin VIIA and Rab interacting protein -1 
Ptgir 292661 prostaglandin I2 (prostacyclin) receptor (IP) -1 
Hrasls 288025 HRAS-like suppressor -1 
Cntn3 54279 contactin 3 -1 
Nrcam 497815 neuronal cell adhesion molecule -1 
Pcdhac2 393092 protocadherin alpha subfamily C, 2 -1 
Thegl 498350 theg spermatid protein-like -1 
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Map7 293016 microtubule-associated protein 7 -1 
Gpr85 64020 G protein-coupled receptor 85 -1 
Rarb 24706 retinoic acid receptor, beta -1 
Rxfp1 295144 relaxin/insulin-like family peptide receptor 1 -1 
Mir143 1E+08 microRNA 143 -1 
Pde1b 29691 phosphodiesterase 1B -1 
Astn2 1E+08 astrotactin 2 -1 
Svop 171442 SV2 related protein -1 
Shisa2 498528 shisa family member 2 -1 
Cacng7 140728 calcium voltage-gated channel auxiliary subunit gamma 7 -1 
Cdnf 361276 cerebral dopamine neurotrophic factor -1 
Sult2a2 361510 sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 2 -1 
Ddit4l2 140582 DNA-damage-inducible transcript 4-like 2 -1 
Pak7 311450 p21 (RAC1) activated kinase 7 -1 
Fli1 315532 Fli-1 proto-oncogene, ETS transcription factor -1 
Slc2a9 501925 solute carrier family 2 member 9 -1 
Mmp9 81687 matrix metallopeptidase 9 -1 
Slc6a7 117100 solute carrier family 6 member 7 -1 
Cd93 84398 CD93 molecule -1 
Ednrb 50672 endothelin receptor type B -1 
Abcb4 24891 ATP binding cassette subfamily B member 4 -1 
Gfra1 25454 GDNF family receptor alpha 1 -1 
Ehhadh 171142 enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase -1 
Htr1f 60448 5-hydroxytryptamine receptor 1F -1 
MGC109340 317409 similar to Microsomal signal peptidase 23 kDa subunit (SPase 22 kDa subunit) (SPC22/23) -1 
Slitrk6 290467 SLIT and NTRK-like family, member 6 -1 
Hcn1 84390 hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 -1 
Slc16a2 259248 solute carrier family 16 member 2 -1 
Ctnna2 297357 catenin alpha 2 -1 
LOC100125362 1E+08 hypothetical protein LOC100125362 -1 
Il13ra2 171060 interleukin 13 receptor subunit alpha 2 -1 
Pcdha3 116780 protocadherin alpha 3 -1 
 
Differentially expressed genes (DEGs) by a fold-change of at least 5 in the rMC-1 cells, relative to primary MCs. 




7.6 Seahorse XF Cell Mito Stress Tests of cultured primary and immortalised Müller 





Appendix 7.6. Seahorse XF Cell Mito Stress Tests of cultured primary and immortalised Müller cells in 
normoxia (associated with Fig 4.3.). Kinetic graphs of oxygen consumption rates (OCRs) and extracellular 
acidification rates (ECARs) from three independent experiments discussed in Figure 4.3 are shown. Primary 
(1o) MC (15,000 cells/well), rMC-1 (15,000 cells/well), SIRMu-1 (10,000 cells/well), 1o MEF (15,000 cells/well), 
and HeLa (10,000 cells/well) cells were seeded in a Seahorse 96-well cell culture. On the following day, cells 
were washed and incubated in fresh assay medium (XF base medium with 10 mM glucose) for an hour before 
the medium of each well was collected to use as samples for lactate assays. Cells were then subjected to an 
XF Cell Mito Stress test where OCRs and ECARs in the presence of glucose (10 mM) were measured by the 
Seahorse XFe96 extracellular flux analyser at a basal state and after the addition of oligomycin (2 µM), FCCP 
(0.5 µM), and rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs were measured three times during 
each of the four conditions. Three independent experiments (each with a minimum of six replicate wells per 
group) were performed, and presented as mean ± SD of each measurement point. In Experiment 1 (labelled in 
the figure), cell numbers not determined. For Experiment 2 and Experiment 3 (labelled in the figure), cell 






7.7 FCCP concentration testing in a Seahorse XF Cell Mito Stress Test in SIRMu-1 
cells 
 
Appendix 7.7. FCCP concentration testing in a Seahorse XF Cell Mito Stress Test in SIRMu-1 cells. Cells 
were seeded in a Seahorse 96-well cell culture plate at 10,000 cells per well. On the following day, an XF Cell 
Mito Stress test was performed where oxygen consumption rates (OCRs) and extracellular acidification rates 
(ECARs) in the presence of glucose (10 mM), glutamine (2 mM) and sodium pyruvate (1 mM) were measured 
simultaneously by the Seahorse XFe96 extracellular flux analyser at a basal state and after the addition of 
oligomycin (2 µM), FCCP (various concentrations as indicated), and rotenone/antimycin A (Rot/AA, 0.5 µM). 
OCRs and ECARs were measured three times during each of the four conditions. Data from one experiment, 















Appendix 7.8. Seahorse XF Cell Mito Stress Tests of PKM2 knockdown rMC-1 cells (associated with Fig 
5.8). Western blots probed for PKM2 and total PKM, PKM2 band intensity normalised to actin (value of the 
shControl is set to 100%), and kinetic graphs of oxygen consumption rates (OCRs) and extracellular acidification 
rates (ECARs) from three independent experiments discussed in Figure 5.8 are shown. rMC-1 (3750 cells/well) 
were seeded in a Seahorse 96-well cell culture plate and transduced with lentivirus encoding either a non-
targeting shRNA (shControl) or one of three shRNAs targeting PKM2 (shPKM2s 1452, 1572, 1499). Three days 
after transduction, cells were washed and incubated in fresh assay medium (XF base medium with 10 mM 
glucose) for an hour before the medium of each well was collected to use as samples for lactate assays. Cells 
were then subjected to a XF Cell Mito Stress Test where OCRs and ECARs in the presence of glucose (10 mM) 
were measured simultaneously by the Seahorse XFe96 extracellular flux analyser at a basal state and after the 
addition of oligomycin (2 µM), FCCP (0.5 µM), and rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs 
were measured three times during each of the four conditions. Three independent experiments (each with a 
minimum of six replicate wells per group) were performed, and presented as mean ± SD of each measurement 
point. In Experiment 1 and Experiment 2 (labelled in the figure), cell numbers were determined in representative 
wells by fluorescence microscopy after Hoechst 33342 nuclear staining. In Experiment 3, cell numbers were 










Appendix 7.9. Seahorse XF Cell Mito Stress Tests of PKM2 knockout (KO) rMC-1 cell lines (associated 
with Fig 5.10). Experiments were performed on three rMC-1 monoclonal cell lines: WT (the empty vector EV1 
line isolated from wildtype control cells generated using a Cas9 nuclease plasmid without gRNA), PKM2 KO I 
(the KO I line 12 isolated from PKM2 KO cells generated using a Cas9 plasmid with gRNAs A1 and B1) and 
PKM2 KO II (the KO II line 1 isolated from PKM2 KO cells generated using a Cas9 plasmid with gRNAs A2 and 
B2). The WT, the PKM2 KO I and the PKM2 KO II rMC-1 cell lines were seeded at 15,000 cells/well in a 
Seahorse 96-well cell culture plate. On the following day, cells were washed and incubated in fresh assay 
medium (XF base medium with 10 mM glucose) for an hour before the medium of each well was collected to 
use as samples for lactate assays. Cells were then subjected to a XF Cell Mito Stress Test where oxygen 
consumption rates (OCRs) and extracellular acidification rates (ECARs) in the presence of glucose (10 mM) 
were measured simultaneously by the Seahorse XFe96 extracellular flux analyser at a basal state and after the 
addition of oligomycin (2 µM), FCCP (0.5 µM), and rotenone/antimycin A (Rot/AA, 0.5 µM). OCRs and ECARs 
were measured three times during each of the four conditions. Three independent experiments (each with a 
minimum of eight replicate wells per group) were performed, and presented as mean ± SD of each measurement 
point. Cell numbers from all three experiments were determined by the ArrayScan after Hoechst 33342 nuclear 
staining. (A) Kinetic graphs of OCRs and ECARs from each of the three independent experiments discussed in 
Figure 5.11. (B) basal OCR (OCRbasal), (C) FCCP-induced OCR (OCRFCCP) and (D) OCR coupled to ATP 
production (OCRcoupled) are presented as mean ± SD from the three independent experiments. Statistical 
significance comparing to WT was determined by one-way ANOVA followed by Dunnett’s multiple comparison 
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